<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006023" GROUP_ID="RENAL" ID="123805021509501813" MERGED_FROM="" MODIFIED="2011-01-17 01:11:08 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="119" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2011-01-17 01:11:08 +0100" MODIFIED_BY="Narelle Willis">
<TITLE>Phosphate binders for preventing and treating bone disease in chronic kidney disease patients</TITLE>
<CONTACT MODIFIED="2011-01-17 01:11:08 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="16132" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sankar</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Navaneethan</LAST_NAME><EMAIL_1>navanes@ccf.org</EMAIL_1><EMAIL_2>sankardass@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Nephrology and Hypertension</DEPARTMENT><ORGANISATION>Glickman Urological and Kidney institute, Cleveland Clinic</ORGANISATION><CITY>Cleveland</CITY><ZIP>44195</ZIP><REGION>OH</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 216 6369230</PHONE_1><FAX_1>+1 216 4449378</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-01-17 01:11:08 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="16132" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sankar</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Navaneethan</LAST_NAME><EMAIL_1>navanes@ccf.org</EMAIL_1><EMAIL_2>sankardass@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Nephrology and Hypertension</DEPARTMENT><ORGANISATION>Glickman Urological and Kidney institute, Cleveland Clinic</ORGANISATION><CITY>Cleveland</CITY><ZIP>44195</ZIP><REGION>OH</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 216 6369230</PHONE_1><FAX_1>+1 216 4449378</FAX_1></ADDRESS></PERSON><PERSON ID="19787" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Suetonia</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Palmer</LAST_NAME><SUFFIX>MBChB</SUFFIX><EMAIL_1>suetonia.palmer@otago.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Otago Christchurch</ORGANISATION><ADDRESS_1>2 Riccarton Ave</ADDRESS_1><ADDRESS_2>PO Box 4345</ADDRESS_2><CITY>Christchurch</CITY><ZIP>8140</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 21626008</PHONE_1><FAX_1>+64 3 3253368</FAX_1></ADDRESS></PERSON><PERSON ID="1F2CD91582E26AA200DA2AF3620CAD78" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mariacristina</FIRST_NAME><LAST_NAME>Vecchio</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>vecchio@negrisud.it</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Pharmacology and Epidemiology</DEPARTMENT><ORGANISATION>Mario Negri Sud Consortium</ORGANISATION><ADDRESS_1>Via Nazionale 8/A</ADDRESS_1><CITY>Santa Maria Imbaro</CITY><ZIP>66030</ZIP><REGION>Chieti</REGION><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+0872570481</PHONE_1></ADDRESS></PERSON><PERSON ID="4552" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Craig</LAST_NAME><POSITION>Head of Clinical Research</POSITION><EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1><EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>a) Cochrane Renal Group, Centre for Kidney Research, The Children's Hospital at Westmead</DEPARTMENT><ORGANISATION>b) Sydney School of Public Health, The University of Sydney</ORGANISATION><CITY>Sydney</CITY><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON><PERSON ID="298FAF2482E26AA2000C5DBB688B141B" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Grahame</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Elder</LAST_NAME><EMAIL_1>g.elder@garvan.unsw.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>a) Department of Renal Medicine, Westmead Hospital</DEPARTMENT><ORGANISATION>b) Osteoporosis and Bone Biology Program, Garvan Institute of Medical Research</ORGANISATION><ADDRESS_1>384 Victoria St</ADDRESS_1><CITY>Darlinghurst</CITY><ZIP>2010</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 96431223</PHONE_1><FAX_1>+61 2 97492569</FAX_1></ADDRESS></PERSON><PERSON ID="16154" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><MIDDLE_INITIALS>FM</MIDDLE_INITIALS><LAST_NAME>Strippoli</LAST_NAME><EMAIL_1>Giovanni.Strippoli@diaverum.com</EMAIL_1><EMAIL_2>strippoli@negrisud.it</EMAIL_2><ADDRESS><DEPARTMENT>a) Mario Negri Sud Consortium, Santa Maria Imbaro (Ch), Italy</DEPARTMENT><ORGANISATION>b) Sydney School of Public Health, University of Sydney, Australia, c) Diaverum Medical-Scientific Office</ORGANISATION><CITY>Lund</CITY><COUNTRY CODE="SE">Sweden</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-07-06 14:03:01 +1000" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="2" MONTH="3" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="3" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="8" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2010-07-07 11:19:26 +1000" MODIFIED_BY="Narelle S Willis"/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2010-12-16 12:17:25 +1100" MODIFIED_BY="Narelle S Willis">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2010-12-16 12:17:25 +1100" MODIFIED_BY="Narelle S Willis">
<SOURCE MODIFIED="2010-12-16 12:17:25 +1100" MODIFIED_BY="Narelle S Willis">
<NAME>SDN is supported by Multidisciplinary Clinical Research Career Development Program CTSA KL2 Grant #: RR024990</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-01-17 10:58:56 +1100" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2010-12-16 11:49:11 +1100" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2010-12-07 14:23:47 +1100" MODIFIED_BY="Narelle S Willis">Phosphate binders for preventing and treating bone disease in chronic kidney disease patients</TITLE>
<SUMMARY_BODY MODIFIED="2010-12-16 11:49:11 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;I have used the background, abstract results and conclusion to create the PLS - please read and check&lt;/p&gt;" NOTES_MODIFIED="2010-12-16 11:49:11 +1100" NOTES_MODIFIED_BY="Narelle S Willis">
<P>People with chronic kidney disease (CKD) develop impaired excretion of the dietary phosphorus. This results in a condition known as mineral and bone disorder in chronic kidney disease (CKD-MBD). CKD-MBD is characterized by high bone turnover, increased musculoskeletal morbidity including bone pain and muscle weakness, and vascular calcification which may contribute to the high incidence of cardiovascular disease and associated deaths. Several agents such as phosphate binders, vitamin D compounds, and calcimimetics are widely used to slow the development and progression of CKD-MBD complications.</P>
<P>Several phosphate binders, including aluminium and calcium-containing agents, have been widely used since 1970. The use of newer non-calcium or aluminium-based agents, such as sevelamer hydrochloride compounds and lanthanum carbonate is increasing although the cost is greater than the older phosphate binders. The avoidance of calcium-based binding agents to lower phosphorus in CKD theoretically reduces the risk of vascular calcification and cardiovascular disease. The balance between calcium-free phosphate binders reducing clinical events in CKD versus their cost remains controversial. Recently released KDIGO guidelines recommend restricting the use of calcium-based binders in people with persistent or recurrent hypercalcaemia or arterial calcification, or both.</P>
<P>We identified 60 studies, enrolling 7631 participants comparing phosphate binders to placebo or other phosphate binders. There was no significant reduction in all-cause mortality (10 studies, 3079 participants) or serum calcium by phosphorus product with sevelamer hydrochloride compared to calcium-based agents. There was a significant reduction in phosphorus (16 studies, 3126 participants) and parathyroid hormone (12 studies, 2551 participants) levels, but a significant increase in the risk of hypercalcaemia (12 studies, 1144 participants) with calcium salts compared to sevelamer hydrochloride. There was a significant increase in the risk of adverse gastrointestinal events with sevelamer hydrochloride compared to calcium salts (5 studies, 498 participants). Compared with calcium-based agents, lanthanum significantly reduced serum calcium (2 studies, 122 participants) and the calcium by phosphorous product, but not serum phosphorus levels. The effects of calcium acetate on biochemical end-points were similar to those of calcium carbonate. The phosphorus lowering effects of novel agents such as ferric citrate, colestilan and niacinamide were only reported in a few studies.</P>
<P>Available phosphate-binding agents have been shown to reduce phosphorus levels in comparison to placebo. However, there are insufficient data to establish the comparative superiority of novel non-calcium binding agents over calcium-containing phosphate binders for patient-level outcomes such as all-cause mortality and cardiovascular end-points in CKD.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-12-22 08:17:42 +1100" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND MODIFIED="2010-12-07 15:30:13 +1100" MODIFIED_BY="Narelle S Willis">
<P>Phosphate binders are widely used to lower serum phosphorus levels in people with chronic kidney disease (CKD) but their impact in CKD remains controversial.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-12-07 14:51:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>To review the effects of various phosphate binders on biochemical and patient-level end-points in CKD stages 3 to 5D.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-12-03 15:29:03 +1100" MODIFIED_BY="Narelle S Willis">
<P>In March 2010 we searched MEDLINE, EMBASE, the Cochrane Renal Group's Specialised Register and CENTRAL for relevant studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-12-07 15:30:21 +1100" MODIFIED_BY="Narelle S Willis">
<P>Randomised controlled trials (RCTs) or quasi-RCTs that assessed the effects of various phosphate binders in adults with CKD.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-12-07 14:52:22 +1100" MODIFIED_BY="Narelle S Willis">
<P>Two authors independently reviewed search results and extracted data. Results were expressed as mean differences (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes with 95% confidence intervals (CI) using a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-12-15 22:08:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sixty studies (7631 participants) were included. There was no significant reduction in all-cause mortality (10 studies, 3079 participants: RR 0.73, 95% CI 0.46 to 1.16), or serum calcium by phosphorus (Ca x P) product with sevelamer hydrochloride compared to calcium-based agents. There was a significant reduction in serum phosphorus (16 studies, 3126 participants: MD 0.23 mg/dL, 95% CI 0.04 to 0.42) and parathyroid hormone (PTH) (12 studies, 2551 participants; MD 56 pg/mL, 95% CI 26 to 84) but a significant increase in the risk of hypercalcaemia (12 studies, 1144 participants: RR 0.45, 95% CI 0.35 to 0.59) with calcium-based agents compared to sevelamer hydrochloride. There was a significant increase in the risk of adverse gastrointestinal events with sevelamer hydrochloride in comparison to calcium salts (5 studies, 498 participants: RR 1.58, 95% CI 1.11 to 2.25). Compared with calcium-based agents, lanthanum significantly reduced serum calcium (2 studies, 122 participants: MD -0.30 mg/dL, 95% CI -0.64 to -0.25) and the Ca x P product, but not serum phosphorus levels. The effects of calcium acetate on biochemical end-points were similar to those of calcium carbonate. The phosphorus lowering effects of novel agents such as ferric citrate, colestilan and niacinamide were only reported in a few studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-08-15 15:40:13 +1000" MODIFIED_BY="[Empty name]">
<P>Available phosphate-binding agents have been shown to reduce phosphorus levels in comparison to placebo. However, there are insufficient data to establish the comparative superiority of novel non-calcium binding agents over calcium-containing phosphate binders for patient-level outcomes such as all-cause mortality and cardiovascular end-points in CKD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2010-12-16 11:49:59 +1100" MODIFIED_BY="Narelle S Willis">
<P>People with chronic kidney disease (CKD) develop impaired excretion of the dietary phosphorus load (<LINK REF="REF-Hurska-2008" TYPE="REFERENCE">Hurska 2008</LINK>). This further leads to high parathyroid hormone (PTH) levels (<LINK REF="REF-Cozzolino-2005" TYPE="REFERENCE">Cozzolino 2005</LINK>; <LINK REF="REF-Hurska-2008" TYPE="REFERENCE">Hurska 2008</LINK>; <LINK REF="REF-Silver-2005" TYPE="REFERENCE">Silver 2005</LINK>) mediated by a rise in fibroblast growth factor 23 (FGF23) levels that reduce calcitriol levels (<LINK REF="REF-Gutierrez-2005" TYPE="REFERENCE">Gutierrez 2005</LINK>) by both inhibiting calcitriol production and increasing calcitriol catabolism. The resulting mineral and bone disorder in CKD (CKD-MBD) is characterized by high bone turnover, exaggerated marrow fibrosis, and increased musculoskeletal morbidity including bone pain and muscle weakness. Epidemiological data have increasingly demonstrated an association between elevated serum phosphorus, PTH, and calcium caused by CKD and increased morbidity, mortality, hospitalisation, reduced quality of life and increased costs of care (<LINK REF="REF-Block-1998" TYPE="REFERENCE">Block 1998</LINK>; <LINK REF="REF-Block-2004" TYPE="REFERENCE">Block 2004</LINK>; <LINK REF="REF-Tentori-2008" TYPE="REFERENCE">Tentori 2008</LINK>).</P>
<P>Over the past few decades, cardiovascular disease has accounted for over half of the deaths in people receiving dialysis (<LINK REF="REF-USRDS-2009" TYPE="REFERENCE">USRDS 2009</LINK>). The development of vascular calcification in the media of arterial vessels, associated with an increased serum calcium by phosphorus (Ca x P) product, is advocated as a major contributing factor (<LINK REF="REF-Guerin-2001" TYPE="REFERENCE">Guerin 2001</LINK>; <LINK REF="REF-Stevens-2004" TYPE="REFERENCE">Stevens 2004</LINK>) to this increased mortality. Several agents such as phosphate binders, vitamin D compounds, and calcimimetics are widely used to retard the development and progression of CKD-MBD complications that include both renal osteodystrophy and vascular calcification.</P>
<P>Several phosphate binders, including aluminium and calcium-containing agents, have been widely used since 1970. Non-calcium or aluminium-based agents such as sevelamer hydrochloride compounds and lanthanum carbonate have recently become available. The use of sevelamer hydrochloride and lanthanum compounds is increasing in nephrology practice, although they incur greater cost than the older phosphate binders (<LINK REF="REF-St-Peter-2008" TYPE="REFERENCE">St Peter 2008</LINK>; <LINK REF="REF-St-Peter-2009" TYPE="REFERENCE">St Peter 2009</LINK>; <LINK REF="REF-USRDS-2009" TYPE="REFERENCE">USRDS 2009</LINK>). The avoidance of calcium-based binding agents to lower phosphorus in CKD theoretically reduces the risk of an elevated serum Ca x P product, and consequently the risk of vascular calcification and cardiovascular disease. For control of hyperphosphataemia, the National Kidney Foundation Kidney Disease Outcomes Quality Initiatives (NKF-KDOQI) recommends the use of calcium-based binders in CKD stages 3 and 4 (glomerular filtration rate (GFR) 30 to 59 mL/min/1.73m² and 15 to 29 mL/min/1.73m², respectively), and both calcium-based and calcium and aluminium-free binders in CKD stages 5 and 5D (GFR &lt; 15 mL/min/1.73m² and dialysis) (<LINK REF="REF-K_x002f_DOQI-2003" TYPE="REFERENCE">K/DOQI 2003</LINK>). The utility of calcium-free phosphate binders in reducing clinical events in CKD, balanced against their cost, remains controversial (<LINK REF="REF-Salusky-2006" TYPE="REFERENCE">Salusky 2006</LINK>; <LINK REF="REF-St-Peter-2009" TYPE="REFERENCE">St Peter 2009</LINK>). Recently released KDIGO guidelines recommend restricting the use of calcium-based binders in people with persistent or recurrent hypercalcaemia or arterial calcification, or both (<LINK REF="REF-KDIGO-2009" TYPE="REFERENCE">KDIGO 2009</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-12-15 21:16:42 +1100" MODIFIED_BY="Narelle S Willis">
<P>The aim of this review was to assess the benefits and harms of various phosphate binders in people with CKD with particular reference to biochemical end-points, musculoskeletal and cardiovascular morbidity, hospitalisation, and mortality. In particular we aimed to:</P>
<OL>
<LI>Evaluate the serum phosphorus lowering effect of aluminium salts, calcium salts, sevelamer hydrochloride, lanthanum carbonate, iron salts and magnesium-based phosphate binders.</LI>
<LI>Assess the impact of phosphate binders on biochemical end-points such as PTH, serum calcium, phosphorus, and Ca x P product. In addition, the influences of these drugs were assessed in relation to lipid profile, tissue calcification, and common symptoms such as pruritis and bone or muscle pain.</LI>
<LI>Assess the impact of these agents on bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DEXA) or quantitative computerised tomography (QCT), and on bone turnover and mineralization based on histomorphometry and fracture events.</LI>
<LI>Assess other clinical end-points such as incidence of cardiovascular events, number of hospital admissions, and all-cause mortality.</LI>
<LI>Assess the impact of various phosphate binders on vascular calcification events.</LI>
<LI>Characterise the adverse events and their incidence for individual phosphate binders.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2010-12-22 12:32:39 +1100" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2010-12-16 11:58:29 +1100" MODIFIED_BY="Narelle S Willis">
<CRIT_STUDIES MODIFIED="2010-12-15 21:18:20 +1100" MODIFIED_BY="Narelle S Willis">
<P>All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth, or other predictable methods) of phosphate binders used for the control of hyperphosphataemia and CKD-MBD of any stage. Studies of phosphate binders, alone or in combination with other (non-randomised) co-interventions (for example vitamin D compounds) were included. The first phase of randomised cross-over studies was included. There were no language restrictions.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-12-15 21:19:38 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>People with CKD in stage 3, 4, 5 and 5D as defined by the K/DOQI guidelines (stage 3: GFR 30-59 mL/min; stage 4: GFR 15-29 mL/min; stage 5: GFR &lt; 15 mL/min; stage 5D: on dialysis) and older than 18 years (<LINK REF="REF-K_x002f_DOQI-2003" TYPE="REFERENCE">K/DOQI 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Studies of participants with a kidney transplant were excluded as these studies are the subject of a separate review (<LINK REF="REF-Palmer-2007" TYPE="REFERENCE">Palmer 2007</LINK>).</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-12-16 11:51:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Studies greater than eight weeks duration of phosphate binders such as aluminium hydroxide, calcium acetate, calcium carbonate, calcium ketoglutarate, sevelamer hydrochloride, sevelamer carbonate, lanthanum carbonate, and magnesium carbonate compared with placebo or to other phosphate binder were included. Comparisons were categorised as:</P>
<OL>
<LI>Calcium salts versus other calcium salts or placebo or other agents.</LI>
<LI>Sevelamer versus calcium salts or placebo or other agents.</LI>
<LI>Lanthanum carbonate versus calcium salts or placebo or other agents.</LI>
<LI>Miscellaneous agents versus placebo or other agents.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-12-16 11:58:29 +1100" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>All-cause mortality, cardiovascular mortality, cardiovascular events, hospitalisation (incidence or duration of hospitalisation), or fracture (incidence of fracture at any site; vertebral compression fractures; fracture of femur, hip, and any long bones identified by radiographic studies).</LI>
<LI>Incidence and nature of treatment-related adverse effects including gastrointestinal (gastritis, diarrhoea, constipation, abdominal bloating), electrolyte imbalance (hypomagnesaemia, hyperkalaemia), accumulation of drug deposits as demonstrated by bone biopsies or anaemia.</LI>
<LI>Hypercalcaemia (defined as serum calcium level &gt; 10.2 mg/dL or as defined by the study investigators)</LI>
<LI>Hyperphosphataemia.</LI>
<LI>Serum phosphorus (mg/dL), serum calcium (mg/dL), Ca x P product (mg²/dL²), PTH (intact (iPTH), or PTH (1-84)); alkaline phosphatase (IU/L), serum bicarbonate (mEq/L).</LI>
<LI>Total serum cholesterol (mg/dL).</LI>
<LI>Vascular calcification, soft tissue or valvular calcification, or incidence of calciphylaxis.</LI>
<LI>Bone mineral density assessed by DEXA or QCT (change in BMD using Z-scores or per cent change (g/cm²) at the lumbar spine, femoral neck, or radius).</LI>
<LI>Bone turnover and mineralisation based on histomorphometry and histology.</LI>
</OL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-12-22 12:32:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Relevant studies were obtained from the following sources.</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-12-22 12:32:39 +1100" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>The Cochrane Renal Group&#8217;s specialised register using keywords relevant to this review. The register is populated using the following strategies:</LI>
<OL>
<LI>Screening of weekly Ovid MEDLINE AutoAlerts using a search strategy covering the scope of the Group (see the Renal Group&#8217;s module under Specialised Register at <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/RENAL/frame.html">http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/RENAL/frame.html</A>) plus the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>).</LI>
<LI>Quarterly searches of NEW records in the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I> using a search strategy covering the scope of the Group.</LI>
<LI>Records handsearched by the Renal Group. The Renal Group has undertaken extensive handsearching of renal-related journals and conference proceedings, therefore we did not specifically search conference proceedings for this review. For a full list of journals and conference proceedings handsearched by the Renal Group use the link to its module (<LINK REF="REF-Renal-Group-2010" TYPE="REFERENCE">Renal Group 2010</LINK>).  </LI>
</OL>
<LI>MEDLINE (from 1966) using the optimally sensitive strategy developed for The Cochrane Collaboration to identify RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) with a specific search strategy developed with input from the Trial Search Coordinator.</LI>
<LI>EMBASE (from 1980) using a search strategy adapted from that developed for The Cochrane Collaboration to identify RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) together with a specific search strategy developed with input from the Trial Search Coordinator.</LI>
</OL>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used.</P>
<P>Date of search: March 2010</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-12-15 21:21:53 +1100" MODIFIED_BY="Narelle S Willis">
<P>Reference lists of nephrology textbooks, review articles, and relevant studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-12-22 10:54:37 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_SELECTION MODIFIED="2010-12-15 21:22:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>The search strategy described was used to obtain titles and abstracts of studies that may have been relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. Studies and reviews that might have included relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-12-16 12:00:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>Studies reported in non-English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Data were extracted on the characteristics of participants, interventions, comparisons, and the outcomes listed above. Authors were contacted if data relating to mortality, phosphorus, calcium, PTH, or Ca x P product were not available or not reported in the published reports. Discrepancies between the assessments of the two data extractors were resolved by discussion with an arbitrator</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-12-16 11:52:43 +1100" MODIFIED_BY="Narelle S Willis">
<P>The quality of studies to be included was assessed independently by two authors, without blinding to authorship or journal, using the checklist developed for the Cochrane Renal Group. Discrepancies were resolved by discussion with a third author. The quality items assessed were allocation concealment; blinding of investigators, participants, outcome assessors, and data analysis; intention-to-treat analysis and completeness to follow-up (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-12-15 22:08:51 +1100" MODIFIED_BY="Narelle S Willis">
<P>Dichotomous data were analysed using the risk ratio (RR) and its 95% confidence interval (CI). Where continuous measurements of outcomes were used, the mean difference (MD) and its 95% CI were computed.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2010-12-03 16:29:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Any further information (relating to serum phosphorus, calcium, PTH, and mortality) required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-12-15 21:29:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Heterogeneity across included studies was analysed by visual analysis of the forest plot and formally using the heterogeneity Chi² and I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-12-22 10:54:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>We had planned to examine for publication bias using a funnel plot, however there were insufficient studies for any of the comparison groups (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-12-15 21:28:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>Risk estimates from individual studies were pooled using the Der Simonian-Laird random-effects model (<LINK REF="REF-Dersimonian-1986" TYPE="REFERENCE">Dersimonian 1986</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-12-15 21:30:16 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sources of heterogeneity that were explored in the subgroup analyses were: older versus newer phosphate binding agents; baseline serum PTH levels; baseline serum phosphorus levels; type of calcium assay used in the study; use of washout of phosphate binder; study duration; quality items including allocation concealment, blinding, use of intention-to-treat analysis; number of participants lost to follow-up; and number of study participants.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<SEARCH_RESULTS MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>The combined search of <I>The Cochrane Library</I>, MEDLINE, and EMBASE identified 2381 citations, of which 2298 were excluded after title and abstract review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Full-text assessment of 90 potentially relevant articles identified 60 eligible studies reported in 67 publications and enrolling 7631 participants (<LINK REF="STD-Al_x002d_Baaj-2005" TYPE="STUDY">Al-Baaj 2005</LINK>; <LINK REF="STD-Almirall-1994" TYPE="STUDY">Almirall 1994</LINK>; <LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK> (two reports); <LINK REF="STD-Birck-1999" TYPE="STUDY">Birck 1999</LINK>; <LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK> (two reports); <LINK REF="STD-Borrego-2000" TYPE="STUDY">Borrego 2000</LINK>; <LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>; <LINK REF="STD-Caravaca-1992" TYPE="STUDY">Caravaca 1992</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>; <LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>; <LINK REF="STD-Chertow-1999" TYPE="STUDY">Chertow 1999</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK> (four reports); <LINK REF="STD-Chiang-2005" TYPE="STUDY">Chiang 2005</LINK>; <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>; <LINK REF="STD-De-Santo-2006" TYPE="STUDY">De Santo 2006</LINK>; <LINK REF="STD-Deuber-2003a" TYPE="STUDY">Deuber 2003a</LINK>; <LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>; <LINK REF="STD-Emmett-1991" TYPE="STUDY">Emmett 1991</LINK>; <LINK REF="STD-Evenepoel-2009" TYPE="STUDY">Evenepoel 2009</LINK>; <LINK REF="STD-Fan-2009" TYPE="STUDY">Fan 2009</LINK>; <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>; <LINK REF="STD-d_x0027_Almeida-Filho-2000" TYPE="STUDY">d'Almeida Filho 2000</LINK>; <LINK REF="STD-Finn-2004" TYPE="STUDY">Finn 2004</LINK> (two reports); <LINK REF="STD-Fischer-2006" TYPE="STUDY">Fischer 2006</LINK>; <LINK REF="STD-Gallieni-2005" TYPE="STUDY">Gallieni 2005</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Hutchison-2005" TYPE="STUDY">Hutchison 2005</LINK> (two reports); <LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>; <LINK REF="STD-Ittel-1991" TYPE="STUDY">Ittel 1991</LINK>; <LINK REF="STD-Janssen-1996" TYPE="STUDY">Janssen 1996</LINK>; <LINK REF="STD-Jespersen-1991" TYPE="STUDY">Jespersen 1991</LINK>; <LINK REF="STD-Joy-2003" TYPE="STUDY">Joy 2003</LINK>; <LINK REF="STD-Kinugasa-2001" TYPE="STUDY">Kinugasa 2001</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>; <LINK REF="STD-Kurihara-2005" TYPE="STUDY">Kurihara 2005</LINK>; <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>; <LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>; <LINK REF="STD-McIntyre-2009" TYPE="STUDY">McIntyre 2009</LINK>; <LINK REF="STD-FORESEE-Study-2008" TYPE="STUDY">FORESEE Study 2008</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>; <LINK REF="STD-Phelps-2002" TYPE="STUDY">Phelps 2002</LINK>; <LINK REF="STD-Ring-1993" TYPE="STUDY">Ring 1993</LINK>; <LINK REF="STD-Roxe-1989" TYPE="STUDY">Roxe 1989</LINK>; <LINK REF="STD-Rudnicki-1994" TYPE="STUDY">Rudnicki 1994</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>; <LINK REF="STD-Sadek-2003" TYPE="STUDY">Sadek 2003</LINK>; <LINK REF="STD-Saif-2007" TYPE="STUDY">Saif 2007</LINK>; <LINK REF="STD-Salusky-1991" TYPE="STUDY">Salusky 1991</LINK>; <LINK REF="STD-Schaefer-1991" TYPE="STUDY">Schaefer 1991</LINK>; <LINK REF="STD-Shaheen-2004" TYPE="STUDY">Shaheen 2004</LINK>; <LINK REF="STD-Shigematsu-2008" TYPE="STUDY">Shigematsu 2008</LINK>; <LINK REF="STD-Spasovski-2006" TYPE="STUDY">Spasovski 2006</LINK>; <LINK REF="STD-Spiegel-2007" TYPE="STUDY">Spiegel 2007</LINK>; <LINK REF="STD-Sprague-2009a" TYPE="STUDY">Sprague 2009a</LINK>; <LINK REF="STD-Sprague-2009b" TYPE="STUDY">Sprague 2009b</LINK>; <LINK REF="STD-Tzanakis-2008" TYPE="STUDY">Tzanakis 2008</LINK>; <LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>). Authors of eight studies responded to requests for additional data or clarification of study methods.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Characteristics of the participants and the interventions of the included studies are detailed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Four different groups of studies were identified.</P>
<UL>
<LI>Any calcium salt versus another calcium salt, placebo, or different doses of the same calcium salt (13 studies, 501 participants):</LI>
<UL>
<LI>Eight studies (371 participants) compared calcium acetate to calcium carbonate (<LINK REF="STD-Almirall-1994" TYPE="STUDY">Almirall 1994</LINK>; <LINK REF="STD-Borrego-2000" TYPE="STUDY">Borrego 2000</LINK>; <LINK REF="STD-Caravaca-1992" TYPE="STUDY">Caravaca 1992</LINK>; <LINK REF="STD-Emmett-1991" TYPE="STUDY">Emmett 1991</LINK>; <LINK REF="STD-d_x0027_Almeida-Filho-2000" TYPE="STUDY">d'Almeida Filho 2000</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>; <LINK REF="STD-Ring-1993" TYPE="STUDY">Ring 1993</LINK>; <LINK REF="STD-Saif-2007" TYPE="STUDY">Saif 2007</LINK>).</LI>
<LI>Two studies (47 participants) compared calcium ketoglutarate to calcium carbonate (<LINK REF="STD-Birck-1999" TYPE="STUDY">Birck 1999</LINK>; <LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>).</LI>
<LI>One study (18 participants) compared calcium salts to placebo (<LINK REF="STD-Rudnicki-1994" TYPE="STUDY">Rudnicki 1994</LINK>).</LI>
<LI>Two studies (65 participants) compared different doses of calcium acetate (<LINK REF="STD-Phelps-2002" TYPE="STUDY">Phelps 2002</LINK>; <LINK REF="STD-Schaefer-1991" TYPE="STUDY">Schaefer 1991</LINK>).</LI>
</UL>
</UL>
<UL>
<LI>Sevelamer hydrochloride versus calcium salts or placebo (21 studies, 4045 participants):</LI>
<UL>
<LI>Six studies (546 participants) compared sevelamer hydrochloride with calcium acetate (<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>; <LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Evenepoel-2009" TYPE="STUDY">Evenepoel 2009</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>; <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>; <LINK REF="STD-Sadek-2003" TYPE="STUDY">Sadek 2003</LINK>).</LI>
<LI>Seven studies (703 participants) compared sevelamer hydrochloride with calcium carbonate (<LINK REF="STD-De-Santo-2006" TYPE="STUDY">De Santo 2006</LINK>; <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>; <LINK REF="STD-Gallieni-2005" TYPE="STUDY">Gallieni 2005</LINK>; <LINK REF="STD-Kinugasa-2001" TYPE="STUDY">Kinugasa 2001</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>; <LINK REF="STD-Shaheen-2004" TYPE="STUDY">Shaheen 2004</LINK>).</LI>
<LI>Two studies (157 participants) compared sevelamer hydrochloride directly with sevelamer hydrochloride and calcium carbonate (<LINK REF="STD-Chertow-1999" TYPE="STUDY">Chertow 1999</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>).</LI>
<LI>Three studies (2369 participants) compared sevelamer hydrochloride to calcium acetate, calcium carbonate, or both (<LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>).</LI>
<LI>One study (203 participants) compared sevelamer hydrochloride plus atorvastatin to calcium acetate plus atorvastatin (<LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>).</LI>
<LI>One study (31 participants) compared sevelamer carbonate powder to sevelamer hydrochloride tablets (<LINK REF="STD-Fan-2009" TYPE="STUDY">Fan 2009</LINK>).</LI>
<LI>One study (36 participants) compared sevelamer hydrochloride to placebo (<LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>).</LI>
</UL>
</UL>
<UL>
<LI>Studies evaluating lanthanum carbonate (12 studies, 2541 participants):</LI>
<UL>
<LI>Four studies (1181 participants) compared lanthanum carbonate to calcium carbonate (<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>; <LINK REF="STD-Hutchison-2005" TYPE="STUDY">Hutchison 2005</LINK>; <LINK REF="STD-Shigematsu-2008" TYPE="STUDY">Shigematsu 2008</LINK>; <LINK REF="STD-Spasovski-2006" TYPE="STUDY">Spasovski 2006</LINK>).</LI>
<LI>Five studies (454 participants) compared lanthanum carbonate to placebo or different doses of lanthanum carbonate (<LINK REF="STD-Al_x002d_Baaj-2005" TYPE="STUDY">Al-Baaj 2005</LINK>; <LINK REF="STD-Chiang-2005" TYPE="STUDY">Chiang 2005</LINK>; <LINK REF="STD-Finn-2004" TYPE="STUDY">Finn 2004</LINK>; <LINK REF="STD-Joy-2003" TYPE="STUDY">Joy 2003</LINK>; <LINK REF="STD-Sprague-2009a" TYPE="STUDY">Sprague 2009a</LINK>).</LI>
<LI>Three studies (906 participants) compared lanthanum carbonate to sevelamer hydrochloride and calcium salts (<LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>; <LINK REF="STD-FORESEE-Study-2008" TYPE="STUDY">FORESEE Study 2008</LINK>; <LINK REF="STD-Sprague-2009b" TYPE="STUDY">Sprague 2009b</LINK>).</LI>
</UL>
</UL>
<UL>
<LI>Other agents (14 studies, 544 participants):</LI>
<UL>
<LI>Four studies (105 participants) compared aluminium and calcium salts (<LINK REF="STD-Ittel-1991" TYPE="STUDY">Ittel 1991</LINK>; <LINK REF="STD-Janssen-1996" TYPE="STUDY">Janssen 1996</LINK>; <LINK REF="STD-Jespersen-1991" TYPE="STUDY">Jespersen 1991</LINK>; <LINK REF="STD-Salusky-1991" TYPE="STUDY">Salusky 1991</LINK>);</LI>
<LI>One study (30 participants) compared aluminium hydroxide and sucralfate (<LINK REF="STD-Roxe-1989" TYPE="STUDY">Roxe 1989</LINK>).</LI>
<LI>One study (55 participants) compared ferric citrate to calcium carbonate in haemodialysis patients (<LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>).</LI>
<LI>One study (46 participants) compared MCI-196 (colestilan) to placebo (<LINK REF="STD-Kurihara-2005" TYPE="STUDY">Kurihara 2005</LINK>).</LI>
<LI>One study (24 participants) compared once daily sevelamer hydrochloride to thrice daily sevelamer hydrochloride (<LINK REF="STD-Fischer-2006" TYPE="STUDY">Fischer 2006</LINK>);</LI>
<LI>One study (33 participants) compared niacinamide to placebo (<LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>).</LI>
<LI>One study (30 participants) compared magnesium carbonate plus calcium carbonate to calcium acetate (<LINK REF="STD-Spiegel-2007" TYPE="STUDY">Spiegel 2007</LINK>).</LI>
<LI>One study (62 participants) compared sevelamer hydrochloride plus calcium carbonate to colestimide plus calcium carbonate (<LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>).</LI>
<LI>One study (63 participants) compared iron-magnesium hydroxycarbonate to placebo (<LINK REF="STD-McIntyre-2009" TYPE="STUDY">McIntyre 2009</LINK>).</LI>
<LI>One study (46 participants) compared magnesium carbonate to calcium carbonate (<LINK REF="STD-Tzanakis-2008" TYPE="STUDY">Tzanakis 2008</LINK>).</LI>
<LI>One study (50 participants) compared calcium carbonate to calcium acetate plus magnesium carbonate (<LINK REF="STD-Deuber-2003a" TYPE="STUDY">Deuber 2003a</LINK>).</LI>
</UL>
</UL>
<P>Four studies included people with CKD stages 3 and 4 (<LINK REF="STD-Borrego-2000" TYPE="STUDY">Borrego 2000</LINK>; <LINK REF="STD-Phelps-2002" TYPE="STUDY">Phelps 2002</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>; <LINK REF="STD-Sprague-2009a" TYPE="STUDY">Sprague 2009a</LINK>) and the rest enrolled haemodialysis patients. The majority of studies were of short duration (1 to 18 months of treatment administration) except for the Dialysis Clinical Outcomes Revisited (DCOR) study (<LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>), which analysed the efficacy of phosphate binders to reduce serum phosphorus, where 42% of participants had a follow-up of more than 24 months. The number of participants ranged from 10 to 2100 with 27/60 (45%) of studies enrolling fewer than 100 participants. Most studies co-administered vitamin D compounds and the route of administration of these agents (IV or oral) varied among the studies. The assays used to measure PTH also differed in the included studies. Most studies defined hypercalcaemia as serum calcium &gt; 10.2 mg/dL, some used &gt; 10.5 mg/dL and others used &gt; 11.0 mg/dL as the cut-off.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-12-15 21:37:55 +1100" MODIFIED_BY="Narelle S Willis">
<P>Reported study quality was variable.</P>
<UL>
<LI>Allocation concealment was adequate in 11/60 (18%) studies and unclear in other studies.</LI>
<LI>Participants and investigators were blinded in 10/60 (17%) studies and outcome assessors were blinded in none of the studies.</LI>
<LI>Only 13/60 (22%) studies were analysed on an intention-to-treat basis.</LI>
<LI>The number of participants lost to follow-up ranged from 0% to 31% but did not differ between the treatment and control groups of the studies.</LI>
</UL>
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> - risk of bias tables.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Vascular calcification and bone outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Vascular calcification</HEADING>
<P>Five studies reported the effects of sevelamer hydrochloride and calcium salts on vascular calcification (<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="REF-Qunibi-2008" TYPE="REFERENCE">Qunibi 2008</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK> reported slower progression of coronary, aortic, and heart valve calcification (measured by electron beam computed tomography) with the use of sevelamer hydrochloride in comparison to calcium acetate, using the Agatston scoring system. Similarly, <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK> showed decreased progression of coronary artery calcification with sevelamer hydrochloride compared to calcium salts in incident haemodialysis patients. By contrast, <LINK REF="REF-Qunibi-2008" TYPE="REFERENCE">Qunibi 2008</LINK> compared sevelamer hydrochloride plus atorvastatin to calcium acetate plus atorvastatin and reported similar coronary artery calcification progression in both groups. <LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK> recorded coronary artery calcium scores in 101 dialysis patients (using a modified Agatston scoring system) and reported no difference in coronary artery calcification progression between the sevelamer hydrochloride and calcium groups (P = 0.59). The included studies used different scoring systems to assess vascular calcification and thus could not be pooled.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bone outcomes</HEADING>
<P>Lanthanum carbonate reduced the number of participants developing low turnover bone disease when compared to calcium carbonate (<LINK REF="STD-Spasovski-2006" TYPE="STUDY">Spasovski 2006</LINK>), and resulted in an improvement of bone volume in comparison to standard phosphate binder therapy (<LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Aluminium-like effects on bone were not noted in follow-up studies that assessed the safety of lanthanum carbonate (<LINK REF="STD-Spasovski-2006" TYPE="STUDY">Spasovski 2006</LINK>). Based upon electron beam computer tomography results, <LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK> reported a significant reduction in trabecular bone attenuation with sevelamer hydrochloride, and a trend towards reduction in cortical bone attenuation (P = 0.05)<I> </I>in thoracic vertebrae, compared to calcium salts. In <LINK REF="STD-Schaefer-1991" TYPE="STUDY">Schaefer 1991</LINK>, enrolling 101 dialysis patients, there was no difference in bone remodelling between sevelamer hydrochloride and calcium groups at the end of one-year follow-up. <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK> reported increased bone formation and improved trabecular architecture but with no significant change in bone turnover or mineralization with sevelamer hydrochloride in comparison to calcium salts. A formal meta-analysis could not be performed for incidence of fracture.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Patient-centred end-points (all-cause mortality, hospitalisation, adverse events)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Calcium salts versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>No deaths were reported in one short-term study comparing calcium acetate to placebo (18 participants) (<LINK REF="STD-Rudnicki-1994" TYPE="STUDY">Rudnicki 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalisation</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypercalcaemia</HEADING>
<P>No hypercalcaemic events were reported in either the calcium acetate or placebo groups (1 study, 18 participants) (<LINK REF="STD-Rudnicki-1994" TYPE="STUDY">Rudnicki 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>Gastrointestinal side effects were not reported in either the calcium acetate or placebo groups (1 study, 18 participants) (<LINK REF="STD-Rudnicki-1994" TYPE="STUDY">Rudnicki 1994</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Calcium acetate versus calcium carbonate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>There was no significant reduction in the risk of all-cause mortality with calcium acetate in comparison to calcium carbonate (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (2 studies, 74 participants): RR 1.13, 95% CI 0.07 to 17.30) (<LINK REF="STD-Almirall-1994" TYPE="STUDY">Almirall 1994</LINK>; <LINK REF="STD-Caravaca-1992" TYPE="STUDY">Caravaca 1992</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalisation</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypercalcaemia</HEADING>
<P>There was no significant difference in the incidence of hypercalcaemia between calcium acetate and calcium carbonate (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (2 studies, 88 participants): RR 1.08, 95% CI 0.11 to 10.99). Significant heterogeneity was identified (Chi² = 2.46, I² = 59%) (<LINK REF="STD-Caravaca-1992" TYPE="STUDY">Caravaca 1992</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>There was no significant difference in the occurrence of gastritis between calcium acetate and calcium carbonate (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.1 (1 study, 30 participants): RR 1.25, 95% CI 0.41 to 3.77) (<LINK REF="STD-d_x0027_Almeida-Filho-2000" TYPE="STUDY">d'Almeida Filho 2000</LINK>).</P>
<P>There was no significant difference in the occurrence of diarrhoea events between calcium acetate and calcium carbonate (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.2 (2 studies, 53 participants): RR 1.65, 95% CI 0.22 to 12.56). No significant heterogeneity was identified (Chi² = 0.32, I² = 0%) (<LINK REF="STD-d_x0027_Almeida-Filho-2000" TYPE="STUDY">d'Almeida Filho 2000</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>).</P>
<P>Similarly there was no significant difference in the occurrence of constipation events between calcium acetate and calcium carbonate (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.3 (2 studies, 53 participants): RR 1.16, 95% CI 0.38 to 3.52). No significant heterogeneity was identified (Chi² = 0.50, I² = 0%) (<LINK REF="STD-d_x0027_Almeida-Filho-2000" TYPE="STUDY">d'Almeida Filho 2000</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>).</P>
<P>
<B>Calcium load</B>
</P>
<P>We planned to assess the daily calcium load with various calcium-based phosphate binders. However, studies did not report calcium intake in a consistent manner that could be pooled in a meta-analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Calcium ketoglutarate versus other calcium salts</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>There were no deaths reported in two short-term studies comparing calcium ketoglutarate to other calcium salts (47 participants) (<LINK REF="STD-Birck-1999" TYPE="STUDY">Birck 1999</LINK>; <LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalisation</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypercalcaemia</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>There was no significant difference in the occurrence of gastrointestinal events between calcium ketoglutarate and other calcium salts (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> (1 study, 17 participants): RR 5.00, 95% CI 0.65 to 38.42) (<LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sevelamer hydrochloride versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>There were no deaths reported in one short-term study comparing sevelamer hydrochloride to placebo (36 participants) (<LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalisation</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypercalcaemia</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>There was no significant difference in the occurrence of gastritis between sevelamer hydrochloride and placebo (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.1 (1 study, 36 participants): RR 1.00, 95% CI 0.10 to 9.96) (<LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>).</P>
<P>There was no significant difference in the occurrence of diarrhoea events between sevelamer hydrochloride and placebo (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.2 (1 study, 36 participants): RR 0.17, 95%CI 0.01 to 3.96) (<LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sevelamer hydrochloride versus calcium salts</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>There was no significant reduction in the risk of all-cause mortality with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> (10 studies, 3079 participants): RR 0.73, 95% CI 0.46 to 1.16). No significant heterogeneity was identified (Chi² = 8.81, I² = 43%) (<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>; <LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>; <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalisation</HEADING>
<P>There was no difference in the number hospitalised in 52 weeks between sevelamer hydrochloride and calcium salts (P = 0.23) (<LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>). There was no statistically significant difference in the number of days hospitalised/patient-year between sevelamer hydrochloride and calcium salts (P = 0.09) (<LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypercalcaemia</HEADING>
<P>There was a significant reduction in the incidence of hypercalcaemia with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK> (12 studies, 1144 participants): RR 0.45, 95% CI 0.35 to 0.59No significant heterogeneity was identified (Chi² = 9.05, I² = 0%) (<LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="STD-De-Santo-2006" TYPE="STUDY">De Santo 2006</LINK>; <LINK REF="STD-Evenepoel-2009" TYPE="STUDY">Evenepoel 2009</LINK>; <LINK REF="STD-Gallieni-2005" TYPE="STUDY">Gallieni 2005</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>; <LINK REF="STD-Sadek-2003" TYPE="STUDY">Sadek 2003</LINK>; <LINK REF="STD-Shaheen-2004" TYPE="STUDY">Shaheen 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>There was no significant increase in the occurrence of nausea with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>.1 (1 study, 203 participants): RR 1.03, 95% CI 0.57 to 1.86) (<LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>).</P>
<P>There was no significant increase in the occurrence of diarrhoea events with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>.2 (1 study, 203 participants): RR 1.03, 95% CI 0.55 to 1.95) (<LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>).</P>
<P>Similarly there was no significant increase in the occurrence of abdominal bloating events with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>.3 (1 study, 56 participants): RR 2.33, CI 0.49 to 11.01) (<LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>).</P>
<P>There was a significant increase in the occurrence of constipation with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>.4 (2 studies, 259 participants): RR 2.63, 95% CI 1.29 to 5.35). No significant heterogeneity was identified (Chi² = 0.40, I² = 0%) (<LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>).</P>
<P>Among studies that reported combined gastrointestinal events there was a higher number of gastrointestinal events with sevelamer hydrochloride compared to calcium salts (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>.5 (5 studies, 498 participants): RR 1.58, 95% CI 1.11 to 2.25) (<LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Evenepoel-2009" TYPE="STUDY">Evenepoel 2009</LINK>; <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>; <LINK REF="STD-Gallieni-2005" TYPE="STUDY">Gallieni 2005</LINK>; <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lanthanum carbonate versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>There were no deaths reported in two studies comparing lanthanum carbonate with placebo, with no deaths reported in two studies (154 participants) (<LINK REF="STD-Chiang-2005" TYPE="STUDY">Chiang 2005</LINK>; <LINK REF="STD-Joy-2003" TYPE="STUDY">Joy 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalisation</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypercalcaemia</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>There was no significant difference in gastrointestinal toxicity with lanthanum carbonate in comparison to placebo (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>.4 (2 studies, 154 participants): RR 1.05, 95% CI 0.45 to 2.45). No significant heterogeneity was identified (Chi² = 0.30, I² = 0%) (<LINK REF="STD-Chiang-2005" TYPE="STUDY">Chiang 2005</LINK>; <LINK REF="STD-Joy-2003" TYPE="STUDY">Joy 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lanthanum carbonate versus calcium carbonate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>There were no deaths reported in the two studies comparing lanthanum carbonate with calcium carbonate (351 participants) (<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>; <LINK REF="STD-Shigematsu-2008" TYPE="STUDY">Shigematsu 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalisation</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hypercalcaemia</HEADING>
<P>There was a significant reduction in hypercalcaemic events with lanthanum carbonate compared with calcium carbonate (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK> (2 studies, 351 participants): RR 0.17, 95% CI 0.09 to 0.31). No significant heterogeneity was identified (Chi² = 0.36, I² = 0%) (<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>; <LINK REF="STD-Shigematsu-2008" TYPE="STUDY">Shigematsu 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>There was no significant difference in gastrointestinal toxicity with lanthanum carbonate in comparison to calcium carbonate (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>.4 (1 study, 98 participants): RR 1.04, 95% CI 0.70 to 1.55) (<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other comparisons</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">All-cause mortality</HEADING>
<P>There were no deaths reported in four short-term studies comparing aluminium salts to other agents (<LINK REF="STD-Ittel-1991" TYPE="STUDY">Ittel 1991</LINK>; <LINK REF="STD-Janssen-1996" TYPE="STUDY">Janssen 1996</LINK>; <LINK REF="STD-Jespersen-1991" TYPE="STUDY">Jespersen 1991</LINK>; <LINK REF="STD-Roxe-1989" TYPE="STUDY">Roxe 1989</LINK>). Similarly, one short-term study comparing ferric citrate and calcium carbonate (<LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>) and single studies comparing niacinamide to placebo (<LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>), magnesium carbonate to calcium acetate (<LINK REF="STD-Spiegel-2007" TYPE="STUDY">Spiegel 2007</LINK>), lanthanum carbonate to placebo (<LINK REF="STD-Sprague-2009a" TYPE="STUDY">Sprague 2009a</LINK>) and sevelamer carbonate powder to sevelamer hydrochloride (<LINK REF="STD-Fan-2009" TYPE="STUDY">Fan 2009</LINK>) did not report any deaths. One patient in the placebo group died while no deaths were reported in the iron-magnesium group in <LINK REF="STD-McIntyre-2009" TYPE="STUDY">McIntyre 2009</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Biochemical and other surrogate end-points</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Calcium salts versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Phosphorus</HEADING>
<P>There were significantly lower phosphorus levels with calcium salts in comparison to placebo (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (1 study, 18 participants): MD -0.82 mg/dL, 95% CI -1.24 to -0.40) (<LINK REF="STD-Rudnicki-1994" TYPE="STUDY">Rudnicki 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcium</HEADING>
<P>There were significantly higher calcium levels with calcium salts in comparison to placebo (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (1 study, 18 participants): MD 0.52 mg/dL, 95% CI 0.13 to 0.91) (<LINK REF="STD-Rudnicki-1994" TYPE="STUDY">Rudnicki 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>Relevant data were not available from the included studies to conduct meta-analyses for iPTH, Ca x P product, alkaline phosphatase, serum bicarbonate, total cholesterol or total calcium intake.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Calcium acetate versus calcium carbonate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Phosphorus</HEADING>
<P>There was no significant difference in phosphorus levels with calcium acetate in comparison to calcium carbonate (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (5 studies, 143 participants): MD -0.19 mg/dL, 95%CI -0.61 to 0.24). No significant heterogeneity was identified (Chi² = 2.13, I² = 0%) (<LINK REF="STD-Almirall-1994" TYPE="STUDY">Almirall 1994</LINK>; <LINK REF="STD-Borrego-2000" TYPE="STUDY">Borrego 2000</LINK>; <LINK REF="STD-Caravaca-1992" TYPE="STUDY">Caravaca 1992</LINK>; <LINK REF="STD-d_x0027_Almeida-Filho-2000" TYPE="STUDY">d'Almeida Filho 2000</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcium</HEADING>
<P>There was no significant difference in calcium levels with calcium acetate in comparison to calcium carbonate (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK> (5 studies, 143 participants): MD -0.09 mg/dL, 95% CI -0.35 to 0.17). No significant heterogeneity was identified (Chi² = 5.00, I² = 20%) (<LINK REF="STD-Almirall-1994" TYPE="STUDY">Almirall 1994</LINK>; <LINK REF="STD-Borrego-2000" TYPE="STUDY">Borrego 2000</LINK>; <LINK REF="STD-Caravaca-1992" TYPE="STUDY">Caravaca 1992</LINK>; <LINK REF="STD-d_x0027_Almeida-Filho-2000" TYPE="STUDY">d'Almeida Filho 2000</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ca x P product</HEADING>
<P>There was no significant difference in Ca x P product with calcium acetate in comparison to calcium carbonate (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK> (2 studies, 31 participants): MD -4.92 mg²/dL², 95% CI -10.03 to 0.19). Significant heterogeneity was identified (Chi² = 3.26, I² = 69%) (<LINK REF="STD-Almirall-1994" TYPE="STUDY">Almirall 1994</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">PTH</HEADING>
<P>There was no significant difference in PTH levels with calcium acetate in comparison to calcium carbonate (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK> (1 study, 16 participants): MD -52.00 pg/mL, 95% CI -211.02 to 107.02) (<LINK REF="STD-Borrego-2000" TYPE="STUDY">Borrego 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serum bicarbonate</HEADING>
<P>There was no significant difference in serum bicarbonate levels with calcium acetate in comparison to calcium carbonate (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK> (2 studies, 53 participants): MD 0.21 mEq/L, 95% CI -1.32 to 1.74). No significant heterogeneity was identified (Chi² = 1.24, I² = 19%) (<LINK REF="STD-d_x0027_Almeida-Filho-2000" TYPE="STUDY">d'Almeida Filho 2000</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serum alkaline phosphatase</HEADING>
<P>There was no significant difference in serum alkaline phosphatase levels with calcium acetate in comparison to calcium carbonate (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>): 4 studies, 74 participants; MD 1.42 IU/L, 95% CI -8.99 to 11.82). No significant heterogeneity was identified (Chi² = 0.37, I² = 0%) (<LINK REF="STD-Almirall-1994" TYPE="STUDY">Almirall 1994</LINK>; <LINK REF="STD-Borrego-2000" TYPE="STUDY">Borrego 2000</LINK>; <LINK REF="STD-Janssen-1996" TYPE="STUDY">Janssen 1996</LINK>; <LINK REF="STD-Pflanz-1994" TYPE="STUDY">Pflanz 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Total cholesterol</HEADING>
<P>Relevant data were not available to conduct a meta-analyses for this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Calcium ketoglutarate versus other calcium salts</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Phosphorus</HEADING>
<P>There was no significant difference in phosphorus levels with calcium ketoglutarate in comparison to other calcium salts (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK> (2 studies, 48 participants): MD -0.10 mg/dL, 95% CI -0.32 to 0.12). No significant heterogeneity was identified (Chi² = 0.02, I² = 0%) (<LINK REF="STD-Birck-1999" TYPE="STUDY">Birck 1999</LINK>; <LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcium</HEADING>
<P>There were significantly lower ionised calcium levels with calcium ketoglutarate in comparison to other calcium salts (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK> (1 study, 20 participants): MD -0.40 mg/dL, 95% CI -0.49 to -0.31) (<LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ca x P product</HEADING>
<P>There was a significant decrease in Ca x P product with calcium ketoglutarate in comparison to other calcium salts (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK> (1 study, 20 participants): MD -4.50 mg²/dL², 95% CI -5.65 to -3.35) (<LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">PTH</HEADING>
<P>There was no significant difference in PTH levels with calcium ketoglutarate in comparison to other calcium salts (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK> (1 study, 20 participants): MD -35.00 pg/mL; 95% CI -155.07 to 85.07) (<LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serum bicarbonate</HEADING>
<P>There was a significantly higher serum bicarbonate levels with calcium ketoglutarate in comparison to other calcium salts (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK> (2 studies, 62 participants): MD 1.66 mEq/L, 95% CI 1.03 to 2.29). No significant heterogeneity was identified (Chi² = 0.13, I² = 0%) (<LINK REF="STD-Birck-1999" TYPE="STUDY">Birck 1999</LINK>; <LINK REF="STD-Bro-1998" TYPE="STUDY">Bro 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>Relevant data were not available to conduct a meta-analysis for the outcomes alkaline phosphatase and total cholesterol.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sevelamer hydrochloride versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Phosphorus</HEADING>
<P>There were significantly lower serum phosphorus levels with sevelamer hydrochloride in comparison to placebo (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK> (1 study, 36 participants): MD -1.80 mg/dL, 95% CI -3.32 to -0.28) (<LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcium</HEADING>
<P>There was no significant difference in calcium levels with sevelamer hydrochloride in comparison to placebo (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK> (1 study, 36 participants): MD -0.10 mg/dL, 95% CI -0.52 to 0.32) (<LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serum bicarbonate</HEADING>
<P>There was no significant difference in serum bicarbonate levels with sevelamer hydrochloride in comparison to placebo (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK> (1 study, 36 participants): MD -0.50 mEq/L, 95% CI -2.53 to 1.53) (<LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Total cholesterol</HEADING>
<P>There were significantly lower total cholesterol levels with sevelamer hydrochloride in comparison to placebo (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK> (1 study, 36 participants): -28.00 mg/dL, 95% CI -51.58 to -4.42) (<LINK REF="STD-Chertow-1997" TYPE="STUDY">Chertow 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>Relevant data were not available to conduct meta-analyses for iPTH, Ca x P product and alkaline phosphatase.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sevelamer versus calcium salts</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Phosphorus</HEADING>
<P>There were significantly higher phosphorus levels with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK> (16 studies, 3126 participants): MD 0.23 mg/dL, 95% CI 0.04 to 0.42). Significant heterogeneity was identified (Chi² = 32.32, I² = 57%) (<LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>; <LINK REF="STD-Gallieni-2005" TYPE="STUDY">Gallieni 2005</LINK>; <LINK REF="STD-Evenepoel-2009" TYPE="STUDY">Evenepoel 2009</LINK>; <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Kinugasa-2001" TYPE="STUDY">Kinugasa 2001</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>; <LINK REF="STD-Sadek-2003" TYPE="STUDY">Sadek 2003</LINK>; <LINK REF="STD-Shaheen-2004" TYPE="STUDY">Shaheen 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcium</HEADING>
<P>There were significantly lower calcium levels with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK> (15 studies, 3039 participants): MD -0.34 mg/dL, 95% CI -0.45 to -0.24). Significant heterogeneity was identified (Chi² = 29.13, I² = 55%) (<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>; <LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>; <LINK REF="STD-Evenepoel-2009" TYPE="STUDY">Evenepoel 2009</LINK>; <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>; <LINK REF="STD-Gallieni-2005" TYPE="STUDY">Gallieni 2005</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Kinugasa-2001" TYPE="STUDY">Kinugasa 2001</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>; <LINK REF="STD-Sadek-2003" TYPE="STUDY">Sadek 2003</LINK>; <LINK REF="STD-Shaheen-2004" TYPE="STUDY">Shaheen 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ca x P product</HEADING>
<P>There was no significant difference in Ca x P product levels with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK> (11 studies, 2674 participants): MD 0.86 mg²/dL², 95% CI -0.69 to 2.40). Significant heterogeneity was identified (Chi² = 15.02, I² = 33%) (<LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>; <LINK REF="STD-Evenepoel-2009" TYPE="STUDY">Evenepoel 2009</LINK>; <LINK REF="STD-Gallieni-2005" TYPE="STUDY">Gallieni 2005</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>; <LINK REF="STD-Shaheen-2004" TYPE="STUDY">Shaheen 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">PTH</HEADING>
<P>There were significantly higher PTH levels with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK> (12 studies, 1009 participants): MD 59.74 pg/mL, 95% CI 27.47 to 92.02). No significant heterogeneity was identified (Chi² = 10.16, I² = 21%) (<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>; <LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="STD-De-Santo-2006" TYPE="STUDY">De Santo 2006</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Kinugasa-2001" TYPE="STUDY">Kinugasa 2001</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>; <LINK REF="STD-Sadek-2003" TYPE="STUDY">Sadek 2003</LINK>; <LINK REF="STD-Shaheen-2004" TYPE="STUDY">Shaheen 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serum bicarbonate</HEADING>
<P>There were significantly lower serum bicarbonate levels with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK> (5 studies, 381 participants): MD -1.43 mEq/L, 95% CI -2.07 to -0.79). No significant heterogeneity was identified (Chi² = 1.75, I² = 0%) (<LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>; <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>; <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>; <LINK REF="STD-Sadek-2003" TYPE="STUDY">Sadek 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serum alkaline phosphatase</HEADING>
<P>There was no significant difference in serum alkaline phosphatase levels with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK> (4 studies, 187 participants): MD 10.13 IU/L, 95% CI -11.28 to 31.53). No significant heterogeneity was identified (Chi² = 1.59, I² = 0%) (<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>; <LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Total cholesterol</HEADING>
<P>There were significantly lower total cholesterol levels with sevelamer hydrochloride in comparison to calcium salts (<LINK REF="CMP-005.10" TYPE="ANALYSIS">Analysis 5.10</LINK> (10 studies, 1705 participants): MD -19.16 mg/dL, 95% CI -27.42 to -10.90). Significant heterogeneity was identified (Chi² = 24.82, I² = 64%) (<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>; <LINK REF="STD-Bleyer-1999" TYPE="STUDY">Bleyer 1999</LINK>; <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>; <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>; <LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>; <LINK REF="STD-Hervas-2003" TYPE="STUDY">Hervas 2003</LINK>; <LINK REF="STD-Koiwa-2005a" TYPE="STUDY">Koiwa 2005a</LINK>; <LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>; <LINK REF="STD-Sadek-2003" TYPE="STUDY">Sadek 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lanthanum carbonate versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Phosphorus</HEADING>
<P>There were significantly lower phosphorus levels with lanthanum carbonate in comparison to placebo (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK> (2 studies, 154 participants): MD -2.01 mg/dL, 95% CI -2.52 to -1.50). No significant heterogeneity was identified (Chi² = 0.13, I² = 0%) (<LINK REF="STD-Chiang-2005" TYPE="STUDY">Chiang 2005</LINK>; <LINK REF="STD-Joy-2003" TYPE="STUDY">Joy 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcium</HEADING>
<P>There were significantly higher calcium levels with lanthanum carbonate in comparison to placebo (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK> (1 study, 93 participants): MD 0.35 mg/dL, 95% CI 0.04 to 0.66) (<LINK REF="STD-Chiang-2005" TYPE="STUDY">Chiang 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ca x P product</HEADING>
<P>There was a significantly lower Ca x P product with lanthanum carbonate in comparison to placebo (<LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK> (1 study, 93 participants): MD -14.20 mg²/dL², 95% CI -21.03 to -7.37) (<LINK REF="STD-Chiang-2005" TYPE="STUDY">Chiang 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">PTH</HEADING>
<P>There were significantly lower PTH levels with lanthanum carbonate in comparison to placebo (<LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK> (1 study, 93 participants): MD -83.00 pg/mL, 95% CI -154.63 to -11.37) (<LINK REF="STD-Chiang-2005" TYPE="STUDY">Chiang 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>Relevant data were not available to conduct meta-analyses for the outcomes serum alkaline phosphatase, serum bicarbonate and total cholesterol.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lanthanum carbonate versus calcium carbonate </HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Phosphorus</HEADING>
<P>There was no significant difference in serum phosphorus levels with lanthanum carbonate in comparison to calcium carbonate (<LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK> (2 studies, 122 participants): MD 0.22 mg/dL, 95% CI -0.32 to 0.75). No significant heterogeneity was identified (Chi² = 1.19, I² = 16%) (<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>; <LINK REF="STD-Spasovski-2006" TYPE="STUDY">Spasovski 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Calcium</HEADING>
<P>There were significantly lower calcium levels with lanthanum carbonate in comparison to calcium carbonate (<LINK REF="CMP-007.05" TYPE="ANALYSIS">Analysis 7.5</LINK> (2 studies, 122 participants): MD -0.30 mg/dL, 95% CI -0.57 to -0.03). No significant heterogeneity was identified (Chi² = 0.92, I² = 0%) (<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>; <LINK REF="STD-Spasovski-2006" TYPE="STUDY">Spasovski 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ca x P product</HEADING>
<P>There was a significantly lower Ca x P product with lanthanum carbonate in comparison with calcium carbonate (<LINK REF="CMP-007.06" TYPE="ANALYSIS">Analysis 7.6</LINK> (1 study, 98 participants): MD -6.01 mg²/dL², 95% CI -9.66 to -2.36) (<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">PTH</HEADING>
<P>There was no significant difference in PTH levels with lanthanum carbonate in comparison to calcium carbonate (<LINK REF="CMP-007.07" TYPE="ANALYSIS">Analysis 7.7</LINK> (2 study, 364 participants; MD 100.91 pg/mL, 95% CI -75.30 to 277.12) (<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>, <LINK REF="STD-Spasovski-2006" TYPE="STUDY">Spasovski 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other outcomes</HEADING>
<P>Relevant data were not available to conduct meta-analyses for the outcomes serum bicarbonate and total cholesterol.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other agents</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Serum calcium, phosphorus and PTH</HEADING>
<P>Studies comparing miscellaneous agents reported outcomes in different ways (e.g. end of treatment values of various biochemical end-points, mean change in biochemical end-points) and sufficient data were not available to meta-analyse. Therefore, these data were tabulated (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Investigation for sources of heterogeneity by subgroup analysis</HEADING>
<P>Since heterogeneity was observed in many analyses, we explored the potential sources of heterogeneity using subgroup analysis (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). This was possible for studies comparing either sevelamer hydrochloride or lanthanum carbonate to calcium salts, while other treatment comparisons contained too few studies to undertake subgroup analyses. Some covariates including measures of study quality (blinding and intention-to-treat analysis), patient characteristics (baseline PTH concentration), and study characteristics (study duration) were significant effect modifiers on some outcomes. However, data were often insufficient to allow definitive conclusions to be drawn.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<SUMMARY_OF_RESULTS MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Several RCTs have examined the impact of various phosphate binders in people with CKD. All phosphate binders reduced serum phosphorus levels when compared with placebo, however use of newer agents such as lanthanum carbonate and sevelamer hydrochloride did not result in consistently superior biochemical outcomes compared with calcium-based therapies. These studies have not demonstrated that phosphate binders compared with placebo, or calcium salts compared with non-calcium or aluminium-containing agents, reduce all-cause or cardiovascular mortality. Rather, in studies comparing calcium salts to sevelamer hydrochloride, calcium salts were superior to sevelamer hydrochloride for reducing serum phosphorus. Compared with calcium salts, sevelamer hydrochloride and lanthanum carbonate were associated with significantly lower rates of treatment-related hypercalcaemia, which may result in reduced vascular calcification. The differential effect on serum levels of calcium and phosphorus resulted in increased PTH suppression by calcium treatment compared with sevelamer hydrochloride or lanthanum. The efficacy of available phosphate-binding agents on the surrogate outcomes of bone mineral density or histomorphometry and vascular calcification were variable and only reported in few studies and reliable conclusions could not be drawn through meta-analysis.</P>
<P>Sevelamer hydrochloride was associated with lower serum calcium, higher phosphorus, and higher PTH levels when compared to calcium salts. This may be due to non-compliance (secondary to increased gastrointestinal events and pill burden) resulting in less phosphorus reduction with sevelamer hydrochloride, or it may be because sevelamer hydrochloride is less effective at the relative doses used. Sevelamer hydrochloride treatment resulted in lower serum calcium levels, which might have contributed to the higher PTH levels noted. The <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>, which was the largest study (2103 participants) conducted at present, reported no difference in the risk of all-cause mortality between sevelamer hydrochloride and calcium salts except for a subgroup analysis in people older than 65 years who completed a two-year follow-up. Because of its size, <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK> was very influential and contributed 46% of the weight in our all-cause mortality analysis. Exclusion of this study resulted in a similar but smaller risk of all-cause mortality (RR 0.59, 95% CI 0.35 to 1.01 versus RR 0.75, 95% CI 0.48 to 1.16). Given the limitations of the analysis by <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>, we also conducted a sensitivity analysis using data from <LINK REF="REF-St-Peter-2008" TYPE="REFERENCE">St Peter 2008</LINK>, who used the centre for Medicare and Medicaid services claims data to reassess the DCOR study results. The risk of all-cause mortality was unchanged (RR 0.75, 95% CI 0.56 to 1.33) using these data.</P>
<P>The occurrence, progression, and prognostic importance of vascular calcification remain important questions in CKD and the influence of calcium-based binders on the progression of vascular calcification is a matter of intense debate (<LINK REF="REF-Bushinsky-2006" TYPE="REFERENCE">Bushinsky 2006</LINK>; <LINK REF="REF-Friedman-2006" TYPE="REFERENCE">Friedman 2006</LINK>; <LINK REF="REF-Moe-2006" TYPE="REFERENCE">Moe 2006</LINK>; <LINK REF="REF-Silver-2007" TYPE="REFERENCE">Silver 2007</LINK>). Two studies in the current analysis reported a higher rate of progression of vascular calcification with calcium salts compared with sevelamer hydrochloride (<LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>; <LINK REF="STD-CARE-Study-2004" TYPE="STUDY">CARE Study 2004</LINK>), while another showed no difference in calcium scores between sevelamer hydrochloride and calcium salts (<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>). The possibility that the cholesterol lowering effect of sevelamer hydrochloride may contribute to this effect (rather than hypercalcaemia from calcium salts) cannot be excluded based on the recently published <LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>. While vascular calcification is associated with an increased risk of mortality in haemodialysis patients, the impact of reducing vascular calcification on survival outcomes has not been demonstrated in RCTS in CKD and non-CKD populations (<LINK REF="REF-McCullough-2009" TYPE="REFERENCE">McCullough 2009</LINK>; <LINK REF="REF-Silver-2007" TYPE="REFERENCE">Silver 2007</LINK>). As the recent negative results of the AURORA study (analysing the beneficial effects of statins in dialysis patients) have shown, even a universally accepted surrogate end-point like LDL cholesterol may not predict patient-centred end-points such as mortality in a different setting; in dialysis patients the causal pathway to cardiovascular endpoints and death may be different (<LINK REF="REF-Fellstrom-2009" TYPE="REFERENCE">Fellstrom 2009</LINK>; <LINK REF="REF-Strippoli-2009" TYPE="REFERENCE">Strippoli 2009</LINK>). A surrogate end-point must be validated and tested in specific settings prior to validating assumptions that modifying the surrogate marker will impact upon clinical outcomes.</P>
<P>Sevelamer hydrochloride has not been well studied in CKD stages 3 to 5 (not requiring dialysis) except for a single study (<LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>). Therefore, this systematic review can only inform the therapeutic use of sevelamer hydrochloride and calcium salts in dialysis patients and only for surrogate biochemical end-points. It is still uncertain whether sevelamer hydrochloride reduces hypercalcaemia and cardiovascular disease in stage 3 to 5 CKD compared with calcium-based agents. Calcium salts are recommended in pre-dialysis patients by various international guideline agencies for the control of hyperphosphataemia (<LINK REF="REF-Elder-2006" TYPE="REFERENCE">Elder 2006</LINK>; <LINK REF="REF-K_x002f_DOQI-2003" TYPE="REFERENCE">K/DOQI 2003</LINK>). Our review confirms that calcium carbonate and calcium acetate are equally effective in reducing phosphorus and PTH levels, with a similar incidence of hypercalcaemia and gastrointestinal adverse events; we identified only two studies conducted in pre-dialysis patients (<LINK REF="STD-Borrego-2000" TYPE="STUDY">Borrego 2000</LINK>; <LINK REF="STD-Phelps-2002" TYPE="STUDY">Phelps 2002</LINK>). Included studies did not separately report net elemental calcium intake for calcium acetate and calcium carbonate. This precluded us from pooling the data to assess the daily calcium load associated with these agents. Thus, the lack of a higher incidence of hypercalcaemia with calcium carbonate compared to calcium acetate should be interpreted with caution. As few studies are available, no strong RCT evidence exists (regarding outcomes of mortality and morbidity) for the use of calcium-based phosphate binders in earlier stages of CKD.</P>
<P>Few studies have analysed the use of lanthanum carbonate, alone or in conjunction with calcium salts, for phosphate binding in CKD. Lanthanum carbonate has been compared to placebo and calcium carbonate in dialysis patients. Available data confirm its efficacy in reducing phosphorus levels, similar to calcium carbonate, with a reduced incidence of hypercalcaemia. Accumulation of lanthanum in bone was assessed in <LINK REF="STD-Spasovski-2006" TYPE="STUDY">Spasovski 2006</LINK> by bone biopsy at the end of two years of treatment and no evidence of aluminium-like toxicity was observed.</P>
<P>In CKD, fibroblast growth factor-23 (FGF-23) levels rise in parallel with declining renal function before a significant increase in serum phosphorus concentration is detected. Results from preliminary animal and human studies suggest that phosphate binders reduce serum FGF-23 levels (<LINK REF="REF-Koiwa-2005b" TYPE="REFERENCE">Koiwa 2005b</LINK>; <LINK REF="REF-Nagano-2006" TYPE="REFERENCE">Nagano 2006</LINK>). However, this has not been examined in well-conducted prospective studies and the impact of this reduction in FGF-23 levels is unknown.</P>
</SUMMARY_OF_RESULTS>
<AGREEMENT MODIFIED="2010-12-16 12:00:10 +1100" MODIFIED_BY="Narelle S Willis">
<P>A previous meta-analysis (including 17 prospective and retrospective studies comparing sevelamer hydrochloride to placebo) showed that sevelamer hydrochloride compared with placebo or no treatment improved biochemical end-points (serum phosphorus, Ca x P product, PTH, and lipids) without increased serum calcium levels. However, data on survival, hospitalisation, and vascular calcification were not included (<LINK REF="REF-Burke-2003" TYPE="REFERENCE">Burke 2003</LINK>). The inclusion of both observational studies and RCTs in that review decreased the strength of its conclusions through potential for bias and unknown confounding. A second systematic review of seven RCTs (746 participants) concluded that sevelamer hydrochloride had similar effects on phosphorus and Ca x P product with a lower incidence of hypercalcaemia (<LINK REF="REF-Manns-2004" TYPE="REFERENCE">Manns 2004</LINK>). Similar to the previous analysis, that review focused only on the effects of sevelamer hydrochloride and included some but not all available studies. Another analysis by <LINK REF="REF-Tonelli-2007" TYPE="REFERENCE">Tonelli 2007</LINK> (an update of their previous review; <LINK REF="REF-Manns-2004" TYPE="REFERENCE">Manns 2004</LINK>) analysed the benefits of sevelamer hydrochloride in comparison to calcium alone and included 10 studies. This review did not assess the role of other phosphate binders and did not explore the risk of vascular calcification (<LINK REF="REF-Palmer-2007" TYPE="REFERENCE">Palmer 2007</LINK>). A more recent analysis by <LINK REF="REF-Jamal-2009" TYPE="REFERENCE">Jamal 2009</LINK> compared calcium salts and non-calcium salts and noted a decrement in coronary calcification with no difference in mortality rates. Similar to previous reviews, other types of phosphate binders were not included.</P>
<SUBSECTION>
<HEADING LEVEL="3">Strengths and limitations</HEADING>
<P>Our systematic review has a number of strengths and some weaknesses. It is based upon prior publication of a prospectively designed peer-reviewed protocol (<LINK REF="REF-Navaneethan-2006" TYPE="REFERENCE">Navaneethan 2006</LINK>) and a systematic search of medical databases, data extraction, analysis, and study quality assessment by two independent review authors with supervision by a third experienced investigator. The key findings are limited by the lack of long-term studies analysing the efficacy of phosphate binders on mortality and musculoskeletal morbidity. Most included studies enrolled few people (except for the large <LINK REF="STD-DCOR-Study-2007" TYPE="STUDY">DCOR Study 2007</LINK>) and all were powered to observe differences in surrogate end-points rather than patient-focused outcomes. This attention to surrogate rather than patient-level end-points in CKD is not new and should be superseded by a focus on major patient-level end-points in future studies (<LINK REF="REF-Hutchinson-2009" TYPE="REFERENCE">Hutchinson 2009</LINK>; <LINK REF="REF-Strippoli-2005" TYPE="REFERENCE">Strippoli 2005</LINK>; <LINK REF="REF-Strippoli-2007" TYPE="REFERENCE">Strippoli 2007</LINK>). The strength of conclusions drawn from this review is also limited by suboptimal reporting of study methods, to determine study quality and significant heterogeneity observed for many outcomes. Further, many studies were sponsored by different pharmaceutical companies. We could not conduct subgroup analysis to explore the potential impacts due to the small number of studies.</P>
<P>The primary advantage for more recently developed phosphate binders (lanthanum carbonate and sevelamer hydrochloride) is a reduction in hypercalcaemia in dialysis patients. Further, newer agents may cause less PTH inhibition, which may offer additional benefits in low bone turnover states. However, such benefits have not been established so far. Existing studies using patient-focused end-points in pre-dialysis patients are inadequate to inform clinical recommendations for any phosphate binder, required before advocating that newer agents are superior to existing, lower cost interventions. Full adoption of sevelamer hydrochloride and lanthanum by government drug reimbursement agencies in place of calcium salts would lead to a large increase in healthcare expenditure (<LINK REF="REF-Manns-2007" TYPE="REFERENCE">Manns 2007</LINK>; <LINK REF="REF-St-Peter-2009" TYPE="REFERENCE">St Peter 2009</LINK>; <LINK REF="REF-Taylor-2008" TYPE="REFERENCE">Taylor 2008</LINK>). This can only be justified by presenting evidence for improved clinical outcomes with these agents compared with calcium salts; current evidence suggests similar phosphate-binding effects but more potent effects on PTH with calcium salts. Additionally, it should be remembered that, to date, no clinical study has shown a survival advantage for calcium salts either, when compared with placebo or other agents.</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-12-07 15:36:19 +1100" MODIFIED_BY="Narelle S Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2010-08-15 19:46:21 +1000" MODIFIED_BY="[Empty name]">
<P>Our review supports the conclusion that the novel phosphate binders such as sevelamer hydrochloride and lanthanum carbonate are not superior to calcium salts for the control of phosphorus levels in dialysis patients and their impact on morbidity and mortality is unknown. The primary advantage of more recently developed phosphate binders (lanthanum carbonate and sevelamer hydrochloride) is a reduction in hypercalcaemia. Data for patient-focused end-points in dialysis patients are inadequate to inform clinical recommendations for any phosphate binder.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-12-07 15:36:19 +1100" MODIFIED_BY="Narelle S Willis">
<P>Further research using a RCT design is required to assess the effect of surrogate biochemical end-points (phosphorus, calcium, PTH, FGF-23) on mortality and morbidity in CKD. These might include studies of:</P>
<OL>
<LI>direct comparisons between sevelamer compounds, calcium salts, and lanthanum carbonate in people with CKD with primary outcomes of all-cause and cardiovascular mortality, fractures, hospitalisation, and parathyroidectomy;</LI>
<LI>any phosphate binder used to control hyperphosphataemia in CKD stage 3 and 4; or</LI>
<LI>efficacy of combination therapy (such as sevelamer hydrochloride with or without calcium salts) on both surrogate and patient-level end-points. </LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-12-08 16:00:02 +1100" MODIFIED_BY="Narelle S Willis">
<P>We thank Narelle Willis (Managing Editor, Cochrane Renal Group), Ruth Mitchell (Trials Search Coordinator, Cochrane Renal Group) and the Cochrane Renal Group for assistance with preparation of this study. We also thank Dr Pooja Chaukiyal (PC) who contributed to the protocol development stage. We thank all the authors who provided additional details of their studies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-01-17 10:58:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>A/Prof Grahame Elder has been a member of the advisory boards of Amgen, Shire and Genzyme Australia and has been a speaker at scientific meetings arranged by all of the above and also by Abbott Australia.</LI>
<LI>Sankar D Navaneethan, Suetonia C Palmer, Mariacristina Vecchio, Jonathan C Craig, Giovanni FM Strippoli: Nothing to declare</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-10-03 16:58:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Writing of protocol and review: SN, SP, MV, JC, GE, SP</LI>
<LI>Screening of titles and abstracts: SN, SCP, MV</LI>
<LI>Assessment for inclusion: SN, SCP, MV, GFMS</LI>
<LI>Quality assessment: SN, SCP, MV, GFMS</LI>
<LI>Data extraction: SN, SCP, MV, GFMS</LI>
<LI>Data entry into RevMan: SN, MV</LI>
<LI>Data analysis: SN</LI>
<LI>Disagreement resolution: GFMS</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<STUDIES MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Baaj-2005" MODIFIED="2010-12-23 12:53:54 +1100" MODIFIED_BY="[Empty name]" NAME="Al-Baaj 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-12-08 16:10:53 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Baaj F, Speake M, Hutchinson J</AU>
<TI>Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>4</NO>
<PG>775-85</PG>
<IDENTIFIERS MODIFIED="2010-03-03 11:06:09 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-03 11:06:09 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15703206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Almirall-1994" MODIFIED="2010-11-06 13:31:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="Almirall 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-06 13:31:41 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Almirall J, Veciana L, Llibre J</AU>
<TI>Calcium acetate versus calcium carbonate for the control of serum phosphorus in haemodialysis patients</TI>
<SO>American Journal of Nephrology</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>3</NO>
<PG>192-6</PG>
<IDENTIFIERS MODIFIED="2010-11-06 13:31:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-06 13:31:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7977479"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birck-1999" MODIFIED="2010-11-06 13:38:09 +1100" MODIFIED_BY="Narelle S Willis" NAME="Birck 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-06 13:38:09 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ</AU>
<TI>Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>6</NO>
<PG>1475-9</PG>
<IDENTIFIERS MODIFIED="2010-11-06 13:38:09 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-06 13:38:09 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10383011"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bleyer-1999" MODIFIED="2010-03-03 16:19:49 +1100" MODIFIED_BY="[Empty name]" NAME="Bleyer 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-03 16:19:49 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, et al</AU>
<TI>A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in haemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>4</NO>
<PG>694-701</PG>
<IDENTIFIERS MODIFIED="2010-03-03 16:19:46 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-03 16:19:46 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10196011"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Block-2005" MODIFIED="2010-12-08 16:59:09 +1100" MODIFIED_BY="Narelle S Willis" NAME="Block 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-12-08 16:59:09 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM</AU>
<TI>Mortality effect of coronary calcification and phosphate binder choice in incident haemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>2007</YR>
<VL>71</VL>
<NO>5</NO>
<PG>438-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17200680"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-03 16:21:53 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al</AU>
<TI>Effects of sevelamer and calcium on coronary artery calcification in patients new to haemodialysis</TI>
<SO>Kidney International</SO>
<YR>2005</YR>
<VL>68</VL>
<NO>4</NO>
<PG>1815-24</PG>
<IDENTIFIERS MODIFIED="2010-03-03 16:21:53 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-03 16:21:53 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16164659"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borrego-2000" MODIFIED="2010-11-06 13:16:24 +1100" MODIFIED_BY="Narelle S Willis" NAME="Borrego 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-06 13:16:24 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borrego J, Perez del Barrio P, Serrano P, Garcia Cortes MJ, Sanchez Perales MC, Borrego FJ, et al</AU>
<TI>A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis</TI>
<SO>Nefrologia</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>4</NO>
<PG>348-54</PG>
<IDENTIFIERS MODIFIED="2010-11-06 13:16:24 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-06 13:16:24 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11039260"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BRiC-Study-2008" MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis" NAME="BRiC Study 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-08-12 01:10:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barreto DV, Barreto FC, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al</AU>
<TI>Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study</TI>
<SO>Nephron</SO>
<YR>2008</YR>
<VL>110</VL>
<NO>4</NO>
<PG>c273-83</PG>
<IDENTIFIERS MODIFIED="2010-03-03 16:10:55 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-03 16:10:55 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19001830"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-03 13:40:31 +1100" MODIFIED_BY="Narelle S Willis" NOTES="journal article. research support, non-u.s. gov't" NOTES_MODIFIED="2010-10-03 13:40:31 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peres AT, Dalboni MA, Canziani ME, Manfredi SR, Carvalho JT, Batista MC, et al</AU>
<TI>Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients</TI>
<SO>Hemodialysis International</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>3</NO>
<PG>271-7</PG>
<IDENTIFIERS MODIFIED="2010-10-03 13:40:31 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 13:40:31 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00747277"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bro-1998" MODIFIED="2010-10-03 13:41:59 +1100" MODIFIED_BY="Narelle S Willis" NAME="Bro 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-10-03 13:41:59 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bro S, Rasmussen RA, Handberg J, Olgaard K, Feld-Rasmussen B</AU>
<TI>Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic haemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>2</NO>
<PG>257-62</PG>
<IDENTIFIERS MODIFIED="2010-03-03 16:30:11 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-03 16:30:11 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9469496"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caravaca-1992" MODIFIED="2010-08-12 01:12:00 +1000" MODIFIED_BY="[Empty name]" NAME="Caravaca 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-08-12 01:12:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caravaca F, Santos I, Cubero JJ, Esparrago JF, Arrobas M, Pizarro JL, et al</AU>
<TI>Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients</TI>
<SO>Nephron</SO>
<YR>1992</YR>
<VL>60</VL>
<NO>4</NO>
<PG>423-7</PG>
<IDENTIFIERS MODIFIED="2010-03-03 16:32:26 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-03 16:32:26 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1584317"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CARE-Study-2004" MODIFIED="2010-11-22 21:50:00 +1100" MODIFIED_BY="Narelle S Willis" NAME="CARE Study 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-22 21:50:00 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, et al</AU>
<TI>Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>5</NO>
<PG>1914-26</PG>
<IDENTIFIERS MODIFIED="2010-11-22 21:50:00 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-22 21:50:00 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15086935"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CARE_x002d_2-Study-2008" MODIFIED="2010-11-08 14:09:31 +1100" MODIFIED_BY="Narelle S Willis" NAME="CARE-2 Study 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-03 15:41:21 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al</AU>
<TI>A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>6</NO>
<PG>952-65</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:41:21 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:41:21 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18423809"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-06 14:08:23 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-06 14:08:23 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CTG" VALUE="NCT00211939"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2008" MODIFIED="2010-10-03 15:04:46 +1100" MODIFIED_BY="Narelle S Willis" NAME="Cheng 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-03 15:04:46 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW</AU>
<TI>A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in haemodialysis patients</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>4</NO>
<PG>1131-8</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:04:46 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:04:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18385391"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chertow-1997" MODIFIED="2010-10-03 13:39:26 +1100" MODIFIED_BY="Narelle S Willis" NAME="Chertow 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-10-03 13:39:26 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Burke SK, Lazarus MJ, Stenzel KH, Wombolt D, Goldberg D, et al</AU>
<TI>Poly(allylamine hydrochloride) (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>1</NO>
<PG>66-71</PG>
<IDENTIFIERS MODIFIED="2010-10-03 13:39:25 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 13:39:25 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9002531"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chertow-1999" MODIFIED="2010-10-03 13:44:04 +1100" MODIFIED_BY="Narelle S Willis" NAME="Chertow 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-10-03 13:44:04 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, et al</AU>
<TI>A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in haemodialysis patients</TI>
<SO>Clinical Nephrology</SO>
<YR>1999</YR>
<VL>51</VL>
<NO>1</NO>
<PG>18-26</PG>
<IDENTIFIERS MODIFIED="2010-10-03 13:44:04 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 13:44:04 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9988142"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chertow-2002" MODIFIED="2010-11-08 14:10:26 +1100" MODIFIED_BY="Narelle S Willis" NAME="Chertow 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-08-15 20:56:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, et al</AU>
<TI>Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>8</NO>
<PG>1653-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15930018"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-08 14:10:26 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group</AU>
<TI>Sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>1</NO>
<PG>245-52</PG>
<IDENTIFIERS MODIFIED="2010-10-03 13:46:04 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 13:46:04 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12081584"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-03 13:49:35 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P</AU>
<TI>Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients</TI>
<SO>American Heart Journal</SO>
<YR>2005</YR>
<VL>149</VL>
<NO>5</NO>
<PG>820-5</PG>
<IDENTIFIERS MODIFIED="2010-10-03 13:49:35 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 13:49:35 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15894962"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-03 13:50:55 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raggi P, James G, Burke SK, Bommer S, Chasan-Taber S, Holzer H, et al</AU>
<TI>Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis</TI>
<SO>Journal of Bone &amp; Mineral Research</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>5</NO>
<PG>764-72</PG>
<IDENTIFIERS MODIFIED="2010-10-03 13:50:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 13:50:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15824849"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiang-2005" MODIFIED="2010-10-03 13:52:01 +1100" MODIFIED_BY="Narelle S Willis" NAME="Chiang 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-03 13:52:01 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiang SS, Chen JB, Yang WC</AU>
<TI>Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease</TI>
<SO>Clinical Nephrology</SO>
<YR>2005</YR>
<VL>63</VL>
<NO>6</NO>
<PG>461-70</PG>
<IDENTIFIERS MODIFIED="2010-10-03 13:52:01 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 13:52:01 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15960148"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-d_x0027_Almeida-Filho-2000" MODIFIED="2010-12-23 13:30:18 +1100" MODIFIED_BY="[Empty name]" NAME="d'Almeida Filho 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-12-16 12:07:33 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>d'Almeida Filho EJ, da Cruz EA, Hoette M, Ruzany F, Keen LN, Lugon JR</AU>
<TI>Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients</TI>
<SO>Revista Paulista de Medicina [Sao Paulo Medical Journal]</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>6</NO>
<PG>179-84</PG>
<IDENTIFIERS MODIFIED="2010-11-08 16:47:22 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-08 16:47:22 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11120549"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Haese-2003" MODIFIED="2010-12-22 11:44:23 +1100" MODIFIED_BY="Narelle S Willis" NAME="D'Haese 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-10-03 13:54:00 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Haese PC, Spasovski GB, Sikole A, Hutchinson A, Freemont TJ, Sulkova S, et al</AU>
<TI>A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients</TI>
<SO>Kidney International - Supplement</SO>
<YR>2003</YR>
<NO>85</NO>
<PG>73-8</PG>
<IDENTIFIERS MODIFIED="2010-10-03 13:53:36 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 13:53:36 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12753271"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-22 11:44:23 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Wilson R</AU>
<TI>Spica Consultants Ltd</TI>
<SO>Personal communication</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DCOR-Study-2007" MODIFIED="2010-11-08 14:26:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="DCOR Study 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-08 14:26:15 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, et al</AU>
<TI>Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>2007</YR>
<VL>72</VL>
<NO>9</NO>
<PG>1130-7</PG>
<IDENTIFIERS MODIFIED="2010-11-08 14:26:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-08 14:26:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17728707"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-08 14:26:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-08 14:26:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CTG" VALUE="NCT00324571"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Santo-2006" MODIFIED="2010-11-08 15:06:18 +1100" MODIFIED_BY="Narelle S Willis" NAME="De Santo 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-08 14:43:36 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, et al</AU>
<TI>Sevelamer worsens metabolic acidosis in hemodialysis patients</TI>
<SO>Journal of Nephrology</SO>
<YR>2006</YR>
<VL>19 Suppl 9</VL>
<PG>S108-14</PG>
<IDENTIFIERS MODIFIED="2010-11-08 14:43:36 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-08 14:43:36 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16736432"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deuber-2003a" MODIFIED="2010-12-23 13:27:17 +1100" MODIFIED_BY="[Empty name]" NAME="Deuber 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-08-12 01:16:49 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deuber HJ</AU>
<TI>Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18 Suppl 4</VL>
<PG>680-1</PG>
<IDENTIFIERS MODIFIED="2010-07-07 11:41:50 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-07-07 11:41:50 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00445085"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emmett-1991" MODIFIED="2010-10-03 14:01:15 +1100" MODIFIED_BY="Narelle S Willis" NAME="Emmett 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-10-03 14:01:15 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emmett M, Sirmon MD, Kirkpatrick GW, Nolan C, Schmitt GW, Cleveland MB</AU>
<TI>Calcium acetate control of serum phosphorus in hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>5</NO>
<PG>544-50</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:01:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:01:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2024656"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evenepoel-2009" MODIFIED="2010-10-03 14:02:12 +1100" MODIFIED_BY="Narelle S Willis" NAME="Evenepoel 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-03 14:02:12 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, et al</AU>
<TI>Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>1</NO>
<PG>278-85</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:02:12 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:02:12 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18820280"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2009" MODIFIED="2010-10-03 14:04:25 +1100" MODIFIED_BY="Narelle S Willis" NAME="Fan 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-03 14:04:25 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, et al</AU>
<TI>A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>12</NO>
<PG>3794-9</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:03:54 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:03:54 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19666658"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferreira-2008" MODIFIED="2010-10-03 14:04:38 +1100" MODIFIED_BY="Narelle S Willis" NAME="Ferreira 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-03 14:04:38 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, et al</AU>
<TI>Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in haemodialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>2</NO>
<PG>405-12</PG>
<IDENTIFIERS MODIFIED="2010-03-04 11:09:51 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-04 11:09:51 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18199805"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finn-2004" MODIFIED="2010-11-08 16:57:04 +1100" MODIFIED_BY="Narelle S Willis" NAME="Finn 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-08-09 16:42:01 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altmann P, Barnett ME, Finn WF; SPD405-307 Lanthanum Carbonate Study Group</AU>
<TI>Cognitive function in Stage 5 chronic kidney disease patients on haemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy</TI>
<SO>Kidney International.</SO>
<YR>2007</YR>
<VL>71</VL>
<NO>3</NO>
<PG>252-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17035945"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-08 16:57:04 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Less than 6 weeks - ? should this be Finn 2006 Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clinical Nephrology 65(3):191-202&lt;/p&gt;" NOTES_MODIFIED="2010-11-08 16:57:04 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Finn WF, Joy MS, Hladik G, Lanthanum Study Group</AU>
<TI>Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>3</NO>
<PG>193-201</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:06:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:06:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15481851"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-2006" MODIFIED="2010-11-08 17:19:09 +1100" MODIFIED_BY="Narelle S Willis" NAME="Fischer 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-08 17:19:09 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT</AU>
<TI>Results of a randomized crossover study comparing once daily and thrice-daily sevelamer dosing</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>48</VL>
<NO>3</NO>
<PG>437-44</PG>
<IDENTIFIERS MODIFIED="2010-11-08 17:19:09 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-08 17:19:09 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16931217"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FORESEE-Study-2008" MODIFIED="2011-01-17 10:54:32 +1100" MODIFIED_BY="Narelle S Willis" NAME="FORESEE Study 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-12-16 12:16:24 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, Fosrenol Overview Research Evaluation Study for Early Experience Study Group</AU>
<TI>Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1437-45</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:35:44 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:35:44 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18579668"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallieni-2005" MODIFIED="2010-10-03 14:07:56 +1100" MODIFIED_BY="Narelle S Willis" NAME="Gallieni 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-03 14:07:56 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallieni M, Cicchetti T, Salvadori M, Sorba G, Stalteri A, Tarchini R, et al</AU>
<TI>Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial - Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>746A</PG>
<IDENTIFIERS MODIFIED="2010-07-07 11:44:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-07-07 11:44:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583853"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hervas-2003" MODIFIED="2010-10-03 14:11:27 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hervas 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-10-03 14:11:27 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hervas JG, Prados D, Cerezo S</AU>
<TI>Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate</TI>
<SO>Kidney International - Supplement</SO>
<YR>2003</YR>
<NO>85</NO>
<PG>69-72</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:11:27 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:11:27 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12753270"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hutchison-2005" MODIFIED="2010-11-08 18:40:06 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hutchison 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-08 18:35:24 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, et al</AU>
<TI>Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus Calcium carbonate</TI>
<SO>Nephron</SO>
<YR>2005</YR>
<VL>100</VL>
<NO>1</NO>
<PG>c8-19</PG>
<IDENTIFIERS MODIFIED="2010-11-08 18:35:24 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-11-08 18:35:24 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15809508"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-03 14:15:01 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, et al</AU>
<TI>Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study</TI>
<SO>Nephron</SO>
<YR>2006</YR>
<VL>102</VL>
<NO>2</NO>
<PG>c61-71</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:15:01 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:15:01 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16224198"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoh-2008" MODIFIED="2010-10-03 14:16:48 +1100" MODIFIED_BY="Narelle S Willis" NAME="Itoh 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-03 14:16:48 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, et al</AU>
<TI>Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis</TI>
<SO>Therapeutic Apheresis &amp; Dialysis</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>2</NO>
<PG>126-32</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:16:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:16:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18387160"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ittel-1991" MODIFIED="2010-10-03 14:18:11 +1100" MODIFIED_BY="Narelle S Willis" NAME="Ittel 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-10-03 14:18:11 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ittel TH, Schfer C, Schmitt H, Gladziwa U, Sieberth HG</AU>
<TI>Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional Aluminium hydroxide on hyperaluminaemia</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1991</YR>
<VL>69</VL>
<NO>2</NO>
<PG>59-67</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:18:09 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:18:09 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2027271"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janssen-1996" MODIFIED="2010-10-03 14:19:58 +1100" MODIFIED_BY="Narelle S Willis" NAME="Janssen 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-10-03 14:19:58 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP</AU>
<TI>Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients</TI>
<SO>Clinical Nephrology</SO>
<YR>1996</YR>
<VL>45</VL>
<NO>2</NO>
<PG>111-9</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:19:58 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:19:58 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8846523"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jespersen-1991" MODIFIED="2010-10-03 14:21:44 +1100" MODIFIED_BY="Narelle S Willis" NAME="Jespersen 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-10-03 14:21:44 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jespersen B, Jensen JD, Nielsen HK, Lauridsen IN, Andersen MJ, Poulsen JH, et al</AU>
<TI>Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients</TI>
<SO>Nephology Dialysis Transplantation</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>2</NO>
<PG>98-104</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:21:44 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:21:44 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1857534"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joy-2003" MODIFIED="2010-12-08 17:01:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Joy 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-12-08 17:01:53 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joy MS, Finn WF, LAM-302 Study Group</AU>
<TI>Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>1</NO>
<PG>96-107</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:23:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:23:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12830461"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinugasa-2001" MODIFIED="2010-12-23 13:35:19 +1100" MODIFIED_BY="[Empty name]" NAME="Kinugasa 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 18:44:46 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinugasa E, Koshikawa S, PB-94 Study Group</AU>
<TI>Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients - a randomized, open label, dose titration study of PB-94 versus caltan® tablet 500 (calcium carbonate) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>755A</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:26:35 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:26:35 +1100" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00626049"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koiwa-2005a" MODIFIED="2010-10-03 15:35:07 +1100" MODIFIED_BY="Narelle S Willis" NAME="Koiwa 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-10-03 14:28:42 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, et al</AU>
<TI>Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan</TI>
<SO>Therapeutic Apheresis &amp; Dialysis</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>4</NO>
<PG>340-6</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:28:25 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:28:25 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16076379"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurihara-2005" MODIFIED="2010-10-03 14:31:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="Kurihara 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-03 14:31:41 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurihara S, Tsuruta Y, Akizawa T</AU>
<TI>Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>2</NO>
<PG>424-30</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:31:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:31:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15673691"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2010-07-07 12:00:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-07-07 12:00:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, et al</AU>
<TI>A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients</TI>
<SO>Renal Failure</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>8</NO>
<PG>701-7</PG>
<IDENTIFIERS MODIFIED="2010-07-07 12:00:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-07-07 12:00:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17162430"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malluche-2008" MODIFIED="2010-10-03 14:32:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Malluche 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-03 14:32:53 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, et al</AU>
<TI>Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years</TI>
<SO>Clinical Nephrology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>4</NO>
<PG>284-95</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:32:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:32:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18826853"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McIntyre-2009" MODIFIED="2010-12-08 17:02:22 +1100" MODIFIED_BY="Narelle S Willis" NAME="McIntyre 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-12-08 17:02:22 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ</AU>
<TI>Iron-magnesium hydroxycarbonate (Fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>2</NO>
<PG>401-9</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:34:23 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:34:23 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19158369"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pflanz-1994" MODIFIED="2010-10-03 14:37:18 +1100" MODIFIED_BY="Narelle S Willis" NAME="Pflanz 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-10-03 14:37:18 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pflanz S, Henderson IS, McElduff N, Jones MC</AU>
<TI>Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1121-4</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:37:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:37:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7800211"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phelps-2002" MODIFIED="2010-10-03 14:38:10 +1100" MODIFIED_BY="Narelle S Willis" NAME="Phelps 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-03 14:38:10 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phelps KR, Stern M, Slingerland A, Heravi M, Strogatz DS, Haqqie SS</AU>
<TI>Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure</TI>
<SO>American Journal of Nephrology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>5-6</NO>
<PG>445-54</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:38:10 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:38:10 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12381942"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ring-1993" MODIFIED="2010-10-03 14:41:13 +1100" MODIFIED_BY="Narelle S Willis" NAME="Ring 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-10-03 14:41:13 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ</AU>
<TI>Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>4</NO>
<PG>341-6</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:41:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:41:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8390009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roxe-1989" MODIFIED="2010-10-03 14:42:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="Roxe 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-10-03 14:42:05 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roxe DM, Mistovich M, Barch DH</AU>
<TI>Phosphate-binding effects of sucralfate in patients with chronic renal failure</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>3</NO>
<PG>194-9</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:42:05 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:42:05 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2919600"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudnicki-1994" MODIFIED="2010-10-03 14:45:02 +1100" MODIFIED_BY="Narelle S Willis" NAME="Rudnicki 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-10-03 14:45:02 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudnicki M, Hyldstrup L, Petersen LJ, Hojsted J, Tranbol I</AU>
<TI>Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double-blind placebo-controlled study</TI>
<SO>Mineral &amp; Electrolyte Metabolism</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>3</NO>
<PG>130-4</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:44:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:44:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7816001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russo-2007" MODIFIED="2010-10-03 14:46:13 +1100" MODIFIED_BY="Narelle S Willis" NAME="Russo 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-03 14:46:13 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, et al</AU>
<TI>The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer</TI>
<SO>Kidney International</SO>
<YR>2007</YR>
<VL>72</VL>
<NO>10</NO>
<PG>1255-61</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:46:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:46:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17805238"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sadek-2003" MODIFIED="2010-10-03 14:47:20 +1100" MODIFIED_BY="Narelle S Willis" NAME="Sadek 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-10-03 14:47:20 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sadek T, Mazouz H, Bahlou H, Oprisiu R, El Esper N, El Esper I, et al</AU>
<TI>Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients An open-label, randomized study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>3</NO>
<PG>582-9</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:47:20 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:47:20 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12584283"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saif-2007" MODIFIED="2010-10-03 14:48:18 +1100" MODIFIED_BY="Narelle S Willis" NAME="Saif 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-03 14:48:18 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saif I, Halim A, Altaf A, Saif M, Khalid M, Ahmad D, et al</AU>
<TI>Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis</TI>
<SO>Journal of Ayub Medical College, Abbottabad: JAMC</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>4</NO>
<PG>26-8</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:48:18 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:48:18 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18693591"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salusky-1991" MODIFIED="2010-10-03 14:49:25 +1100" MODIFIED_BY="Narelle S Willis" NAME="Salusky 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-10-03 14:49:25 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salusky IB, Foley J, Nelson P, Goodman WG</AU>
<TI>Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<NO>8</NO>
<PG>527-31</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:49:25 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:49:25 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1992306"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaefer-1991" MODIFIED="2010-10-03 14:52:11 +1100" MODIFIED_BY="Narelle S Willis" NAME="Schaefer 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-10-03 14:52:11 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D</AU>
<TI>The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>3</NO>
<PG>170-5</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:52:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:52:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1866045"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaheen-2004" MODIFIED="2010-10-03 14:53:16 +1100" MODIFIED_BY="Narelle S Willis" NAME="Shaheen 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-03 14:53:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaheen A, Akeel NM, Badawi LS, Souqiyyeh MZ</AU>
<TI>Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients</TI>
<SO>Saudi Medical Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>6</NO>
<PG>785-91</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:53:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:53:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15195212"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shigematsu-2008" MODIFIED="2010-12-23 13:44:26 +1100" MODIFIED_BY="[Empty name]" NAME="Shigematsu 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-03 14:54:32 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shigematsu T, Lanthanum Carbonate Group</AU>
<TI>Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia</TI>
<SO>Clinical Nephrology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>5</NO>
<PG>404-10</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:54:32 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:54:32 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19000540"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spasovski-2006" MODIFIED="2010-10-03 14:56:22 +1100" MODIFIED_BY="Narelle S Willis" NAME="Spasovski 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-03 14:56:22 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, et al</AU>
<TI>Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>8</NO>
<PG>2217-24</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:56:22 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:56:22 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16595583"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spiegel-2007" MODIFIED="2010-10-03 14:57:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="Spiegel 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-03 14:57:19 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spiegel DM, Farmer B, Smits G, Chonchol M</AU>
<TI>Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>6</NO>
<PG>416-22</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:57:19 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:57:19 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17971314"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sprague-2009a" MODIFIED="2010-10-03 14:58:23 +1100" MODIFIED_BY="Narelle S Willis" NAME="Sprague 2009a" YEAR="2009">
<REFERENCE MODIFIED="2010-10-03 14:58:23 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sprague SM, Abboud H, Qui P, Dauphin M, Zhang P, Finn W</AU>
<TI>Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>1</NO>
<PG>178-85</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:58:23 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:58:23 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19056618"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sprague-2009b" MODIFIED="2010-10-03 14:59:30 +1100" MODIFIED_BY="Narelle S Willis" NAME="Sprague 2009b" YEAR="2009">
<REFERENCE MODIFIED="2010-10-03 14:59:30 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R</AU>
<TI>Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study</TI>
<SO>Clinical Nephrology</SO>
<YR>2009</YR>
<VL>72</VL>
<NO>4</NO>
<PG>252-8</PG>
<IDENTIFIERS MODIFIED="2010-10-03 14:59:30 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 14:59:30 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19825330"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tzanakis-2008" MODIFIED="2010-10-03 14:59:50 +1100" MODIFIED_BY="Narelle S Willis" NAME="Tzanakis 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-03 14:59:50 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, et al</AU>
<TI>Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial</TI>
<SO>International Urology &amp; Nephrology</SO>
<YR>2008</YR>
<VL>40</VL>
<NO>1</NO>
<PG>193-201</PG>
<IDENTIFIERS MODIFIED="2010-07-07 11:50:02 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-07-07 11:50:02 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18193489"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2002" MODIFIED="2010-12-23 13:48:58 +1100" MODIFIED_BY="[Empty name]" NAME="Yang 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-03 15:01:24 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH</AU>
<TI>An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>2</NO>
<PG>265-70</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:00:46 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:00:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11812877"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES MODIFIED="2010-07-14 00:32:06 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-12-22 12:00:11 +1100" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_REFERENCES MODIFIED="2010-12-22 12:00:11 +1100" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Block-1998" MODIFIED="2009-12-06 08:26:23 +1100" MODIFIED_BY="[Empty name]" NAME="Block 1998" TYPE="JOURNAL_ARTICLE">
<AU>Block GA, Hulbert-Shearon TE, Levin NW, Port FK</AU>
<TI>Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic haemodialysis patients: a national study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>4</NO>
<PG>607-17</PG>
<IDENTIFIERS MODIFIED="2008-09-02 15:54:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="9531176"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Block-2004" MODIFIED="2010-12-08 17:03:37 +1100" MODIFIED_BY="Narelle S Willis" NAME="Block 2004" TYPE="JOURNAL_ARTICLE">
<AU>Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM</AU>
<TI>Mineral metabolism, mortality, and morbidity in maintenance haemodialysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>8</NO>
<PG>2208-18</PG>
<IDENTIFIERS MODIFIED="2008-09-02 15:54:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15284307"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burke-2003" MODIFIED="2008-09-02 15:54:25 +1000" MODIFIED_BY="[Empty name]" NAME="Burke 2003" TYPE="JOURNAL_ARTICLE">
<AU>Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM</AU>
<TI>Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients</TI>
<SO>Advances in Renal Replacement Therapy</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>2</NO>
<PG>133-45</PG>
<IDENTIFIERS MODIFIED="2008-09-02 15:54:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="12879374"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bushinsky-2006" MODIFIED="2010-10-03 15:12:13 +1100" MODIFIED_BY="Narelle S Willis" NAME="Bushinsky 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bushinsky DA</AU>
<TI>Phosphate binders: hold the calcium?</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>4</NO>
<PG>695-6</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:12:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:12:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17699274"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cozzolino-2005" MODIFIED="2008-09-02 15:54:25 +1000" MODIFIED_BY="[Empty name]" NAME="Cozzolino 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E</AU>
<TI>Pathogenesis of vascular calcification in chronic kidney disease</TI>
<SO>Kidney International</SO>
<YR>2005</YR>
<VL>68</VL>
<NO>2</NO>
<PG>429-36</PG>
<IDENTIFIERS MODIFIED="2008-09-02 15:54:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="16014020"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dersimonian-1986" MODIFIED="2010-10-03 15:14:09 +1100" MODIFIED_BY="Narelle S Willis" NAME="Dersimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:14:09 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:14:09 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3802833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elder-2006" MODIFIED="2010-10-03 15:15:17 +1100" MODIFIED_BY="Narelle S Willis" NAME="Elder 2006" TYPE="JOURNAL_ARTICLE">
<AU>Elder G, Faull R, Branley P, Hawley C. Caring for Australasians with Renal Impairment (CARI)</AU>
<TI>The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone.</TI>
<SO>Nephrology</SO>
<YR>2006</YR>
<VL>11 Suppl 1</VL>
<PG>230-61</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:15:17 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:15:17 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16684078"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fellstrom-2009" MODIFIED="2010-10-03 15:17:14 +1100" MODIFIED_BY="Narelle S Willis" NAME="Fellstrom 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al</AU>
<TI>Rosuvastatin and cardiovascular events in patients undergoing hemodialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>14</NO>
<PG>1395-407</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:17:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:17:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19332456"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Friedman-2006" MODIFIED="2010-10-03 15:18:21 +1100" MODIFIED_BY="Narelle S Willis" NAME="Friedman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Friedman EA</AU>
<TI>Calcium-based phosphate binders are appropriate in chronic renal failure</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>4</NO>
<PG>704-809</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:18:20 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:18:20 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17699276"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guerin-2001" MODIFIED="2008-09-02 15:54:25 +1000" MODIFIED_BY="[Empty name]" NAME="Guerin 2001" TYPE="JOURNAL_ARTICLE">
<AU>Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM</AU>
<TI>Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<NO>7</NO>
<PG>987-92</PG>
<IDENTIFIERS MODIFIED="2008-09-02 15:54:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="11181474"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gutierrez-2005" MODIFIED="2010-10-03 15:19:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="Gutierrez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al</AU>
<TI>Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>7</NO>
<PG>2205-15</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:19:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:19:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15917335"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-12-03 13:39:15 +1100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-12-08 17:13:09 +1100" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hurska-2008" MODIFIED="2010-10-03 15:20:55 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hurska 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hruska KA, Mathew S, Lund R, Qiu P, Pratt R</AU>
<TI>Hyperphosphatemia of chronic kidney disease</TI>
<SO>Kidney International</SO>
<YR>2008</YR>
<VL>74</VL>
<NO>2</NO>
<PG>148-57</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:20:55 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:20:55 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18449174"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hutchinson-2009" MODIFIED="2010-10-03 15:21:46 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hutchinson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hutchinson AJ</AU>
<TI>Oral phosphate binders</TI>
<SO>Kidney International</SO>
<YR>2009</YR>
<VL>75</VL>
<NO>9</NO>
<PG>906-14</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:21:46 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:21:46 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19279554"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jamal-2009" MODIFIED="2010-10-03 15:22:40 +1100" MODIFIED_BY="Narelle S Willis" NAME="Jamal 2009" TYPE="JOURNAL_ARTICLE">
<AU>Jamal SA, Fitchett D, Lok CE, Mendelssohn DC, Tsuyuki RT</AU>
<TI>The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>10</NO>
<PG>3168-74</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:22:40 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:22:40 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19622572"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-K_x002f_DOQI-2003" MODIFIED="2010-10-03 15:26:16 +1100" MODIFIED_BY="Narelle S Willis" NAME="K/DOQI 2003" TYPE="JOURNAL_ARTICLE">
<AU>National Kidney Foundation</AU>
<TI>K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>4 Suppl 3</NO>
<PG>70-7</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:26:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:26:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14520607"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDIGO-2009" MODIFIED="2010-10-03 15:32:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="KDIGO 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group</AU>
<TI>KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)</TI>
<SO>Kidney International - Supplement</SO>
<YR>209</YR>
<VL>76</VL>
<NO>113</NO>
<PG>S1-130</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:32:00 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:32:00 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19644521"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koiwa-2005b" MODIFIED="2010-10-03 15:34:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Koiwa 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, et al</AU>
<TI>Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients</TI>
<SO>Therapeutic Apheresis &amp; Dialysis</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>4</NO>
<PG>336-9</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:33:31 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:33:31 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16076378"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2010-12-08 17:09:49 +1100" MODIFIED_BY="Narelle S Willis" NAME="Lefebvre 2008" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manns-2004" MODIFIED="2008-09-02 15:54:25 +1000" MODIFIED_BY="[Empty name]" NAME="Manns 2004" TYPE="JOURNAL_ARTICLE">
<AU>Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M</AU>
<TI>A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>3</NO>
<PG>1239-47</PG>
<IDENTIFIERS MODIFIED="2008-09-02 15:54:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15327423"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manns-2007" MODIFIED="2010-10-03 15:36:06 +1100" MODIFIED_BY="Narelle S Willis" NAME="Manns 2007" TYPE="JOURNAL_ARTICLE">
<AU>Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M</AU>
<TI>Economic evaluation of sevelamer in patients with end-stage renal disease</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>10</NO>
<PG>2867-78</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:36:06 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:36:06 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17595182"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCullough-2009" MODIFIED="2010-10-03 15:36:48 +1100" MODIFIED_BY="Narelle S Willis" NAME="McCullough 2009" TYPE="JOURNAL_ARTICLE">
<AU>McCullough PA, Chinnaiyan M</AU>
<TI>Annual progression of coronary calcification in trials of preventive therapies: a systematic review</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>22</NO>
<PG>2064-70</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:36:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:36:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20008688"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moe-2006" MODIFIED="2010-10-03 15:37:35 +1100" MODIFIED_BY="Narelle S Willis" NAME="Moe 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moe SM, Chertown G</AU>
<TI>The case against calcium-based phosphate binders</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>4</NO>
<PG>697-703</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:37:35 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:37:35 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17699275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nagano-2006" MODIFIED="2010-10-03 15:38:27 +1100" MODIFIED_BY="Narelle S Willis" NAME="Nagano 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, et al</AU>
<TI>Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats</TI>
<SO>Kidney International</SO>
<YR>2006</YR>
<VL>69</VL>
<NO>3</NO>
<PG>531-7</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:38:27 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:38:27 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16395276"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2007" MODIFIED="2010-10-03 17:21:11 +1100" MODIFIED_BY="Narelle S Willis" NAME="Palmer 2007" TYPE="COCHRANE_REVIEW">
<AU>Palmer SC, McGregor DO, Strippoli GFM</AU>
<TI>Interventions for preventing bone disease in kidney transplant recipients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-10-03 17:20:48 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 17:20:48 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005015.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Qunibi-2008" MODIFIED="2010-10-03 15:41:38 +1100" MODIFIED_BY="Narelle S Willis" NAME="Qunibi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al</AU>
<TI>A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>6</NO>
<PG>952-8</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:41:36 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:41:36 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18423809"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Renal-Group-2010" MODIFIED="2010-12-08 17:15:18 +1100" MODIFIED_BY="Narelle S Willis" NAME="Renal Group 2010" TYPE="OTHER">
<AU>Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC</AU>
<TI>Cochrane Renal Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2010, Issue 12. Art. No.: RENAL</SO>
<YR>(accessed December 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salusky-2006" MODIFIED="2010-10-03 15:42:53 +1100" MODIFIED_BY="Narelle S Willis" NAME="Salusky 2006" TYPE="JOURNAL_ARTICLE">
<AU>Salusky IB</AU>
<TI>A new era in phosphate binder therapy: what are the options?</TI>
<SO>Kidney International - Supplement</SO>
<YR>2006</YR>
<VL>70</VL>
<NO>105</NO>
<PG>10-5</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:42:53 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:42:53 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17136110"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Silver-2005" MODIFIED="2010-10-03 15:44:31 +1100" MODIFIED_BY="Narelle S Willis" NAME="Silver 2005" TYPE="JOURNAL_ARTICLE">
<AU>Silver J, Levi R</AU>
<TI>Cellular and molecular mechanisms of secondary hyperparathyroidism</TI>
<SO>Clinical Nephrology</SO>
<YR>2005</YR>
<VL>63</VL>
<NO>2</NO>
<PG>119-26</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:44:31 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:44:31 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15730054"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Silver-2007" MODIFIED="2010-10-03 15:45:10 +1100" MODIFIED_BY="Narelle S Willis" NAME="Silver 2007" TYPE="JOURNAL_ARTICLE">
<AU>Silver J</AU>
<TI>The details bedevil DCOR</TI>
<SO>Kidney International</SO>
<YR>2007</YR>
<VL>72</VL>
<NO>9</NO>
<PG>1041-3</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:45:10 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:45:10 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17943149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-St-Peter-2008" MODIFIED="2010-10-03 15:49:32 +1100" MODIFIED_BY="Narelle S Willis" NAME="St Peter 2008" TYPE="JOURNAL_ARTICLE">
<AU>St Peter WL, Liu J, Weinhandl E, Fan Q</AU>
<TI>A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>3</NO>
<PG>445-54</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:47:30 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:47:30 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18295060"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-St-Peter-2009" MODIFIED="2010-10-03 15:49:19 +1100" MODIFIED_BY="Narelle S Willis" NAME="St Peter 2009" TYPE="JOURNAL_ARTICLE">
<AU>St Peter W, Fan Q, Weinhandl E, Liu J</AU>
<TI>Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>12</NO>
<PG>1954-61</PG>
<IDENTIFIERS MODIFIED="2010-10-03 15:49:08 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 15:49:08 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19833904"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stevens-2004" MODIFIED="2010-12-08 17:04:34 +1100" MODIFIED_BY="Narelle S Willis" NAME="Stevens 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A</AU>
<TI>Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>3</NO>
<PG>770-9</PG>
<IDENTIFIERS MODIFIED="2008-09-02 15:54:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="14978180"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2005" MODIFIED="2010-10-03 16:24:11 +1100" MODIFIED_BY="Narelle S Willis" NAME="Strippoli 2005" TYPE="JOURNAL_ARTICLE">
<AU>Strippoli GF, Craig JC</AU>
<TI>Hypothesis versus association: the optimal hemoglobin target debate</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>5</NO>
<PG>970-3</PG>
<IDENTIFIERS MODIFIED="2010-10-03 16:24:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 16:24:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16253741"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2007" MODIFIED="2010-10-03 16:24:59 +1100" MODIFIED_BY="Narelle S Willis" NAME="Strippoli 2007" TYPE="JOURNAL_ARTICLE">
<AU>Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC</AU>
<TI>Haemoglobin targets: we were wrong, time to move on</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<NO>9559</NO>
<PG>346-50</PG>
<IDENTIFIERS MODIFIED="2010-10-03 16:24:59 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 16:24:59 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17276756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strippoli-2009" MODIFIED="2010-10-03 16:25:40 +1100" MODIFIED_BY="Narelle S Willis" NAME="Strippoli 2009" TYPE="JOURNAL_ARTICLE">
<AU>Strippoli GF, Craig JC</AU>
<TI>Sunset for statins after AURORA?</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>14</NO>
<PG>1455-7</PG>
<IDENTIFIERS MODIFIED="2010-10-03 16:25:40 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 16:25:40 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19332454"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2008" MODIFIED="2010-10-03 16:26:29 +1100" MODIFIED_BY="Narelle S Willis" NAME="Taylor 2008" TYPE="JOURNAL_ARTICLE">
<AU>Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA</AU>
<TI>An economic evaluation of sevelamer in patients new to dialysis</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>2</NO>
<PG>601-8</PG>
<IDENTIFIERS MODIFIED="2010-10-03 16:26:27 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 16:26:27 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18205996"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tentori-2008" MODIFIED="2010-10-03 16:27:20 +1100" MODIFIED_BY="Narelle S Willis" NAME="Tentori 2008" TYPE="JOURNAL_ARTICLE">
<AU>Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J</AU>
<TI>Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2008</YR>
<VL>52</VL>
<NO>3</NO>
<PG>519-30</PG>
<IDENTIFIERS MODIFIED="2010-10-03 16:27:20 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 16:27:20 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18514987"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tonelli-2007" MODIFIED="2010-10-03 16:28:13 +1100" MODIFIED_BY="Narelle S Willis" NAME="Tonelli 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, et al</AU>
<TI>Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>10</NO>
<PG>2856-66</PG>
<IDENTIFIERS MODIFIED="2010-10-03 16:28:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 16:28:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17906326"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-USRDS-2009" MODIFIED="2010-10-03 16:30:38 +1100" MODIFIED_BY="Narelle S Willis" NAME="USRDS 2009" TYPE="OTHER">
<AU>United States Renal Data System (USRDS)</AU>
<TI>Costs of ESRD</TI>
<SO>http://www.usrds.org/2009/pdf/V2_11_09.pdf</SO>
<YR>(accessed October 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-10-03 16:33:54 +1100" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Navaneethan-2006" MODIFIED="2010-10-03 16:33:54 +1100" MODIFIED_BY="Narelle S Willis" NAME="Navaneethan 2006" TYPE="COCHRANE_PROTOCOL">
<AU>Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder G, Strippoli GFM</AU>
<TI>Phosphate binders for preventing and treating bone disease in chronic kidney disease patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-10-03 16:33:32 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-10-03 16:33:32 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD006023"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-12-22 11:44:52 +1100" MODIFIED_BY="Narelle S Willis"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-12-22 11:56:00 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Al_x002d_Baaj-2005">
<CHAR_METHODS MODIFIED="2010-11-06 12:41:30 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 23</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:36:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>&gt;18 years; HD or CAPD for &gt; 6 months, including those who had undergone a kidney transplant</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 17</LI>
<LI>placebo: 19</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>lanthanum: 57 years (± 17)</LI>
<LI>placebo: 53.3 years (± 16)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>lanthanum: 10/7</LI>
<LI>placebo: 10/9</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Hypercalcaemia; severe hyperparathyroidism; serum phosphorus &gt; 3 mg/dL after the washout phase; other clinically significant abnormal laboratory values; positive pregnancy test; significant GI disorder (including known active peptic ulcer, Crohn's disease, ulcerative colitis, irritable bowel syndrome and past or present malignancies); unstable dietary habits; life-threatening malignancy or HIV-status; history of drug or alcohol abuse</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:56:00 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>375 to 2250 mg/d</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Oral or IV vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-04 17:38:08 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:04 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Almirall-1994">
<CHAR_METHODS MODIFIED="2010-11-06 13:31:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 weeks</LI>
<LI>Lost to follow-up: 3</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:23:15 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Spain</LI>
<LI>Setting: hospital</LI>
<LI>Chronic HD for 54 ± 38 months (3 times/week)</LI>
<LI>Number: 7/10 completed study</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-04 17:46:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium acetate group</P>
<UL>
<LI>3.8 g/d</LI>
</UL>
<P>Calcium carbonate group</P>
<UL>
<LI>4 g/d</LI>
</UL>
<P>Co-interventions: Oral calcitriol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:56:16 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Birck-1999">
<CHAR_METHODS MODIFIED="2010-11-06 13:38:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 weeks</LI>
<LI>Lost to follow-up: 4</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:56:16 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Germany</LI>
<LI>Setting: multicentre</LI>
<LI>HD for at least 12 months; hyperphosphataemia after withdrawal of phosphate-binding agents; known adherence to therapy; iPTH smaller than the 10-fold upper normal level</LI>
<LI>Number: 28</LI>
<LI>Mean age (range): 61 years (37 to 87)</LI>
<LI>Sex (M/F): 18/10</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-04 18:03:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Group 1</P>
<UL>
<LI>Calcium ketoglutarate and then calcium carbonate to achieve serum phosphorus &lt; 5.3 mg/dL</LI>
</UL>
<P>Group 2</P>
<UL>
<LI>Calcium carbonate and then calcium ketoglutarate to achieve serum phosphorus &lt; 5.3 mg/dL</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-04 18:03:55 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:47:57 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bleyer-1999">
<CHAR_METHODS MODIFIED="2010-11-06 13:28:09 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: July 1996 to February 1997</LI>
<LI>Follow-up period: 16 weeks</LI>
<LI>Lost to follow-up: 4</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:37:59 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>&gt; 18 years; HD patients on stable doses of calcium or aluminium-based phosphate binders and on stable doses or no calcitriol for 1 month</LI>
<LI>Number: 80</LI>
<LI>Mean age (± SD): 54.5 years (± 15)</LI>
<LI>Sex: 53% male</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:47:57 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride 2 to 4 capsules 3 times/day to achieve serum phosphorus 2.5 to 5.5 mg/dL</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium acetate 1 to 3 capsules 3 times/day to achieve serum phosphorus 2.5 to 5.5 mg/dL</LI>
</UL>
<P>Co-interventions: Calcitriol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:05 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
<LI>Lipid profile</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:01:14 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Block-2005">
<CHAR_METHODS MODIFIED="2010-11-08 14:48:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT, stratified by DM</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 18 months</LI>
<LI>Lost to follow-up: 39</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:38:01 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>&gt;18 years; new to HD patients</LI>
<LI>Number</LI>
<UL>
<LI>calcium: 55</LI>
<LI>sevelamer: 54</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>calcium: 59 years (± 15)</LI>
<LI>sevelamer: 57 years (± 15)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>calcium: 36/9</LI>
<LI>sevelamer: 31/22</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Prior history of dialysis; kidney transplant; coronary artery bypass surgery; weight &gt; 300 pounds; current atrial fibrillation or atrial flutter</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-08 16:01:06 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium-containing phosphate binders</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 14:19:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Outcomes for <LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>
</LI>
<UL>
<LI>CAC score</LI>
</UL>
<LI>Outcomes for <B>Block 2007</B>
</LI>
<UL>
<LI>All-cause mortality</LI>
<LI>Progression of CAC score</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-08 16:01:14 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>"Investigators were free to alter phosphate binder dose and, within the calcium treatment arm, to alternate between various types of calcium containing phosphate binders at their discretion. Patients randomised to sevelamer were allowed to take calcium as a nightly supplement at the discretion of the investigator."</LI>
<LI>"The dialysate calcium concentration was maintained at 2.5 mEq/L throughout the study period. No estimate of patient adherence (pill count) was performed, and no patient received calcimimetic agents during the course of the clinical trial."</LI>
<LI>
<B>Block 2007</B>
</LI>
<UL>
<LI>This was a follow-up study</LI>
<LI>Follow-up period: 44 months</LI>
</UL>
</UL>
<UL>
<LI>Study supported by Genzyme Corp.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:56:36 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Borrego-2000">
<CHAR_METHODS MODIFIED="2010-11-06 13:07:41 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 months</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:56:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Brazil</LI>
<LI>Setting: hospital</LI>
<LI>CKD with CrCl &lt; 21 mL/min; serum phosphorus &gt; 5 mg/dL</LI>
<LI>Number</LI>
<UL>
<LI>calcium carbonate: 14</LI>
<LI>calcium acetate: 14</LI>
</UL>
<LI>Age (range)</LI>
<UL>
<LI>calcium carbonate: 55 years (23 to 76)</LI>
<LI>calcium acetate: 63 years (23 to 90)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>calcium carbonate: 5/9</LI>
<LI>calcium acetate: 7/7</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>DKD; treatment with vitamin D analogues; serum calcium &gt; 10.5 mg/dL</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-06 13:20:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium carbonate group</P>
<UL>
<LI>2.5 g/day</LI>
</UL>
<P>Calcium acetate group</P>
<UL>
<LI>1g/day</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 13:21:02 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
<LI>CrCl</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-BRiC-Study-2008">
<CHAR_METHODS MODIFIED="2010-11-06 12:41:39 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Lost to follow-up: 30</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-08 16:00:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Brazil</LI>
<LI>Setting: multicentre</LI>
<LI>On maintenance HD for at least 3 months</LI>
<LI>Number</LI>
<UL>
<LI>calcium: 49</LI>
<LI>sevelamer: 52</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>calcium: 47 years (± 14)</LI>
<LI>sevelamer: 47 years (± 13)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>calcium: 21/9</LI>
<LI>sevelamer: 27/14</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>GI disease; ethanol or drug abuse; active malignancy; HIV infection; chronic inflammatory disease; current use of steroids; severe hyperparathyroidism; body weight &gt; 100 kg; continuous use of antiarrhythmic or seizure drugs; pregnancy or breast-feeding; previous myocardial revascularization; uncontrolled DM or hypertension</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 23:10:19 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium acetate adjusted monthly up to 2.028 mg of elemental calcium daily</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride adjusted monthly up to 12 mg daily</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Outcomes reported in <LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>
</LI>
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum i-Ca level</LI>
<LI>iPTH</LI>
<LI>Histomorphometric data from bone biopsies</LI>
<LI>Vascular calcification</LI>
</UL>
<LI>Outcomes reported in <B>Peres 2009</B>
</LI>
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
<LI>Ca x P product</LI>
<LI>Serum albumin</LI>
<LI>Total cholesterol</LI>
<LI>Markers of inflammation: CRP, TNF-alpha, IL-10</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 15:37:08 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Data about age and sex are reported for 30 and 41 participants (calcium acetate and sevelamer respectively)</LI>
<LI>
<B>Peres 2009</B>
</LI>
<UL>
<LI>This is a substudy. Data relating to total cholesterol only was used for analysis.</LI>
</UL>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:56:42 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bro-1998">
<CHAR_METHODS MODIFIED="2010-11-06 13:44:34 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: 9</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:56:42 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Denmark</LI>
<LI>Setting: hospital</LI>
<LI>&gt;18 years; HD treatment for at least 1 month; stable protein and energy intake; treatment with a dialysate calcium concentration of 1.25 mmol/L; stable dosage of alfacalcidol for the last 2 months</LI>
<LI>Number: 19 enrolled, 10 completed study</LI>
<LI>Median age (range): 54 years (25 to 80)</LI>
<LI>Sex(M/F): 12/7 (completed study: NS)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Pregnancy or lactation; mental retardation or dementia; psychiatric illness; recent infection or surgical trauma within 3 months; insufficient dialysis (Kt/V &lt; 1.2); malignancies; immobilization; prior parathyroidectomy and tertiary hyperparathyroidism</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-08 16:02:56 +1100" MODIFIED_BY="Narelle S Willis">
<P>Group 1</P>
<UL>
<LI>Calcium ketoglutarate and then calcium carbonate to achieve serum phosphorus &lt; 5.3 mg/dL</LI>
</UL>
<P>Group 2</P>
<UL>
<LI>Calcium carbonate and then calcium ketoglutarate to achieve serum phosphorus &lt; 5.3 mg/dL</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Oral alfacalcidol</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 13:49:51 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 13:53:59 +1100" MODIFIED_BY="Narelle S Willis">
<P>Study received financial support from the Danish Kidney Foundation and Leo Pharmaceuticals, Ballerup, Denmark. Calcium ketoglutarate was kindly provided by Gambro Medicoteknik A/S, Vallensbaek, Denmark.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:56:50 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Caravaca-1992">
<CHAR_METHODS MODIFIED="2010-11-06 14:01:08 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 16 weeks</LI>
<LI>Lost to follow-up: 14</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:56:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Spain</LI>
<LI>Setting: hospital</LI>
<LI>Chronic HD treatment for 2 to 175 months; CrCl &lt; 1 mL/min; treatment with aluminium hydroxide</LI>
<LI>Number</LI>
<UL>
<LI>calcium acetate: 31</LI>
<LI>calcium carbonate: 35</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>calcium acetate: 51 years (± 10)</LI>
<LI>calcium carbonate: 45 years (± 16)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>calcium acetate: 20/11</LI>
<LI>calcium carbonate: 17/16</LI>
</UL>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-06 14:04:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium acetate group</P>
<UL>
<LI>6.5 g/day</LI>
</UL>
<P>Calcium carbonate group</P>
<UL>
<LI>3.75 g/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 14:04:30 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:56:59 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-CARE-Study-2004">
<CHAR_METHODS MODIFIED="2010-11-22 21:53:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8</LI>
<LI>Lost to follow-up: 2</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:32:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (6 outpatient clinics at 2 centres)</LI>
<LI>HD for at least 3 months; receiving a stable dose of phosphate binder and IV vitamin D for at least 1 month</LI>
<LI>Number</LI>
<UL>
<LI>sevelamer: 50</LI>
<LI>calcium): 48</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>sevelamer: 52.3 years (± 14.7)</LI>
<LI>calcium: 53.9 years (± 13.3)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>sevelamer: 28/22</LI>
<LI>calcium: 28/20</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>iPTH &gt; 1000 pg/mL; history of previous parathyroidectomy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:56:59 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride: 2 to 4 capsules (403 mg) 3 times/day to achieve serum phosphorus &lt; 5.5 mg/dL</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium acetate: 2 to 4 capsules (667 mg) 3 times/day to achieve serum phosphorus &lt; 5.5 mg/dL</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>IV vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:06 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 19:03:36 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-CARE_x002d_2-Study-2008">
<CHAR_METHODS MODIFIED="2010-11-06 14:10:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: January 2005 to November 2005</LI>
<LI>Follow-up period: 52 weeks</LI>
<LI>Lost to follow-up: 2</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-01 19:03:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: 26 dialysis centres</LI>
<LI>ESKD; &#8805;18 years; HD for 3 months to 5 years</LI>
<LI>Number</LI>
<UL>
<LI>calcium: 103</LI>
<LI>sevelamer: 100</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>calcium: 58.5 years (± 12.8)</LI>
<LI>sevelamer: 60.3 years (± 12.1)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>calcium: 61/42</LI>
<LI>sevelamer: 46/54</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Condition that could restrict survival of participants for the duration of the study or interfere with their ability to follow the study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-06 16:51:18 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium acetate to achieve a phosphorus level of 3.5 to 5.5 mg/dL and LDL &lt; 70</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride to achieve a phosphorus level of 3.5 to 5.5 mg/dL and LDL &lt; 70</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 14:19:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in CAC score assessed by means of electron-beam computed tomography</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 14:20:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>This study was supported by a grant from Fresenius Medical Care North America, Waltham, MA.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:07 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Cheng-2008">
<CHAR_METHODS MODIFIED="2010-11-06 14:32:17 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: placebo-controlled, crossover RCT</LI>
<LI>Time frame: February 2006 to December 2006</LI>
<LI>Follow-up period: 16 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:33:57 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Inclusion criteria</LI>
<LI>Country: USA</LI>
<LI>Setting: 2 dialysis units</LI>
<LI>&#8805;18 years; capacity for informed consent; long term HD &gt; 90 days; stable dosage of phosphorus binders during the previous 2-week period; serum phosphorus level &gt; 5.0 mg/dL</LI>
<LI>Number: 33</LI>
<LI>Age: 52.6 years</LI>
<LI>Sex (M/F): 23/10</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Pregnancy; history of liver disease; active peptic ulcer disease; treatment with carbamazepine; niacin therapy; more than one missed HD session in the past 30 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-06 14:37:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Niacinamide</P>
<UL>
<LI>250 mg twice daily increased to 500 mg twice daily at week 3 and 750 mg twice daily at week 5</LI>
</UL>
<P>Placebo</P>
<UL>
<LI>250 mg twice daily increased to 500 mg twice daily at week 3 and 750 mg twice daily at week 5</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Phosphorus binders, vitamin D, paracalcitol, cinacalcet</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:07 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
<LI>Uric acid levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 14:39:18 +1100" MODIFIED_BY="Narelle S Willis">
<P>One author "received support for this study through the Amgen Fellowship Support Stipend during the 2006 to 2007 academic year"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:57:21 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chertow-1997">
<CHAR_METHODS MODIFIED="2010-11-06 16:04:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:57:21 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>&gt; 18 years; thrice weekly HD for at least 3 months; administration of calcium-based phosphate binders with or without vitamin D or vitamin D metabolite replacement therapy at stable doses for at least 1 month before screening</LI>
<LI>Number</LI>
<UL>
<LI>sevelamer: 24</LI>
<LI>placebo: 12</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>sevelamer: 58.8 years (± 17.1)</LI>
<LI>placebo: 53.7 years (± 13.9)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>sevelamer: 13/11</LI>
<LI>placebo: 10/2</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Unstable medical condition; including poorly controlled DM or hypertension, or any GI abnormality</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-06 16:51:31 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride: mean 7.2 capsules/day</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>IV or oral vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 16:11:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Lipid profile</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 16:12:02 +1100" MODIFIED_BY="Narelle S Willis">
<P>Supported by a grant from GelTex Pharmaceuticals, Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:48:50 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chertow-1999">
<CHAR_METHODS MODIFIED="2010-11-06 16:42:19 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: 16</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-08 16:07:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>&gt; 18 years; thrice weekly HD for at least three months; regular administration of calcium- and/or aluminium-based phosphate binders, with or without vitamin D metabolite replacement therapy at stable doses for at least one month before screening</LI>
<LI>Number</LI>
<UL>
<LI>sevelamer: 35</LI>
<LI>sevelamer + calcium: 36</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>sevelamer: 55.9 years (± 14.1)</LI>
<LI>sevelamer + calcium: 60.7 years (± 15.0)</LI>
</UL>
<LI>Sex(M/F)</LI>
<UL>
<LI>sevelamer: 10/25</LI>
<LI>sevelamer + calcium: 14/22</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Total parathyroidectomy; serious GI disease (including dysphagia, vomiting, motility disorder, major intestinal surgery, markedly irregular bowel function); ethanol or drug dependence or abuse; active malignancy; HIV infection; vasculitis; poorly controlled DM or hypertension</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:48:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride 2 to 4 capsules (465 mg) 3 times/day to achieve serum phosphorus 2.5 to 5.5 mg/dL</LI>
</UL>
<P>Sevelamer + calcium carbonate group</P>
<UL>
<LI>Sevelamer hydrochloride 2 to 4 capsules (465 mg) 3 times/day + calcium carbonate 900 mg/day to achieve serum phosphorus 2.5 to 5.5 mg/dL</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>IV or oral vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:08 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
<LI>Lipid profile</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:07:11 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chertow-2002">
<CHAR_METHODS MODIFIED="2010-11-08 12:04:26 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: May 1999 to January 2001</LI>
<LI>Follow-up period: 52 weeks</LI>
<LI>Lost to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:40:21 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Countries: USA, Germany, Austria</LI>
<LI>Setting: Dialysis centres; USA (15), Germany (7), Austria (1)</LI>
<LI>&lt; 19 years; HD patients</LI>
<LI>Number</LI>
<UL>
<LI>sevelamer: 99</LI>
<LI>calcium: 101</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>sevelamer: 57 years (± 14)</LI>
<LI>calcium: 56 years (± 16)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>sevelamer: 36/63</LI>
<LI>calcium: 34/67</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Serious GI disease (dysphagia, active untreated gastroparesis, severe motility disorder, major intestinal surgery, markedly irregular bowel function); ethanol or drug dependence or abuse; active malignancy; HIV infection; vasculitis; poorly controlled DM or hypertension</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-08 12:03:46 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride, dose to achieve serum phosphorus of 3 to 5 mg/dL and serum calcium 8.5 to 10.5 mg/dL</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium acetate/carbonate, dose to achieve serum phosphorus level of 3 to 5 mg/dL and serum calcium level of 8.5 to 10.5mg/dL</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>IV or oral vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 16:07:11 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Outcomes reported in <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>
</LI>
<UL>
<LI>Serum phosphorus, calcium, iPTH, lipid profile</LI>
<LI>Cardiovascular calcification</LI>
<LI>Changes in calcification score</LI>
</UL>
<LI>Outcomes reported in <B>Asmus 2005</B> (N = 72)</LI>
<UL>
<LI>Hypercalcaemic episodes</LI>
<LI>Ca x P product</LI>
<LI>iPTH serum concentration</LI>
<LI>Increases in CAC score</LI>
<LI>Increases in aortic calcification score</LI>
<LI>Trabecular bone density</LI>
<LI>Cortical bone density</LI>
</UL>
<LI>Outcomes reported in <B>Ferramosca 2005</B> (N = 108)</LI>
<UL>
<LI>Changes in CAC score</LI>
<LI>Changes in lipids and markers of inflammation</LI>
</UL>
<LI>Outcomes reported in <B>Raggi 2005</B> (N = 111)</LI>
<UL>
<LI>Serum phosphorus, calcium, iPTH, Ca x P product</LI>
<LI>Changes in bone attenuation</LI>
<LI>Markers of bone turnover</LI>
<LI>Change in coronary artery and aortic calcification</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 15:37:44 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>
<B>Asmus 2005</B>
</LI>
<UL>
<LI>114 participants were randomised, but data about allocation, age, and sex are reported for only 72 participants</LI>
<LI>This was a secondary analysis</LI>
<LI>Follow-up period: 24 months</LI>
</UL>
<LI>
<B>Ferramosca 2005</B>
</LI>
<UL>
<LI>This was a secondary analysis</LI>
</UL>
<LI>
<B>Raggi 2005</B>
</LI>
<UL>
<LI>This was a secondary analysis</LI>
</UL>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:49:04 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chiang-2005">
<CHAR_METHODS MODIFIED="2010-11-08 13:46:09 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 4 weeks</LI>
<LI>Lost to follow-up: 31</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:42:10 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Taiwan</LI>
<LI>Setting: multicentre</LI>
<LI>&gt; 20 years; HD 3 times/week for a minimum of 2 consecutive months</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 30</LI>
<LI>placebo: 31</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>lanthanum: 53.6 years (± 11.2)</LI>
<LI>placebo: 51.7 years (± 9.4)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>lanthanum: 16/14</LI>
<LI>placebo: 14/17</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>GI surgery or disorder such as Crohn's disease or peptic ulcers; hyperparathyroidism</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:49:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum 375 to 3000 mg/day</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>iPTH</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 15:40:47 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-d_x0027_Almeida-Filho-2000">
<CHAR_METHODS MODIFIED="2010-11-08 16:49:00 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 4 weeks</LI>
<LI>Lost to follow-up: 29</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:40:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Brazil</LI>
<LI>Setting: private hospital dialysis centre</LI>
<LI>HD, 3 times/week (Ca dialysate 3.5 mEq/L)</LI>
<LI>Number: 52 enrolled, 23 completed study</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Parathyroidectomy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 20:33:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>Group 1</P>
<UL>
<LI>Calcium acetate 5.6 g/day and then calcium carbonate 6.2 g/day</LI>
</UL>
<P>Group 2</P>
<UL>
<LI>Calcium carbonate 6.2 g/day and then calcium acetate 5.6 g/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-08 16:51:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Kt/V</LI>
<LI>Serum bicarbonate</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 15:37:54 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-D_x0027_Haese-2003">
<CHAR_METHODS MODIFIED="2010-11-08 14:03:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year</LI>
<LI>Lost to follow-up: 30</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:37:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Countries: Belgium, Czech Republic, Italy, Macedonia, Poland, Portugal, South Africa, Tenerife, Yugoslavia, UK, USA</LI>
<LI>Setting: international multicentre study (18 centres)</LI>
<LI>&gt; 18 years; HD or CAPD within 12 weeks; people who had been diagnosed with CKD and were scheduled to begin dialysis</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 49 enrolled, 34 completed study</LI>
<LI>calcium: 49 enrolled; 34 completed study</LI>
</UL>
<LI>Mean age (± SD): 55 years (± 14.3)</LI>
<LI>Sex (M/F): 59/39</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Hypocalcaemia or concurrent illness</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-08 14:08:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum up to 3750 mg/day</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate up to 9000 mg/day</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Oral or IV vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-08 14:08:55 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>iPTH</LI>
<LI>Markers of bone turnover</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:07:23 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-DCOR-Study-2007">
<CHAR_METHODS MODIFIED="2010-11-08 14:32:08 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: March 2001 to December 2004</LI>
<LI>Follow-up period: 20.3 ± 13.9 months (sevelamer); 19.6 ± 13.6 months (calcium)</LI>
<LI>Lost to follow-up: 207</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-08 16:07:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: 75 Fresenius dialysis centres</LI>
<LI>&gt; 18 years; patients on dialysis for more than 3 months required phosphate binders therapy</LI>
<LI>Number</LI>
<UL>
<LI>calcium: 1050</LI>
<LI>sevelamer: 1053</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>calcium: 60.1 years (± 15.2)</LI>
<LI>sevelamer: 59.9 years (± 14.3)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>calcium: 569/481</LI>
<LI>sevelamer: 574/479</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Dysphagia/swallowing disorders; severe GI motility disorders; bowel obstruction</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-02 17:43:35 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium-based binders: calcium acetate (mean 5.3 g); calcium carbonate (mean 4.9 g)</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride 6.9 g daily (mean)</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-08 14:37:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>Cause-specific mortality: myocardial infarction, pericarditis, atherosclerotic heart disease, cardiomyopathy, cardiac arrhythmia, cardiac arrest, valvular heart disease, pulmonary oedema, cerebrovascular accident, ischaemic brain damage/anoxic encephalopathy</LI>
<LI>Hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-04 19:33:36 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:49:23 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-De-Santo-2006">
<CHAR_METHODS MODIFIED="2010-11-08 14:47:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT with crossover to second treatment at 24 weeks</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:49:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: hospital</LI>
<LI>Excellent albumin levels and blood pressure; stable haemodynamic condition</LI>
<LI>Number</LI>
<UL>
<LI>calcium: 8</LI>
<LI>sevelamer: 8</LI>
</UL>
<LI>Age range: 36 to 50 years</LI>
<LI>Sex (M/F): All male</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>DM; severe osteitis fibrosa; use of corticosteroids; phosphorus levels &lt; 5.5 mg/dL; not requiring phosphate binders; iPTH &gt; 400 pg/mL; non-compliant; ethanol or drugs dependence; HIV infection; vasculitis; active malignancy; severe GI disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 15:39:08 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate to achieve a phosphorus level of 5.5 mg/dL and calcium concentrations in the range of 8.5 to 10.5 mg/dL for 24 weeks</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride: based on manufacturer's instructions</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>After 24 weeks participants were crossed to the other treatment</LI>
<LI>Vitamin D</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-08 14:55:42 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Time course of plasma bicarbonate concentration</LI>
<LI>Time course of serum albumin concentration</LI>
<LI>Time course of iPTH concentration</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-30 01:22:55 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 15:39:25 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Deuber-2003a">
<CHAR_METHODS MODIFIED="2010-11-08 14:59:06 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 30 months</LI>
<LI>Lost to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:39:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Germany</LI>
<LI>Setting: dialysis centre</LI>
<LI>HD for at least 15 ± 6 months; had been on a constant doses of calcium carbonate for 12 months</LI>
<LI>Number</LI>
<UL>
<LI>calcium carbonate: 27</LI>
<LI>calcium acetate: 23</LI>
</UL>
<LI>Mean age (± SD): 62 years (± 11.7)</LI>
<LI>Sex (M/F): 23/27</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-08 15:02:16 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium carbonate group</P>
<UL>
<LI>500 mg calcium carbonate/tablet</LI>
</UL>
<P>Calcium acetate + magnesium carbonate<SUP> </SUP>group</P>
<UL>
<LI>435 mg calcium acetate + 235 mg magnesium carbonate/tablet</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-08 15:02:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Serum magnesium</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-08 14:58:34 +1100" MODIFIED_BY="Narelle S Willis">
<P>Conference abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:07:25 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Emmett-1991">
<CHAR_METHODS MODIFIED="2010-11-08 15:38:42 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: 16</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:45:09 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: 4 centres in Texas</LI>
<LI>HD 3 times/week; treatment with phosphorus-binding drugs to reduce serum phosphorus</LI>
<LI>Number: 69</LI>
<LI>Age: 55.5 years</LI>
<LI>Sex (M/F): 38/31</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Pregnant (or intending to become pregnant); mentally unstable; unable to comply with the study protocol; persistent hypercalcaemia (&gt; 11 mg/dL)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-08 15:38:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium acetate: dose to achieve serum phosphorus of 4.5 to 5.5 mg/dL</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Oral or IV vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:11 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-08 16:07:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>Study supported by a grant from Baintree Laboratories, Baintree MA, and the Renal Research and Education Fund, Baylor University Medical centre, Dallas TX</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:49:36 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Evenepoel-2009">
<CHAR_METHODS MODIFIED="2010-11-08 15:49:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 13 weeks</LI>
<LI>Lost to follow-up: 0 (39 dropped out)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:49:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Belgium, Denmark, France, Italy, Spain, Netherlands</LI>
<LI>Setting: multicentre (15 sites)</LI>
<LI>&gt; 18 years; stable PD for &gt; 8 weeks; serum phosphorus &gt; 5.5 mg/dL and serum calcium within the normal range (8.4 to 10.4 mg/dL); compliant with dialysis and phosphate binder therapy</LI>
<LI>Number</LI>
<UL>
<LI>sevelamer: 97</LI>
<LI>calcium: 46</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>sevelamer: 54.6 years (± 15.7)</LI>
<LI>calcium: 54.1 years (± 15.8)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>sevelamer: 65/32</LI>
<LI>calcium: 28/18</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>History of peritonitis, dysphagia, bowel obstruction or severe GI motility disorder; unstable concurrent clinical condition; use of anti-arrhythmic or anti seizure medications for the control of these disorders; alcohol or drug abuse; hypersensitivity to sevelamer or hydrochloride</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-08 15:55:10 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride: starting dose 1600 mg, 3 times/day titrated as necessary to achieve a target serum phosphorus of 3.0 to 5.5 mg/dL</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate: starting dose 538 mg, 3 times/day titrated as necessary to achieve a target serum phosphorus of 3.0 to 5.5 mg/dL</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-08 15:46:50 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Changes in serum phosphorus, calcium, iPTH</LI>
<LI>Changes in lipids and plasma biomarkers</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-08 15:46:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>P.E. has received speakers&#8217; honoraria from Genzyme Corporation. A.O. has received an honorarium from Genzyme Corporation. A.K., S.C. and A.D. are employees of Genzyme Corporation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:50:05 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Fan-2009">
<CHAR_METHODS MODIFIED="2010-11-08 16:02:34 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:39:44 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: UK</LI>
<LI>Setting: multicentre</LI>
<LI>HD for 3 months or more; &#8805;18 years; maintained on sevelamer hydrochloride alone or in combination with other binders; serum phosphorus level &#8805;1.76 mmol/L after phosphate binders washout; iPTH &#8804; 800 ng/L; serum calcium level within the normal range</LI>
<LI>Number</LI>
<UL>
<LI>powder: 17</LI>
<LI>tablets: 14</LI>
</UL>
<LI>Mean age (± SD): 52.9 years ± (13.2)</LI>
<LI>Sex (M/F): 21/10</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Severe GI motility disorder; poorly controlled DM; hypertension; any other clinically significant unstable medical condition</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:50:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Powder group</P>
<UL>
<LI>Sevelamer carbonate powder: dose was individualized based on the participants' most recent carbonate dose during the run-in period given 3 times/day with meals for weeks 1 to 4</LI>
<LI>Sevelamer hydrochloride tablets: 3 times/day with meals for weeks 5 to 8</LI>
</UL>
<P>Tablet group</P>
<UL>
<LI>Sevelamer hydrochloride tablets: dose was individualized based on the participants' most recent hydrochloride dose during the run-in period given 3 times/day with meals for weeks 1 to 4</LI>
<LI>Sevelamer carbonate powder: 3 times/day with meals for weeks 5 to 8</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Ca x P product</LI>
<LI>Serum bicarbonate</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
<LI>Safety of medications</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-08 16:14:19 +1100" MODIFIED_BY="Narelle S Willis">
<P>"Stanley Fan has received speaker&#8217;s honoraria from Genzyme Corporation and the department has received educational and research grants. Jeremy Heaton, John Hunter and Melissa Plone are employees of Genzyme Corporation"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 15:40:15 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ferreira-2008">
<CHAR_METHODS MODIFIED="2010-11-08 16:29:55 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 54 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:40:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Portugal</LI>
<LI>Setting: multicentre (16 centres)</LI>
<LI>&gt; 18 years; HD 3 times/week (&gt; 3 months); stable serum phosphorus &lt; 8.1 mg/dL for &gt; 1 month before screening and who were receiving treatment with a phosphate binder</LI>
<LI>Number</LI>
<UL>
<LI>calcium: 47</LI>
<LI>sevelamer: 44</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>calcium: 53.9 years (± 13.7)</LI>
<LI>sevelamer: 55.5 years (± 15.4)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>calcium: 18/17</LI>
<LI>sevelamer: 22/11</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Use of aluminium-based binders in the previous year; treatment with medication that are known to affect bone metabolism; tetracycline allergy; alcohol or drug abuse; any significant concurrent clinical condition</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-08 16:41:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate to achieve serum phosphorus of 3.2 to 5.0mg/dL and to maintain serum calcium at &lt;10.4 mg/dL</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride to achieve serum phosphorus of 3.2 to 5.0 mg/dL and to maintain serum calcium at &lt; 10.4 mg/dL</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-08 16:28:44 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Changes in serum biochemical parameters</LI>
<LI>Changes in parameters of bone mineralization</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 15:40:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>This study was supported by Genzyme Corp. A.F. is a member of a speaker bureau for Genzyme Corp. and an advisor for Abbott; J.M.F. is a consultant for Genzyme Portugal and Amgen Portugal; R.M.H. and A.D. are employees of Genzyme Corp.</LI>
<LI>Data about age and sex are reported for 33 and 35 participants (sevelamer and calcium respectively)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:13 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Finn-2004">
<CHAR_METHODS MODIFIED="2010-11-08 17:02:35 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
<LI>Lost to follow-up: 53</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:37:43 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>&gt; 18 years; HD 3 times/week for a minimum of 6 months</LI>
<LI>Number</LI>
<UL>
<LI>group 1: 27</LI>
<LI>group 2: 29</LI>
<LI>group 3: 30</LI>
<LI>group 4: 26</LI>
<LI>placebo: 32</LI>
</UL>
<LI>Age:</LI>
<UL>
<LI>group 1: 53.6 years</LI>
<LI>group 2: 57.5 years</LI>
<LI>group 3: 59.4 years</LI>
<LI>group 4: 54.0 years</LI>
<LI>placebo: 56.8 years</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>group 1: 14/13</LI>
<LI>group 2: 19/10</LI>
<LI>group 3: 17/13</LI>
<LI>group 4: 16/10</LI>
<LI>placebo: 13/19</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Significant hypercalcaemia; severe hyperparathyroidism; clinically significant abnormal laboratory values; significant GI disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-08 17:14:59 +1100" MODIFIED_BY="Narelle S Willis">
<P>Group 1</P>
<UL>
<LI>Lanthanum 225 mg/day</LI>
</UL>
<P>Group 2</P>
<UL>
<LI>Lanthanum 675 mg/day</LI>
</UL>
<P>Group 3</P>
<UL>
<LI>Lanthanum 1350 mg/day</LI>
</UL>
<P>Group 4</P>
<UL>
<LI>Lanthanum 2250 mg/day</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Oral or IV vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Outcomes reported in <LINK REF="STD-Finn-2004" TYPE="STUDY">Finn 2004</LINK>
</LI>
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
</UL>
<LI>Outcomes reported in <B>Altmann 2007</B>
</LI>
<UL>
<LI>Differences in cognitive function</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-03 11:28:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>
<B>Altmann 2007</B>
</LI>
<UL>
<LI>This is a secondary analysis</LI>
<LI>This study was funded by Shire Pharmaceuticals</LI>
</UL>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:14 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Fischer-2006">
<CHAR_METHODS MODIFIED="2010-11-08 17:23:02 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: August 2003 to May 2004</LI>
<LI>Follow-up period: 8 months</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:40:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: 2 nephrology centres</LI>
<LI>Life expectancy of at least 12 months; HD 3 times/week for 3 months or longer; maintained on sevelamer in a daily dose &#8804; 9600 mg as their only phosphate binder; serum phosphorus concentrations at last 2 measurements between 3.0 and 6.5 mg/dL</LI>
<LI>Number: 21</LI>
<LI>Age: 63.4 years</LI>
<LI>Sex (M/F): 13/5</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Active bowel obstruction; dysphagia; swallowing disorders; significant GI disease; methanol or drug abuse; need for antiarrhythmic or anti seizure medication to control these condition; poorly controlled DM or hypertension; active vasculitis or active malignancy other than basal cell carcinoma; immunodeficiency virus infection</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 11:30:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Once per day</P>
<UL>
<LI>Sevelamer hydrochloride standard dose once/day for 4 weeks</LI>
</UL>
<P>Three times per day</P>
<UL>
<LI>Sevelamer hydrochloride standard dose 3 times/day for 4 weeks</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Vitamin D</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:14 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus level</LI>
<LI>Serum calcium corrected for albumin level</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
<LI>Albumin</LI>
<LI>Total, LDL, HDL and non-HDL cholesterol</LI>
<LI>Triglyceride levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-08 17:30:14 +1100" MODIFIED_BY="Narelle S Willis">
<P>This clinical study (GTC-68-209) was funded by Genzyme Corp. Potential conflicts of interest: M.A.P., M.D., S.K.B., and A.T.B are employed by Genzyme Corp, the sponsor of the clinical trial reported in this article.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:52:18 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-FORESEE-Study-2008">
<CHAR_METHODS MODIFIED="2010-11-10 18:46:26 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: quasi-RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
<LI>Lost to follow-up: 56</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:52:18 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>&gt;18 years old; HD 3 times/week</LI>
<LI>Number</LI>
<UL>
<LI>cohort A: 215</LI>
<LI>cohort B: 142</LI>
</UL>
<LI>Mean age (range)</LI>
<UL>
<LI>cohort A: 56.7 years (27 to 89)</LI>
<LI>cohort B: 51.6 years (19 to 87)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>cohort A: 125/90</LI>
<LI>cohort B: 85/57</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Phosphorus &lt; 5.5 mg/dL, PTH &gt; 800 pg/mL</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-08 16:08:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>Initial washout and open-label titration phase</P>
<UL>
<LI>Washout period followed by open label titration of 1500 mg/day, 2250 mg/d and 3000 mg/d to achieve target phosphorus level 3.5 to 5.5 mg/dL</LI>
</UL>
<P>Cohort A</P>
<UL>
<LI>In participants who achieved target level, an open label treatment up to 3000 mg/d was adopted</LI>
</UL>
<P>Cohort B</P>
<UL>
<LI>In participants who did not reach target, an double blind forced dose titration was followed (forced titration to 3000 mg, 3750 mg or 4500 mg/day)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
<LI>Ca x P product</LI>
<LI>Serum albumin</LI>
<LI>Side effects (GI)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 18:53:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>This study was funded by Shire Pharmaceuticals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:14 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gallieni-2005">
<CHAR_METHODS MODIFIED="2010-12-03 11:30:47 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:41:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: NS</LI>
<LI>HD; previously treated with calcium carbonate;<SUB> </SUB>phosphorus level at study entry 5.5 to 8.0 mg/dL</LI>
<LI>Number: 115</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 20:34:15 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride to decrease serum phosphorus level below 5 mg/dL (if phosphorus levels &gt; 5 mg/dL, binder dose could be increased by 1 to 5 capsules/day)</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate to decrease serum phosphorus level below 5 mg/dL (if phosphorus levels &gt; 5 mg/dL, binder dose could be increased by 1 to 5 capsules/day)</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:14 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>Ca x P product</LI>
<LI>Serum bicarbonate</LI>
<LI>Total and LDL cholesterol</LI>
<LI>Total adverse events</LI>
<LI>GI side effects</LI>
<LI>Hypercalcaemia</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-08 17:44:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Conference abstract</LI>
<LI>Dompé Biotec (MG); Honoraria: Genzyme (MG)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:50:33 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hervas-2003">
<CHAR_METHODS MODIFIED="2010-11-08 18:23:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 34 weeks</LI>
<LI>Lost to follow-up: 10</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:37:45 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Spain</LI>
<LI>Setting: University</LI>
<LI>&gt; 18 years; HD 3 times/week; calcium-based phosphate binders and vitamin D therapy at stable doses for at least one month</LI>
<LI>Number: 51 randomised, 40 completed study</LI>
<LI>Mean age (± SD): 60.4 years (± 15.1)</LI>
<LI>Sex (M/F): 40% female</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Unstable medical condition including poorly controlled DM; hypertension or any GI abnormality</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:50:33 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride 2 to 4 capsules (403 mg) 3 times/day</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium acetate 1 to 4 capsules (500 mg) 3 times/day</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>IV or oral vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-08 18:29:00 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Alkaline phosphatase</LI>
<LI>iPTH</LI>
<LI>Lipid profile</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-08 18:33:13 +1100" MODIFIED_BY="Narelle S Willis">
<P>Supported in part by grants of Sociedad Espanola de Dialisisy Transplante (SEDYT).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:16 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hutchison-2005">
<CHAR_METHODS MODIFIED="2010-12-03 11:36:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: September 1998 to October 1999</LI>
<LI>Follow-up period: 6 months initially with a 6 month and 2 year open-label study extension</LI>
<LI>Lost to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:41:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Countries: UK, Germany, The Netherlands, Belgium</LI>
<LI>Setting: multicentre (67 centres)</LI>
<LI>&gt;18 years; HD 3 times/week for at least 3 consecutive months (including those who had previously undergone kidney transplantation)</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 510</LI>
<LI>calcium: 257</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>lanthanum: 57.0 years (± 14.3)</LI>
<LI>calcium: 58.4 years (± 13.3)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>lanthanum: 341/169</LI>
<LI>calcium: 164/113</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Hypercalcaemia, severe hyperparathyroidism or other clinically significant abnormal laboratory values; lactating females or those with a positive screening pregnancy test; HIV-positive, known hepatitis B or C, or other significant concurrent liver disorder; life-threatening malignancy, multiple myeloma or a history of epilepsy; drug or alcohol abuse within 2 years; treatment with an investigational drug 30 days prior to screening; those who, in the opinion of the investigators, would not comply with the study requirements</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 15:02:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum doses to achieve serum phosphorus &lt; 5.5 mg/dL</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate doses to achieve serum phosphorus &lt; 5.5 mg/dL</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Oral or IV vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Outcomes reported in <B>Hutchinson 2005</B>
</LI>
<UL>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH and vitamin D</LI>
</UL>
<LI>Outcomes reported in <B>Hutchinson 2006</B>
</LI>
<UL>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH and vitamin D</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-03 11:37:48 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>
<B>Hutchinson 2006</B>
</LI>
<UL>
<LI>Extension study performed in Germany, Belgium and Netherlands</LI>
<LI>Follow-up period 3 years</LI>
</UL>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:18 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Itoh-2008">
<CHAR_METHODS MODIFIED="2010-12-03 11:38:34 +1100" MODIFIED_BY="Narelle S Willis">
<P>Study design: parallel RCT<BR/>Time frame: NS<BR/>Follow-up period: 8 weeks<BR/>Lost to follow-up: 35/62 dropped out</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-03 11:38:38 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: multicentre (4 institutions)</LI>
<LI>HD patients with hyperphosphataemia</LI>
<LI>Number</LI>
<UL>
<LI>sevelamer: 31 enrolled, 13 completed study</LI>
<LI>colestimide: 31 enrolled, 14 completed study</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>sevelamer: 55.9 years (± 9.8)</LI>
<LI>colestimide: 57.5 years (± 14.7)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>sevelamer: 11/2</LI>
<LI>colestimide: 11/3</LI>
</UL>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 11:38:45 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride 3.0 g/day for 8 weeks</LI>
</UL>
<P>Colestimide group</P>
<UL>
<LI>Colestimide 3.0 g/day for 8 weeks</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>CaCO<SUB>3</SUB> 3.0 g/day for weeks 5 to 8</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:18 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
<LI>Serum alkaline phosphatase</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 17:50:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>"During the study period, 35 of the 62 subjects (56.5%) dropped out, almost all because of gastrointestinal problems, such as the onset or exacerbation of constipation, abdominal bloating, nausea or abdominal pain"</P>
<P>"The authors acknowledge the support of the Kirin Brewery Pharmacological Fund for this study"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-03 11:40:04 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ittel-1991">
<CHAR_METHODS MODIFIED="2010-11-09 15:24:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 months</LI>
<LI>Lost to follow-up: 10</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:35:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Germany</LI>
<LI>Setting: hospital</LI>
<LI>Previous compliance with medication regimen; acceptable control of serum phosphorus with a moderate dose (&lt; 5 g) of aluminium hydroxide; HD for at least 12 months</LI>
<LI>Number: 21</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 11:40:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>Group 1</P>
<UL>
<LI>Calcium carbonate gastric-coated preparation and the calcium carbonate enteric coated capsules</LI>
</UL>
<P>Group 2</P>
<UL>
<LI>Calcium carbonate enteric-coated capsules and the calcium carbonate gastric-coated preparation</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Aluminium hydroxide</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 15:27:53 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:08:12 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Janssen-1996">
<CHAR_METHODS MODIFIED="2010-11-09 15:34:31 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Lost to follow-up: 16</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-08 16:08:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: Multicentre</LI>
<LI>Regular HD</LI>
<LI>Number</LI>
<UL>
<LI>aluminium: 15</LI>
<LI>calcium acetate: 18</LI>
<LI>calcium carbonate: 20</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>aluminium: 62 years (± 4)</LI>
<LI>calcium acetate: 51 years (± 4)</LI>
<LI>calcium carbonate: 58 years (± 4)</LI>
</UL>
<LI>Sex(M/F)</LI>
<UL>
<LI>aluminium: 5/10</LI>
<LI>calcium acetate: 11/7</LI>
<LI>calcium carbonate: 7/13</LI>
</UL>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 11:57:11 +1100" MODIFIED_BY="Narelle S Willis">
<P>Aluminium group</P>
<UL>
<LI>Aluminium doses to achieve serum phosphorus &lt; 5.0 mg/dL and serum calcium 8.8 to 11.0 mg/dL</LI>
</UL>
<P>Calcium acetate group</P>
<UL>
<LI>Calcium acetate doses to achieve serum phosphorus &lt; 5.0 mg/dL and serum calcium 8.8 to 11.0 mg/dL</LI>
</UL>
<P>Calcium carbonate group</P>
<UL>
<LI>Calcium carbonate doses to achieve serum phosphorus &lt; 5.0 mg/dL and serum calcium 8.8 to 11.0 mg/dL</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>1-alpha-hydroxyvitamin D3</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 15:40:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-02 15:44:56 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:51:14 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Jespersen-1991">
<CHAR_METHODS MODIFIED="2010-11-09 15:47:11 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Lost to follow-up: 3</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:51:00 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Denmark</LI>
<LI>Setting: University</LI>
<LI>Chronic HD; &gt;18 years; serum phosphorus &gt; 2 mmol/L without treatment with a phosphate binder to maintain serum phosphorus &lt; 2 mmol/L; serum calcium &lt; 2.6 mmol/L</LI>
<LI>Number</LI>
<UL>
<LI>aluminium: 5</LI>
<LI>calcium: 6</LI>
</UL>
<LI>Age (range)</LI>
<UL>
<LI>aluminium: 41 years (22 to 69)</LI>
<LI>calcium: 49 years (27 to 65)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>aluminium: 2/3</LI>
<LI>calcium: 4/2</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Previous parathyroidectomy; ongoing treatment with 1,25(OH2)D3; glucocorticoid treatment</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:51:14 +1100" MODIFIED_BY="Narelle S Willis">
<P>Aluminium group</P>
<UL>
<LI>Aluminium hydroxide 33 to 66 mg/kg/day and then calcium carbonate 83 to 166 mg/kg/day</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate 83 to 166 mg/kg/day and then aluminium hydroxide 33 to 66 mg/kg/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 15:51:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>Effect on bone turnover and hyperparathyroidism</LI>
<LI>Bone mineral content and extraskeletal calcification</LI>
<LI>Serum aluminium</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 15:52:23 +1100" MODIFIED_BY="Narelle S Willis">
<P>This study was supported by grants from the Danish Medical Research Council and Livens Kemiske Fabrik (Leo Pharmaceuticals), Ballerup, Denmark</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:19 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Joy-2003">
<CHAR_METHODS MODIFIED="2010-11-09 18:34:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: October 1999 to July 2000</LI>
<LI>Follow-up period: 16 weeks</LI>
<LI>Lost to follow-up: 44</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:37:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (14 sites)</LI>
<LI>HD 3 times/week for at least 2 months; &gt; 18 years</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 49</LI>
<LI>placebo: 44</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>lanthanum: 60.2 years (± 13.3)</LI>
<LI>placebo: 60.2 years (± 13.3)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>lanthanum: 65.3% male</LI>
<LI>placebo: 65.9% male</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Pregnant or lactating or who were not using appropriate birth control; significant hypercalcaemia or hypocalcaemia, clinically significant abnormal laboratory values, severe hyperparathyroidism; uncontrolled concurrent illness, significant GI disorders, any life-threatening malignancy or current multiple myeloma, or any exposure to other investigational drugs within 30 days prior to the start of the study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 18:42:18 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum carbonate dose to achieve serum phosphorus &lt; 5.9 mg/dL</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Matched placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Oral or IV vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:19 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 18:43:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>"Study supported by Shire Pharmaceutical Development Inc."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-03 11:49:27 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kinugasa-2001">
<CHAR_METHODS MODIFIED="2010-12-03 11:49:07 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel open-label RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-03 11:47:34 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Hospital</LI>
<LI>Number</LI>
<UL>
<LI>calcium: 115</LI>
<LI>sevelamer: 115</LI>
</UL>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 11:49:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate mean dose 4.7 g/day (range 1.3 to 7.7)</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride mean dose 2.8 g/day (range 1.0 to 5.0)</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 18:52:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 18:49:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>Conference abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:51:39 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Koiwa-2005a">
<CHAR_METHODS MODIFIED="2010-12-03 11:50:08 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: 24</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-16 12:04:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: multicentre (9 centres)</LI>
<LI>Not restricted on the basis of aetiology of kidney failure, age, sex, or duration of dialysis, but doctors at each institution decided if patients were suitable for the study.</LI>
<LI>Number (86 enrolled, 62 completed study)</LI>
<UL>
<LI>sevelamer: 29</LI>
<LI>sevelamer+calcium: 30</LI>
<LI>calcium: 27</LI>
</UL>
<LI>Mean age (± SD): 57.1 years (± 10.6)</LI>
<LI>Sex (M/F): 39/23</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-22 11:51:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Observation and first non-randomised study periods (all participants)</P>
<UL>
<LI>Calcium carbonate: 3 g/day for weeks 1 to 4</LI>
<LI>Sevelamer hydrochloride: 3 g/day for weeks 5 to 8</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride: 6 g/day for weeks 9 to 12</LI>
</UL>
<P>Sevelamer + calcium group</P>
<UL>
<LI>Sevelamer hydrochloride (3 g/day) + calcium carbonate (3 g/day) for weeks 9 to 12</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate (3 g/day) for weeks 9 to 12</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 17:07:47 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum corrected calcium</LI>
<LI>Serum phosphorus</LI>
<LI>Serum bicarbonate</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 15:42:36 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kurihara-2005">
<CHAR_METHODS MODIFIED="2010-11-10 17:14:32 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: July 2002 to January 2003</LI>
<LI>Follow-up period: 2 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:42:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: multicentre (2)</LI>
<LI>HD, &gt; 20 years; on HD therapy 3 times/week continuously for 3 months; stable dosage of vitamin D (if used) and calcium concentration (3.0 mEq/L) for 1 month</LI>
<LI>Number</LI>
<UL>
<LI>MCI-196: 21</LI>
<LI>placebo: 12</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>MCI-196: 53.0 years (±10.9)</LI>
<LI>placebo: 58.4 years (± 9.8)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>MCI-196: 18/3</LI>
<LI>placebo: 10/2</LI>
</UL>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 11:51:31 +1100" MODIFIED_BY="Narelle S Willis">
<P>MCI-196 group</P>
<UL>
<LI>MCI-196: 2 g (4 tablets) 3 times/day with meals</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Placebo 3 times/day with meals</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 17:08:11 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Effectiveness and safety of short term administration of MCI-196</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 17:21:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>This work was supported by Mitsubishi Pharma Corporation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:20 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Liu-2006">
<CHAR_METHODS MODIFIED="2010-11-10 17:26:05 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:42:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Taiwan</LI>
<LI>Setting: hospital</LI>
<LI>Hyperphosphataemia (serum phosphorus level &gt; 6.0 mg/dL) during the 2-week washout period; age &#8805; 20 years; HD 3 times/week for at least 3 months; stable doses of calcium-based phosphate binders for at least 1 month if this therapy was given; stable doses of vitamin D replacement for at least 1 month if this therapy was given</LI>
<LI>Number</LI>
<UL>
<LI>sevelamer: 37</LI>
<LI>calcium: 33</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>sevelamer: 47.6 years (± 11.9)</LI>
<LI>calcium: 50.4 years (± 10.9)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>sevelamer: 21/16</LI>
<LI>calcium: 17/16</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Adjusted serum calcium level &gt; 11 mg/dL during the washout period; Hb &lt; 8.0 g/dL; ALT or AST &#8805; 3 times the upper limit of normal</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 11:53:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Starting dosage of sevelamer hydrochloride depended on the degree of hyperphosphataemia.</LI>
<UL>
<LI>&gt; 6.0 to 7.5 mg/dL: 2 tablets, 3 times/day</LI>
<LI>&#8805; 7.5 to &lt; 9.0 mg/dL: 3 tablets, 3 times/day</LI>
<LI>&#8805; 9.0 mg/dL: 4 tablets, 3 times/day</LI>
</UL>
<LI>The dose was titrated every 2 weeks as necessary to achieve a serum phosphorus level of 3.5 to 6.0 mg/dL. The largest daily dose of sevelamer was 12 g.</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Starting dosage of calcium acetate depended on the degree of hyperphosphataemia.</LI>
<UL>
<LI>&gt;6.0 to 7.5 mg/dL: 1 tablet, 3 times/day</LI>
<LI>&#8805;7.5 to &lt; 9.0 mg/dL: 2 tablets, 3 times/day</LI>
<LI>&#8805; 9.0 mg/dL: 3 tablets, 3 times/day</LI>
</UL>
<LI>The dose was titrated every 2 weeks as necessary to achieve a serum phosphorus level of 3.5 to 6.0 mg/dL. The largest daily dose of calcium acetate was 12 g.</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
<LI>ALP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 17:38:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Chugai Pharma Taiwan Ltd. provided the sevelamer hydrochloride tablets for this study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 15:42:55 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Malluche-2008">
<CHAR_METHODS MODIFIED="2010-11-10 17:42:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
<LI>Lost to follow-up: 4</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-02 17:35:01 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA, Puerto Rico, Poland, South Africa</LI>
<LI>Setting: multicentre</LI>
<LI>&gt;18 years; HD 3 times/week</LI>
<LI>Number</LI>
<UL>
<LI>standard phosphate binder: 103</LI>
<LI>lanthanum: 108</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>standard phosphate binder: 50.6 years (±13.9)</LI>
<LI>lanthanum: 48.5 years (± 13.4)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>standard phosphate binder: 37/11</LI>
<LI>lanthanum: 37/14</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Abnormal laboratory values at screening or screening calcium level &lt; 7.9 mg/dL; prior GI surgery, GI disorders, GI bleeding within last 6 months, GI malignancy; elevated serum transaminases; HIV-positive status; malignancy; pregnancy or lactation, women of reproductive ages who did not agree to use effective birth control methods; allergy to tetracycline; use of cyclosporin; corticosteroid therapy; parathyroid surgery within 6 months; failed transplant within 2 months before bone biopsy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 17:53:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Standard phosphate binder group</P>
<UL>
<LI>Standard phosphate binder to achieve target phosphorus levels of 5.9 mg/dL</LI>
</UL>
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum carbonate to achieve target phosphorus levels of 5.9 mg/dL (maximum dose 3 mg/day)</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 17:53:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Serum PTH</LI>
<LI>Changes in bone turnover</LI>
<LI>Bone volume</LI>
<LI>Bone lanthanum content</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 15:42:55 +1100" MODIFIED_BY="Narelle S Willis">
<P>Data about age and sex are reported for 51 and 48 participants (lanthanum carbonate and standard phosphate binder respectively)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 18:58:46 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-McIntyre-2009">
<CHAR_METHODS MODIFIED="2010-11-10 18:25:17 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel, 3-arm RCT</LI>
<LI>Time frame: February 2004 to May 2005</LI>
<LI>Follow-up period: 5 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-01 18:58:46 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: UK</LI>
<LI>Setting: multicentre (5 centres)</LI>
<LI>&gt;18 years; HD 3 times/week for at least 3 months</LI>
<LI>Number</LI>
<UL>
<LI>fermagate-1g: 21</LI>
<LI>fermagate-2g: 21</LI>
<LI>placebo: 21</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>fermagate-1g: 60.6 years (± 15.2)</LI>
<LI>fermagate-2g: 58.1 years (± 14.0)</LI>
<LI>placebo: 58.6 years (± 13.8)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>fermagate-1g: 16/5</LI>
<LI>fermagate-2g: 13/8</LI>
<LI>placebo: 16/5</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>History of haemochromatosis; serum ferritin concentration &#8805;1000 ng/mL; clinically significant GI motility disorder; dysphagia or swallowing disorder; Hb &lt; 10 g/dL</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-01 18:58:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>Fermagate-1g group</P>
<UL>
<LI>Fermagate 1 g, 3 times/day</LI>
</UL>
<P>Fermagate-2g group</P>
<UL>
<LI>Fermagate: 2 g, 3 times/day</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Matching placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Vitamin D supplements was to remain unchanged during the study period</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 18:32:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Adverse events and serious adverse events</LI>
<LI>Death</LI>
<LI>Serum magnesium</LI>
<LI>Serum calcium</LI>
<LI>Other haematology and biochemistry parameters</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:52:27 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Pflanz-1994">
<CHAR_METHODS MODIFIED="2010-11-10 18:55:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 weeks</LI>
<LI>Lost to follow-up: 8</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:52:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: UK</LI>
<LI>Setting: hospital</LI>
<LI>HD (4 hour dialysis treatment 3 times/week) whose usual phosphate binding therapy consisted of calcium carbonate in a total daily dose of between 2.5 and 5.0 g</LI>
<LI>Number: 31</LI>
<LI>Mean age (range): 59.5 years (23 to 79)</LI>
<LI>Sex (M/F): 21/10</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Other doses or on other phosphate binders</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-01 18:56:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium acetate group</P>
<UL>
<LI>Calcium acetate: 2 g, 3 times/day</LI>
</UL>
<P>Calcium carbonate group</P>
<UL>
<LI>Calcium carbonate: 2g, 3 times/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:22 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>Ca x P product</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-16 12:05:28 +1100" MODIFIED_BY="Narelle S Willis">
<P>Financial support from Tayside Health Board Research Committee</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-03 11:57:44 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Phelps-2002">
<CHAR_METHODS MODIFIED="2010-11-10 20:19:03 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 2</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-03 11:57:22 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre</LI>
<LI>Men &gt;18 years; CrCl 10 to 70 mL/min; iPTH &gt; 65 pg/mL; 1,25 dihydroxyvitamin D &gt; 15 ng/mL; F-thyroxine 0.77 to 1.61 ng/mL; TSH 0.35 to 5.5 µIU/mL</LI>
<LI>Number</LI>
<UL>
<LI>calcium-2g: 8</LI>
<LI>calcium-6g: 10</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>calcium-2g: 71.3 years (± 8.6)</LI>
<LI>calcium-6g: 69.4 years (± 7.3)</LI>
</UL>
<LI>Sex (M/F): 100% male</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Current corticosteroid ingestion; any allograft; any disorder other than CKD associated with bone loss</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 11:57:44 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium-2g group</P>
<UL>
<LI>Calcium acetate 2 g/day</LI>
</UL>
<P>Calcium-6g group</P>
<UL>
<LI>Calcium acetate 6 g/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 20:41:52 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>iPTH</LI>
<LI>Changes in the ratio of phosphorus to creatinine excreted</LI>
<LI>Changes in serum calcium, phosphorus and 1,25 dihydroxyvitamin D</LI>
<LI>Changes in BMD at sites in lumbar spine and femur</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 20:43:06 +1100" MODIFIED_BY="Narelle S Willis">
<P>Financial support from the National Kidney Foundation of Northeast New York</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:52:43 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ring-1993">
<CHAR_METHODS MODIFIED="2010-11-22 22:03:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:52:43 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Denmark</LI>
<LI>Setting: Hospital</LI>
<LI>Chronic HD, 4 hours 3 times/week or 4 hours 2 times/week; treatment with calcium carbonate as the only phosphorus binder for at least 1 month; no vitamin D</LI>
<LI>Number: 21 enrolled, 15 analysed</LI>
<LI>Age range: 19 to 75 years</LI>
<LI>Sex(M/F): 9/6</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-22 22:06:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium acetate group</P>
<UL>
<LI>3.8 g/day</LI>
</UL>
<P>Calcium carbonate group</P>
<UL>
<LI>4 g/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-22 22:07:03 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:52:48 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Roxe-1989">
<CHAR_METHODS MODIFIED="2010-11-30 14:55:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 2</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:52:48 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: University</LI>
<LI>18 to 70 years; HD 3 times/week</LI>
<LI>Number: 27 randomised, 21 analysed</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): 6/15</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Treatment with phenytoin, cardiac glycosides or calcium carbonate; chronic anticoagulation</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 12:00:06 +1100" MODIFIED_BY="Narelle S Willis">
<P>Aluminium group</P>
<UL>
<LI>Aluminium hydroxide 3 g/day and then sucralfate 6 g/day to achieve serum phosphorus &lt; 4.5 mg/dL</LI>
</UL>
<P>Sucralfate group</P>
<UL>
<LI>Sucralfate 6 g/day and then aluminium hydroxide 3 g/day to achieve serum phosphorus &lt; 4.5 mg/dL</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 14:58:18 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum aluminium</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:52:54 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Rudnicki-1994">
<CHAR_METHODS MODIFIED="2010-11-30 15:08:42 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:52:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Denmark</LI>
<LI>Setting: hospital</LI>
<LI>HD 3 times/week (6 months to 10 years); iPTH above the normal range and serum ionised calcium within or below it</LI>
<LI>Number</LI>
<UL>
<LI>calcium: 9</LI>
<LI>placebo: 9</LI>
</UL>
<LI>Mean age (range): 55 years (31 to 70)</LI>
<LI>Sex (M/F): 13/5</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 12:04:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate 2 g/day for 6 months</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Placebo for 6 months</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Oral vitamin D analogues</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 15:11:46 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Bone markers</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-27 22:10:58 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:08:47 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Russo-2007">
<CHAR_METHODS MODIFIED="2010-11-30 15:40:25 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 ± 4.2 months</LI>
<LI>Lost to follow-up: 6</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-08 16:08:45 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: NS </LI>
<LI>Constant low dietary phosphorus intake; stable serum concentration of phosphorus, calcium, Ca x P product, PTH; no previous therapy with aluminium or calcium based phosphate binders, vitamin D sterols, statins; comparable mean baseline total calcium score at CT scan</LI>
<LI>Number</LI>
<UL>
<LI>low phosphate diet: 30 randomised, 29 analysed</LI>
<LI>sevelamer: 30 randomised, 27 analysed</LI>
<LI>calcium carbonate: 30 randomised, 28 analysed</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>low phosphate diet: 54.4 years (± 3.7)</LI>
<LI>sevelamer: 55.2 years (± 12.0)</LI>
<LI>calcium carbonate: 54.4 years (± 12.9)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>low phosphate diet: 25/4</LI>
<LI>sevelamer: 23/5</LI>
<LI>calcium carbonate: 24/3</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>&lt; 18 years; symptomatic coronary disease, past myocardial infarction, previous coronary surgery/angioplasty, stroke, arrhythmia; progressive kidney disease; diabetes</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-08 16:08:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>Low phosphate diet</P>
<UL>
<LI>Not described</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride:1600 mg/day</LI>
<LI>Low phosphate diet</LI>
</UL>
<P>Calcium carbonate group</P>
<UL>
<LI>Calcium carbonate: 2 g/day</LI>
<LI>Low phosphate diet  </LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 15:57:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Changes in total calcium score</LI>
<LI>Progression of CAC</LI>
<LI>Changes in biochemical variables</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 15:43:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>Data about age and sex are reported for 29, 28 and 27 participants (controls, calcium carbonate and sevelamer respectively)</P>
<P>This is an unsupported study. No funding was provided by the Government, corporations, or manufacturers of the drugs evaluated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:09:00 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sadek-2003">
<CHAR_METHODS MODIFIED="2010-11-30 16:02:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: November 2000 to April 2001</LI>
<LI>Follow-up period: 5 months</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-03 12:11:06 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: France</LI>
<LI>Setting: Hospital</LI>
<LI>HD 3 times/week</LI>
<LI>Number</LI>
<UL>
<LI>sevelamer: 21</LI>
<LI>calcium: 21</LI>
</UL>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-08 16:09:00 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Initial dose: 1.2 g at lunch and dinner</LI>
<LI>Dose progressively increased to 4.4 g/d</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Continued their pre-existing treatment with calcium carbonate</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 16:09:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>Serum PTH</LI>
<LI>25-OH vitamin D</LI>
<LI>Triglycerides, LDL, HDL, total cholesterol</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 15:44:10 +1100" MODIFIED_BY="Narelle S Willis">
<P>The result were analysed in only 16 participants of the calcium carbonate group and 15 of the sevelamer group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 15:44:32 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Saif-2007">
<CHAR_METHODS MODIFIED="2010-11-30 16:13:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: 23</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:44:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Pakistan</LI>
<LI>Setting: HD centre</LI>
<LI>ESKD, on maintenance HD for at least 3 months</LI>
<LI>Number: 64 randomised, 41 analysed</LI>
<LI>Mean age (± SD): 42.6 years (± 15.7)</LI>
<LI>Sex(M/F): 24/17</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Previous parathyroidectomy and advanced malignancy/metastasis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 16:18:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>Calcium acetate group</P>
<UL>
<LI>Calcium acetate: 4.002 g/day</LI>
<LI>After crossover: 5.625 g/day calcium carbonate</LI>
</UL>
<P>Calcium carbonate group</P>
<UL>
<LI>Calcium carbonate: 5.625g/day</LI>
<LI>After crossover: 4.002 g/day calcium acetate</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 16:19:02 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum urea</LI>
<LI>SCr</LI>
<LI>Calcium</LI>
<LI>Albumin</LI>
<LI>Phosphate</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-30 16:19:22 +1100" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:09:04 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Salusky-1991">
<CHAR_METHODS MODIFIED="2010-12-08 16:09:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 13 months</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:44:38 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: US</LI>
<LI>Setting: Hospital</LI>
<LI>Chronic PD</LI>
<LI>Number</LI>
<UL>
<LI>aluminium: 10 randomised, 7 analysed</LI>
<LI>calcium: 12 randomised, 10 analysed</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>aluminium: 14.1 years (3.7)</LI>
<LI>calcium: 15.5 years (3.7)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>aluminium: 3/4</LI>
<LI>calcium: 2/8</LI>
</UL>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 14:37:51 +1100" MODIFIED_BY="Narelle S Willis">
<P>Aluminium group</P>
<UL>
<LI>Aluminium hydroxide: adjusted according to serum phosphorus levels, maximal daily dose was limited to 30 mg/kg</LI>
</UL>
<P>Calcium</P>
<UL>
<LI>Calcium carbonate: adjusted according to serum phosphorus levels, dose range 2.5 to 12 g</LI>
</UL>
<P>Co-intervention</P>
<UL>
<LI>Oral calcitriol</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 16:35:35 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-16 12:19:49 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Schaefer-1991">
<CHAR_METHODS MODIFIED="2010-11-30 21:23:55 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 7 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:44:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Germany</LI>
<LI>Setting: Hospital</LI>
<LI>Chronic HD (for at least 40 months)</LI>
<LI>Number: 47</LI>
<UL>
<LI>group 1: 12</LI>
<LI>group 2: 12</LI>
<LI>group 3: 10</LI>
<LI>group 4: 13</LI>
</UL>
<LI>Mean age: 62.5 years</LI>
<LI>Sex (M/F): 21/26</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-16 12:19:49 +1100" MODIFIED_BY="Narelle S Willis">
<P>Group 1</P>
<UL>
<LI>Calcium acetate: oral 6 g/day</LI>
</UL>
<P>Group 2</P>
<UL>
<LI>Calcium acetate: oral 6 g/day</LI>
<LI>Calcitriol: 4 µg twice/week</LI>
</UL>
<P>Group 3</P>
<UL>
<LI>Calcium acetate: 6 g/day</LI>
<LI>Calcitriol: 0.5 µg twice/week</LI>
</UL>
<P>Group 4</P>
<UL>
<LI>Aluminium hydroxide: given aluminium hydroxide by way of phosphate-reducing medication exclusively during the first study period and the second study period</LI>
<LI>Calcitriol: 4 µg twice/week</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 21:34:02 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum calcium</LI>
<LI>Serum phosphorus</LI>
<LI>iPTH</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:53:22 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Shaheen-2004">
<CHAR_METHODS MODIFIED="2010-11-30 21:46:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: March 2003 to June 2003</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 3</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:53:22 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Kingdom of Saudi Arabia</LI>
<LI>Setting: Hospital</LI>
<LI>15 to 75 years; chronic HD (2 or 3 times/week) for at least 3 months and optimally dialysed as judged by usual dialysis and serum chemistry parameters; current phosphorus: 5.5 mg/dL</LI>
<LI>Number: 20</LI>
<LI>Mean age (± SD): 42.7 years (± 9.9)</LI>
<LI>Sex (M/F): 12/8</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Serious GI disease including dysphasia, vomiting, motility disorder, major intestinal surgery or markedly irregular bowel function; alcohol abuse or drug dependence; clinically relevant liver disease, uncontrolled diabetes or uncontrolled hypertension, malignancy, human immunodeficiency virus infection, active vasculitis or illness at the time of entry to the study</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-08 16:09:18 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride: 800 mg tablets orally 3 times/day post meals</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate (Caltrate 600): 1500 mg tablet 3 times/day post meals</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:26 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH levels</LI>
<LI>Lipid profile</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-07 15:44:46 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Shigematsu-2008">
<CHAR_METHODS MODIFIED="2010-11-30 21:54:06 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:44:46 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Multicentre  </LI>
<LI>&gt; 20 years; on maintenance HD with hyperphosphataemia; serum phosphate levels &gt; 5.6 mg/dL at 1 week after the initiation of the washout period</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 126</LI>
<LI>calcium: 132</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>lanthanum: 58.8 years (± 10.5)</LI>
<LI>calcium: 56.1 years (± 11.5)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>lanthanum: 87/39</LI>
<LI>calcium: 87/45</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Serum phosphate levels &gt; 10 mg/dL at the start of the washout period or 11.0 mg/dL during the washout period; corrected serum calcium level of &lt; 7.0 mg/dL; iPTH &gt; 1 pg/mL at the start of the washout period</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 22:01:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum carbonate: starting dose 750 mg/day</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate: starting dose 1500 mg/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 22:01:14 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in serum phosphate levels</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
<LI>Serum phosphorus</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-05-06 20:25:21 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-16 12:12:58 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Spasovski-2006">
<CHAR_METHODS MODIFIED="2010-11-30 22:07:26 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 years</LI>
<LI>Lost to follow-up: 1</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-03 12:23:12 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Macedonia</LI>
<LI>Setting: Dialysis centre</LI>
<LI>Dialysis patients who had required oral phosphate binders to control serum phosphorus levels</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 12</LI>
<LI>calcium: 12</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>lanthanum: 55 years (± 10)</LI>
<LI>calcium: 57 years (± 10)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>lanthanum: 7/5</LI>
<LI>calcium: 7/5</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Any significant GI problem; history of treatment with corticosteroids or bisphosphonates; hypocalcaemia at screening</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-16 12:12:58 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum carbonate: to achieve optimal control of serum phosphorus levels (&lt; 1.8 mmol/L) (maximum dose of 3000 mg/day)</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate: to achieve optimal control of serum phosphorus levels (&lt; 1.8 mmol/L) (maximum dose of 4000 mg/day)</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 22:11:58 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Biochemical parameters</LI>
<LI>Lanthanum level in plasma and bone</LI>
<LI>Safety and efficacy of treatments</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-07 15:45:02 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Treatment period was 1 year</LI>
<LI>During the other 2 years all participants were switched to calcium carbonate</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-16 12:13:30 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Spiegel-2007">
<CHAR_METHODS MODIFIED="2010-12-03 12:24:03 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel, open-label RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-03 12:24:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>&gt; 18 years; chronic HD for at least 3 months; receiving phosphate binders before entry into the study; serum calcium of 8.0 to 10.2 mg/dL and serum phosphorus of 3.0 to 6.9 mg/dL</LI>
<LI>Number</LI>
<UL>
<LI>magnesium: 20</LI>
<LI>calcium: 10</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>magnesium: 55.5 years (± 12.6)</LI>
<LI>calcium: 55.9 years (± 12.0)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>magnesium: 12/8</LI>
<LI>calcium: 4/6</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Frequent diarrhoea; declined to give informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-16 12:13:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>Magnesium group</P>
<UL>
<LI>Magnesium carbonate: to achieve the target phosphorus of &lt; 5.5 mg/dL</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium acetate: to achieve the target phosphorus of &lt; 5.5 mg/dL</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 22:20:40 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum magnesium</LI>
<LI>Serum calcium</LI>
<LI>iPTH</LI>
<LI>Serum bicarbonate</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-27 22:10:24 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:28 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sprague-2009a">
<CHAR_METHODS MODIFIED="2010-11-30 22:32:26 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:45:13 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (28 dialysis centres)</LI>
<LI>&#8805;18 years; eGFR 15 to 59 mL/min/1.73 m² at screening; undergoing physician care for CKD for &gt; 2 months; not expected to begin dialysis for &#8805; 4 months</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 78</LI>
<LI>placebo: 41</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>lanthanum: 61.8 years (± 12.9)</LI>
<LI>placebo: 63.0 years (± 12.7)</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>lanthanum: 40/38</LI>
<LI>placebo: 21/20</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Requirement for treatment with cinacalcet HCl or compounds containing phosphorus, aluminium, magnesium or calcium; AKI within 12 weeks of screening; rapidly progression of glomerulonephritis; significant GI surgery or disorders; evidence of clinically significant liver disease; pregnant or lactating women; women on reproductive potential who did not agree to use effective contraception</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-07 15:45:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum carbonate: 750 mg/day to a maximum of 3000 mg/day to achieve a target serum phosphorus level of &lt; 4.0 mg/dL</LI>
</UL>
<P>Placebo group</P>
<UL>
<LI>Matching placebo</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Participants receiving vitamin D or calcium supplements before screening could continue treatment during the study. Treatments could not be initiated during the study, and the dose could not be increased, but it could be decreased if a patient experienced hypercalcaemia</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in serum phosphorus</LI>
<LI>Change in Ca x P product</LI>
<LI>Change in iPTH levels</LI>
<LI>Safety and tolerability of treatment</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-22 11:53:39 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sprague-2009b">
<CHAR_METHODS MODIFIED="2010-11-30 22:42:05 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-22 11:53:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA, Puerto Rico, Germany, UK</LI>
<LI>&#8805;18 years; CKD stage 5; undergoing stable HD 2 to 3 times/week for at least 2 months before screening</LI>
<LI>Number</LI>
<UL>
<LI>lanthanum: 95</LI>
<LI>sevelamer: 86</LI>
</UL>
<LI>Mean age (± SD): 55.5 years (± 13.1)</LI>
<LI>Sex (M/F): 102/79</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Previously received treatment with lanthanum carbonate or sevelamer; iPTH levels &gt; 600 pg/mL</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 12:26:54 +1100" MODIFIED_BY="Narelle S Willis">
<P>Lanthanum group</P>
<UL>
<LI>Lanthanum carbonate: 2250 mg/day. After the first week, dose was increased to 3000 mg/day</LI>
</UL>
<P>Sevelamer group</P>
<UL>
<LI>Sevelamer hydrochloride: 4800 mg/day. After the first week, dose was increased to 6400 mg/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-30 22:46:08 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>PTH levels</LI>
<LI>Safety and tolerability of treatments</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 16:09:29 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Tzanakis-2008">
<CHAR_METHODS MODIFIED="2010-11-30 22:54:08 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: quasi-RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
<LI>Lost to follow-up: 1 (who moved to another hospital)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-08 16:09:29 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Greece</LI>
<LI>Setting: Dialysis unit</LI>
<LI>Stable ESKD, on maintenance HD</LI>
<LI>Number</LI>
<UL>
<LI>magnesium: 26</LI>
<LI>calcium: 25</LI>
</UL>
<LI>Mean age (± SD)</LI>
<UL>
<LI>magnesium: 63.2 years (± 12.2)</LI>
<LI>calcium: 65.3 years (± 11.7)</LI>
</UL>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>&lt; 18 years; HD &lt; 6 months; psychiatric or other disorders leading to non-compliance; unlikeliness to continue HD for more than 6 months in the same facility; critical illness at the time of recruitment; previous parathyroidectomy; severe hyperparathyroidism (iPTH &gt; 500 pg/mL); normal serum phosphorus (&lt; 5.5 mg/dL) without phosphate binders; diseases resulting in diarrhoea; lack of informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 12:27:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>Magnesium group</P>
<UL>
<LI>Magnesium carbonate: 750 mg/day</LI>
</UL>
<P>Calcium group</P>
<UL>
<LI>Calcium carbonate: 1260 mg/day</LI>
</UL>
<P>Co-interventions: None</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-18 01:33:51 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-08 15:45:30 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Yang-2002">
<CHAR_METHODS MODIFIED="2010-11-30 23:03:02 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 9</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-07 15:45:46 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: USA</LI>
<LI>Setting: Multicentre</LI>
<LI>HD; concentration of calcium in the dialysate was 2.5 mEq/L; predictable compliance with their medical regimen; serum iron or ferritin level within or below the normal range; serum calcium of 8 to 10 mg/dL</LI>
<LI>Number: 54 randomised, 45 analysed</LI>
<LI>Mean age: 52.5 ± 11.8 years</LI>
<LI>Sex (M/F): 22/23</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>&lt; 18 years; pregnancy; active GI bleeding; use of calcitriol; tertiary hyperparathyroidism; immediate post-operative parathyroidectomy (within the first 3 months or serum calcium &lt; 7 mg/dL); severe congestive heart failure; anorexia and cachexia; DM with gastroparesis and malignancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-03 12:29:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>Group 1</P>
<UL>
<LI>Ferric citrate: 1g, 3 times/day</LI>
</UL>
<P>Group 2</P>
<UL>
<LI>Calcium carbonate: 1g, 3 times/day</LI>
</UL>
<P>Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-08 15:45:30 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Serum phosphorus</LI>
<LI>Serum calcium</LI>
<LI>Ca x P product</LI>
<LI>iPTH levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-18 18:54:47 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AKI - acute kidney injury; ALP - alkaline phosphatase; AST - aspartate aminotransferase;<B> </B>Ca x P product - calcium by phosphorus; CAC - coronary artery calcium/calcification; CAPD - continuous ambulatory peritoneal dialysis; CKD - chronic kidney disease; CrCl - creatinine clearance; DKD - diabetic kidney disease; DM - diabetes mellitus; ESKD - end-stage kidney disease; GI - gastrointestinal; Hb - haemoglobin; HD - haemodialysis; iPTH - intact parathyroid hormone; ITT - intention to treat; NS - not stated; PD - peritoneal dialysis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-07-14 00:32:06 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-12-08 16:08:43 +1100" MODIFIED_BY="Narelle S Willis">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-12-08 16:08:43 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:37:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Baaj-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:36:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Almirall-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:36:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-BRiC-Study-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:37:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Birck-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:37:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bleyer-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:01:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Block-2005">
<DESCRIPTION>
<P>"randomisation to treatment was computer generated in blocks of 10"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:06:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Borrego-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:43:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bro-1998">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 21:52:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-CARE-Study-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:03:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-CARE_x002d_2-Study-2008">
<DESCRIPTION>
<P>"randomisation was stratified by centre using computerized lists for each site, prepared by using permuted blocks of 4 to attain balance within strata"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:00:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Caravaca-1992">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:31:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2008">
<DESCRIPTION>
<P>"Research pharmacist also randomly assigned patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:03:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chertow-1997">
<DESCRIPTION>
<P>2:1 randomisation, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:41:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chertow-1999">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:49:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chertow-2002">
<DESCRIPTION>
<P>Randomised 1:1, stratified by site and DM using a computer generated randomisation sequence (SAS 6.12 (Cary, NC, USA)).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:07:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chiang-2005">
<DESCRIPTION>
<P>1:1 randomisation, method not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:02:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Haese-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:07:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-DCOR-Study-2007">
<DESCRIPTION>
<P>"randomisation was executed in blocks assuring a 1:1 ratio between treatment groups within strata defined by race (black and non-black), sex, diabetic status, and by age (&lt; 55 and &#8805; 55 years). Institutional balancing was used to assure comparable number of subjects between treatment groups within a site."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:44:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-De-Santo-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:58:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Deuber-2003a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:36:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Emmett-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:07:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Evenepoel-2009">
<DESCRIPTION>
<P>"patients were stratified (anuric or non-anuric) at each treatment site and were randomised to sevelamer hydrochloride or calcium acetate in a 2:1 ratio in order to maximize sevelamer hydrochloride data generation" - method of randomisation not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:43:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-FORESEE-Study-2008">
<DESCRIPTION>
<P>NS; double-dummy, double-blind, forced-dosage titration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:07:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fan-2009">
<DESCRIPTION>
<P>"patients were randomised in a 1:1 fashion to one of two treatment sequences" method of randomisation not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:07:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ferreira-2008">
<DESCRIPTION>
<P>"randomly assigned to treatment with either sevelamer or calcium in a 1:1 manner. randomisation was performed centrally by an independent study coordinator"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:01:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Finn-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:08:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Fischer-2006">
<DESCRIPTION>
<P>"patients then were assigned randomly (based on computer generated random numbers)... randomisation was stratified by site to ensure equal allocation of patients within sites"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:37:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Gallieni-2005">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 18:21:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hervas-2003">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-03 11:37:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hutchison-2005">
<DESCRIPTION>
<P>Randomised 2:1, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:09:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:24:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ittel-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:33:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Janssen-1996">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:46:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jespersen-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:34:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Joy-2003">
<DESCRIPTION>
<P>1:1 randomisation; method not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:49:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kinugasa-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:58:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Koiwa-2005a">
<DESCRIPTION>
<P>Patients were registered with the secretariat and comprised the study group (ROD 21). The patients were randomly allocated to three groups by the secretariat and notified by fax or email.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:18:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-2005">
<DESCRIPTION>
<P>2:1 randomisation, method not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:25:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:41:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:08:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-McIntyre-2009">
<DESCRIPTION>
<P>"A randomisation schedule was generated, each treatment packed accordingly in a block size of six (two sets of each treatment per block)<BR/>and sent to the site. A unique randomisation number was indicated on<BR/>the label of each drug pack and sequentially dispensed to new patients<BR/>at each centre."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:54:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pflanz-1994">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 20:18:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Phelps-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-03 12:03:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ring-1993">
<DESCRIPTION>
<P>"Using random numbers patients were assigned to receive either calcium acetate or calcium carbonate as the first drug and then crossed over to the other in the last period."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 14:58:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roxe-1989">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:08:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Rudnicki-1994">
<DESCRIPTION>
<P>"randomised by a computer-generated list to receive in a double-blind manner..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:37:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:00:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sadek-2003">
<DESCRIPTION>
<P>"patients were randomised into two groups with stratification for PTH"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:12:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saif-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:22:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Salusky-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:46:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schaefer-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:37:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shaheen-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:53:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shigematsu-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:06:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Spasovski-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:15:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Spiegel-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-03 12:26:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sprague-2009a">
<DESCRIPTION>
<P>Randomised 2:1, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:41:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sprague-2009b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:53:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakis-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 23:02:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:48:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-d_x0027_Almeida-Filho-2000">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-12-08 16:01:27 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:37:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Baaj-2005">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:36:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Almirall-1994">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:25:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-BRiC-Study-2008">
<DESCRIPTION>
<P>Yes (A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:37:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Birck-1999">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:27:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bleyer-1999">
<DESCRIPTION>
<P>No (C)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-08 16:01:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Block-2005">
<DESCRIPTION>
<P>"assigned by the coordinating centre using concealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:07:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Borrego-2000">
<DESCRIPTION>
<P>Unclear (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:44:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bro-1998">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 21:52:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-CARE-Study-2004">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:09:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-CARE_x002d_2-Study-2008">
<DESCRIPTION>
<P>Yes (A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:00:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Caravaca-1992">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:31:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Cheng-2008">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:03:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chertow-1997">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:41:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chertow-1999">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 11:46:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chertow-2002">
<DESCRIPTION>
<P>Yes (A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 12:18:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chiang-2005">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:02:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Haese-2003">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:31:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-DCOR-Study-2007">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:44:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-De-Santo-2006">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:58:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Deuber-2003a">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:37:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Emmett-1991">
<DESCRIPTION>
<P>Yes (A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:48:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Evenepoel-2009">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:43:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-FORESEE-Study-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:00:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fan-2009">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:28:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ferreira-2008">
<DESCRIPTION>
<P>Yes (A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:01:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Finn-2004">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:22:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-2006">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:37:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Gallieni-2005">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 18:21:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hervas-2003">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 14:57:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hutchison-2005">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:09:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:24:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ittel-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:34:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Janssen-1996">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:46:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jespersen-1991">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:34:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Joy-2003">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:49:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kinugasa-2001">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:58:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Koiwa-2005a">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:09:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-2005">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:25:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:41:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:23:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-McIntyre-2009">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:54:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Pflanz-1994">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 20:18:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Phelps-2002">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:02:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ring-1993">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:11:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Roxe-1989">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:07:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rudnicki-1994">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 15:43:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Russo-2007">
<DESCRIPTION>
<P>participants were randomly assigned to low-phosphate diet alone and to receive either calcium carbonate or sevelamer by the coauthor (YB), who was unaware of their baseline demographic and clinical characteristics and biochemistry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:00:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sadek-2003">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:12:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saif-2007">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:22:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Salusky-1991">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:46:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schaefer-1991">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:37:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shaheen-2004">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:53:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shigematsu-2008">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:06:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Spasovski-2006">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:15:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Spiegel-2007">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:30:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sprague-2009a">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:41:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sprague-2009b">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-07 15:45:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tzanakis-2008">
<DESCRIPTION>
<P>4 participants did not agree to consume magnesium carbonate and they were allocated to the calcium carbonate group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 23:02:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2002">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:48:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-d_x0027_Almeida-Filho-2000">
<DESCRIPTION>
<P>NS (B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-10-04 17:21:37 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-12-03 12:07:03 +1100" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Blinding of participants?</NAME>
<DESCRIPTION>
<P>Were the participants blinded to the intervention?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Al_x002d_Baaj-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Almirall-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:25:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-BRiC-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:27:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Birck-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:27:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bleyer-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:40:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Block-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:07:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Borrego-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:44:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bro-1998">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 21:52:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-CARE-Study-2004">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:21:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-CARE_x002d_2-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:57:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Caravaca-1992">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:30:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Cheng-2008">
<DESCRIPTION>
<P>"provided blinded bottles to the research staff for distribution"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:04:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-1997">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:41:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 11:48:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 12:18:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chiang-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:02:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-D_x0027_Haese-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:31:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-DCOR-Study-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:45:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-De-Santo-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:58:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Deuber-2003a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:37:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Emmett-1991">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:49:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Evenepoel-2009">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:43:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-FORESEE-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:01:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Fan-2009">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:29:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ferreira-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:01:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Finn-2004">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:22:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:37:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Gallieni-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 18:22:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hervas-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 14:57:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hutchison-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:09:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:24:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ittel-1991">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:34:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Janssen-1996">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:46:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jespersen-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:34:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Joy-2003">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:49:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kinugasa-2001">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:59:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Koiwa-2005a">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:09:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kurihara-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:25:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:41:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:24:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-McIntyre-2009">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:55:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pflanz-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 20:18:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Phelps-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:03:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ring-1993">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:11:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Roxe-1989">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-03 12:07:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Rudnicki-1994">
<DESCRIPTION>
<P>"in a double-blind manner"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:38:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Russo-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:01:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sadek-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:12:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saif-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:22:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Salusky-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:48:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Schaefer-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:50:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shaheen-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:53:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Shigematsu-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:07:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spasovski-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:15:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spiegel-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:30:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Sprague-2009a">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:41:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sprague-2009b">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:53:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakis-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 23:02:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yang-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:48:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-d_x0027_Almeida-Filho-2000">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2010-12-03 12:07:07 +1100" MODIFIED_BY="Narelle S Willis" NO="8">
<NAME>Blinding of investigators?</NAME>
<DESCRIPTION>
<P>Were the investigators blinded to the interventions?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Al_x002d_Baaj-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Almirall-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:25:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-BRiC-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:27:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Birck-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:27:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bleyer-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:40:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Block-2005">
<DESCRIPTION>
<P>No (except the EBCT results)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:07:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Borrego-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:44:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bro-1998">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 21:52:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-CARE-Study-2004">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:21:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-CARE_x002d_2-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:57:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Caravaca-1992">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:31:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Cheng-2008">
<DESCRIPTION>
<P>"provided blinded bottles to the research staff for distribution"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:04:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-1997">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:41:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 11:48:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 12:18:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chiang-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:02:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-D_x0027_Haese-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:31:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-DCOR-Study-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:45:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-De-Santo-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:58:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Deuber-2003a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:37:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Emmett-1991">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:49:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Evenepoel-2009">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:43:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-FORESEE-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:01:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Fan-2009">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:29:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ferreira-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:01:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Finn-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:22:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:37:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Gallieni-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 18:22:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hervas-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 14:58:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hutchison-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:09:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:24:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ittel-1991">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:34:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Janssen-1996">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:46:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jespersen-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:34:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Joy-2003">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:49:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kinugasa-2001">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:59:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Koiwa-2005a">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:09:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kurihara-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:25:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:41:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:24:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-McIntyre-2009">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:55:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pflanz-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 20:18:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Phelps-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:03:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ring-1993">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:11:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Roxe-1989">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-03 12:07:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Rudnicki-1994">
<DESCRIPTION>
<P>"in a double-blind manner"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:38:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Russo-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:01:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sadek-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:12:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saif-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:22:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Salusky-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:48:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Schaefer-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:50:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shaheen-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:53:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Shigematsu-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:07:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spasovski-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:15:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spiegel-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:31:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Sprague-2009a">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:41:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sprague-2009b">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:53:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakis-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 23:02:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yang-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:48:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-d_x0027_Almeida-Filho-2000">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2010-12-02 17:28:00 +1100" MODIFIED_BY="Narelle S Willis" NO="9">
<NAME>Blinding of outcome assessors?</NAME>
<DESCRIPTION>
<P>Were the outcome assessors blinded to the interventions?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Al_x002d_Baaj-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Almirall-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:25:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-BRiC-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:27:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Birck-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:28:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bleyer-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:40:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Block-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:07:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Borrego-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:44:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bro-1998">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 21:52:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-CARE-Study-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:21:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-CARE_x002d_2-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:57:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Caravaca-1992">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:31:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Cheng-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:04:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-1997">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:42:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 11:48:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 12:18:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chiang-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:02:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-D_x0027_Haese-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:31:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-DCOR-Study-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:45:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-De-Santo-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:58:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Deuber-2003a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:37:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Emmett-1991">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:49:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Evenepoel-2009">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:43:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-FORESEE-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:00:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fan-2009">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:29:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ferreira-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:01:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Finn-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:22:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:37:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Gallieni-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 18:22:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hervas-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 14:58:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hutchison-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:09:59 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:24:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ittel-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:34:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Janssen-1996">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:46:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jespersen-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:34:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Joy-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:49:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kinugasa-2001">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:59:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Koiwa-2005a">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:09:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:25:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:41:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:24:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-McIntyre-2009">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:55:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pflanz-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 20:18:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Phelps-2002">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:03:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ring-1993">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:11:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Roxe-1989">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:08:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Rudnicki-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:38:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Russo-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:01:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sadek-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:12:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saif-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:22:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Salusky-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:48:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Schaefer-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:50:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shaheen-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:53:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shigematsu-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:07:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spasovski-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:15:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spiegel-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:30:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sprague-2009a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:41:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sprague-2009b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:53:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakis-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 23:02:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yang-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:48:42 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-d_x0027_Almeida-Filho-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2010-12-02 17:28:01 +1100" MODIFIED_BY="Narelle S Willis" NO="10">
<NAME>Blinding of data analysers?</NAME>
<DESCRIPTION>
<P>Were the people analysing the data blinded to intervention groups?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Al_x002d_Baaj-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Almirall-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:25:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-BRiC-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:27:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Birck-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:28:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bleyer-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 12:40:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Block-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:07:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Borrego-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:44:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bro-1998">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 21:52:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-CARE-Study-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:21:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-CARE_x002d_2-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:57:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Caravaca-1992">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:31:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Cheng-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:04:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-1997">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:42:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 11:48:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 12:18:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chiang-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:02:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-D_x0027_Haese-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:31:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-DCOR-Study-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:45:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-De-Santo-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:58:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Deuber-2003a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:37:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Emmett-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:49:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Evenepoel-2009">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:43:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-FORESEE-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:00:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fan-2009">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:29:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ferreira-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:01:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Finn-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:22:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:37:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Gallieni-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 18:22:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hervas-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 14:58:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hutchison-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:10:00 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:24:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ittel-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:34:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Janssen-1996">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:46:55 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jespersen-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:34:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Joy-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:49:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kinugasa-2001">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:59:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Koiwa-2005a">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:09:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:25:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:41:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:24:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-McIntyre-2009">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:55:06 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pflanz-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 20:18:49 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Phelps-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:03:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ring-1993">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:11:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Roxe-1989">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:08:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Rudnicki-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:38:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Russo-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:01:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sadek-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:12:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saif-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:22:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Salusky-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:48:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Schaefer-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:50:22 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shaheen-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:53:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Shigematsu-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:07:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spasovski-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:15:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spiegel-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:30:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sprague-2009a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:41:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sprague-2009b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:53:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakis-2008">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 23:02:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yang-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:48:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-d_x0027_Almeida-Filho-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2010-12-02 17:29:32 +1100" MODIFIED_BY="Narelle S Willis" NO="11">
<NAME>Intention to treat?</NAME>
<DESCRIPTION>
<P>Was intention-to-treat analysis undertaking?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Al_x002d_Baaj-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:22:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Almirall-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:25:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-BRiC-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:27:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Birck-1999">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:28:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Bleyer-1999">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-02 17:29:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Block-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:07:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Borrego-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:44:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Bro-1998">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 21:52:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-CARE-Study-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:21:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-CARE_x002d_2-Study-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 13:57:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Caravaca-1992">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 14:31:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Cheng-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:04:11 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chertow-1997">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-06 16:42:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chertow-1999">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 11:48:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chertow-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 12:18:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chiang-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:02:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-D_x0027_Haese-2003">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:31:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-DCOR-Study-2007">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:45:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-De-Santo-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 14:58:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Deuber-2003a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:37:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Emmett-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 15:49:08 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Evenepoel-2009">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:43:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-FORESEE-Study-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:01:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Fan-2009">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:28:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ferreira-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:01:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Finn-2004">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:22:48 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fischer-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 17:37:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Gallieni-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 18:22:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hervas-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 14:58:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hutchison-2005">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:10:01 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Itoh-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:24:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ittel-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:34:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Janssen-1996">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 15:46:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jespersen-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:34:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Joy-2003">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:49:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kinugasa-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 18:59:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Koiwa-2005a">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:09:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kurihara-2005">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:25:36 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Liu-2006">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 17:41:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Malluche-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:24:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-McIntyre-2009">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 18:55:07 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Pflanz-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 20:18:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Phelps-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:03:17 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ring-1993">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-22 22:11:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Roxe-1989">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:08:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Rudnicki-1994">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:38:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Russo-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:01:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sadek-2003">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:12:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Saif-2007">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:22:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Salusky-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 16:48:32 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Schaefer-1991">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:50:27 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Shaheen-2004">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 21:53:53 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Shigematsu-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:07:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spasovski-2006">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:15:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Spiegel-2007">
<DESCRIPTION>
<P>no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:31:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sprague-2009a">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:41:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Sprague-2009b">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 22:53:30 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tzanakis-2008">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 23:02:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yang-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-08 16:48:45 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-d_x0027_Almeida-Filho-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-01-17 11:02:59 +1100" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-01-17 10:54:54 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2010-12-08 16:10:09 +1100" MODIFIED_BY="Narelle S Willis">Characteristics and key results of studies analysing the effects of various phosphate binders on bone densitometry, bone histomorphometry and vascular calcification</TITLE>
<TABLE COLS="6" ROWS="11">
<TR>
<TH VALIGN="MIDDLE">
<P>
<B>Study, year </B>
</P>
</TH>
<TH VALIGN="MIDDLE">
<P>
<B>Comparisons</B>
</P>
</TH>
<TH VALIGN="MIDDLE">
<P>
<B>Study duration (months)</B>
</P>
</TH>
<TH VALIGN="MIDDLE">
<P>
<B>Number of participants</B>
</P>
</TH>
<TH VALIGN="MIDDLE">
<P>
<B>Outcomes </B>analysed</P>
</TH>
<TH VALIGN="MIDDLE">
<P>
<B>Key findings </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-BRiC-Study-2008" TYPE="STUDY">BRiC Study 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer versus calcium acetate</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P>CAC scores using electron beam computer tomography</P>
<P>Bone histomorphometry</P>
</TD>
<TD VALIGN="TOP">
<P>CAC progression and bone remodelling did not differ between the two groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Block-2005" TYPE="STUDY">Block 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer versus calcium carbonate plus calcium acetate</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>129</P>
</TD>
<TD VALIGN="TOP">
<P>CAC scores using electron beam computer tomography</P>
</TD>
<TD VALIGN="TOP">
<P>Calcium-containing phosphate binders increased coronary artery calcium scores compared with sevelamer (P = 0.01)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer versus calcium acetate</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>132</P>
</TD>
<TD VALIGN="TOP">
<P>Vascular calcification scores<SUP>$</SUP> (Agatston scores) using electron beam computer tomography</P>
</TD>
<TD VALIGN="TOP">
<P>Coronary, aortic and valvular calcification progressed in calcium-treated participants but no significant progression was noted in the sevelamer treated group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-CARE_x002d_2-Study-2008" TYPE="STUDY">CARE-2 Study 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer plus atorvastatin versus calcium acetate plus atorvastatin</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>203</P>
</TD>
<TD VALIGN="TOP">
<P>Vascular calcification scores (Agatston scores) using electron beam computer tomography</P>
</TD>
<TD VALIGN="TOP">
<P>Coronary calcification scores was similar in both groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Raggi 2005*</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer versus calcium acetate</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>111</P>
</TD>
<TD VALIGN="TOP">
<P>Thoracic vertebral bone attenuation using electron beam computed tomography</P>
</TD>
<TD VALIGN="TOP">
<P>Trabecular bone attenuation decreased significantly in sevelamer-treated participants (P &lt; 0.05)</P>
<P>Cortical bone attenuation did not decrease significantly with sevelamer (P = 0.05)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Russo-2007" TYPE="STUDY">Russo 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer versus calcium carbonate versus low-phosphorus diet</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>90</P>
</TD>
<TD VALIGN="TOP">
<P>CAC scores using electron beam computer tomography</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer reduced the progression of CAC while calcium carbonate did not increase or reduce the progression on CAC</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-D_x0027_Haese-2003" TYPE="STUDY">D'Haese 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Lanthanum carbonate versus placebo</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
<TD VALIGN="TOP">
<P>Bone histomorphometry analysing</P>
</TD>
<TD VALIGN="TOP">
<P>The prevalence of renal osteodystrophy decreased from 36% to 18% in the lanthanum carbonate group and increased from 43% to 53% in calcium carbonate-treated participants.</P>
<P>Bone lanthanum levels were higher in lanthanum carbonate-treated participants than calcium carbonate-treated participants</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Phelps-2002" TYPE="STUDY">Phelps 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Calcium acetate 2 g/day versus calcium acetate 6 g/day</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>BMD at lumbar spine, femoral neck and greater trochanter using DEXA</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference between treatment groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ferreira-2008" TYPE="STUDY">Ferreira 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer versus calcium carbonate</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>91</P>
</TD>
<TD VALIGN="TOP">
<P>Mineralization lag time, changes in bone turnover, development of osteomalacia, adynamic bone disease</P>
</TD>
<TD VALIGN="TOP">
<P>Bone formation and trabecular architecture increased with sevelamer with no changes in bone turnover or mineralization</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Malluche-2008" TYPE="STUDY">Malluche 2008</LINK>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Lanthanum carbonate versus standard phosphate binder therapy</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>211</P>
</TD>
<TD VALIGN="TOP">
<P>Bone histomorphometry analysing changes in bone turnover, mineralization, bone volume and lanthanum content in bone</P>
</TD>
<TD VALIGN="TOP">
<P>Participants on lanthanum carbonate had an improvement in bone turn over and bone volume.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>$</SUP> Agatston score was obtained by multiplying the area of calcified focus by a weighted density coefficient based on the peak density of the calcification noted in the electron beam computed tomography<BR/>*Substudy of <LINK REF="STD-Chertow-2002" TYPE="STUDY">Chertow 2002</LINK>
<BR/>CAC - coronary artery calcium/calcification<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-12-23 13:48:58 +1100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-12-15 22:15:33 +1100" MODIFIED_BY="Narelle S Willis">Serum phosphorus data from miscellaneous studies not included in the meta-analysis</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH ROWSPAN="2" VALIGN="MIDDLE">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Comparison</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="TOP">
<P>Phosphorus (mg/dL)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Comment</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Treatment group</P>
</TH>
<TH ALIGN="CENTER">
<P>Control group</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Niacinamide versus placebo</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-0.79</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>+ 0.13</P>
</TD>
<TD VALIGN="TOP">
<P>A significant decrease in serum phosphorus levels was noted only in the niacinamide group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Fan-2009" TYPE="STUDY">Fan 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer carbonate powder versus sevelamer hydrochloride</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.0 ± 1.5</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.2 ± 1.1</P>
</TD>
<TD VALIGN="TOP">
<P>Both agents reduced serum phosphorus and no significant difference between two groups was noted</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer hydrochloride and calcium carbonate versus colestimide and calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.63 ± 1.93</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.11 ± 1.31</P>
</TD>
<TD VALIGN="TOP">
<P>Both agents reduced serum phosphorus and no significant difference between two groups was noted</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-McIntyre-2009" TYPE="STUDY">McIntyre 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Iron-magnesium hydroxycarbonate 1 g versus 2 g versus placebo</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1 g: -1.4</P>
<P>2 g: -2.1</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>NR</P>
</TD>
<TD VALIGN="TOP">
<P>Significant decrease in phosphorus levels were noted in both groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tzanakis-2008" TYPE="STUDY">Tzanakis 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Magnesium carbonate versus calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.12 ± 0.70</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.28 ± 0.74</P>
</TD>
<TD>
<P>Significant decrease in phosphorus levels were noted in both groups</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Ferric citrate versus calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.7 ± 1.6</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5.2 ± 1.5</P>
</TD>
<TD VALIGN="TOP">
<P>Both agents reduced serum phosphorus and no significant difference between two groups was noted</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NR - not reported</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-12-23 13:48:58 +1100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-12-15 22:15:17 +1100" MODIFIED_BY="Narelle S Willis">Serum calcium data from miscellaneous studies not included in the meta-analysis</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH ROWSPAN="2" VALIGN="MIDDLE">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Comparison</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="TOP">
<P>Calcium (mg/dL)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Comment</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Treatment group</P>
</TH>
<TH ALIGN="CENTER">
<P>Control group</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Niacinamide versus placebo</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9.52 ± 0.76</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9.45 ± 0.70</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference in serum calcium levels was noted between the groups </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Fan-2009" TYPE="STUDY">Fan 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer carbonate powder versus sevelamer hydrochloride</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9.1 ± 0.8</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9.1 ± 0.9</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference in serum calcium levels was noted between the groups </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer hydrochloride and calcium carbonate versus colestimide and calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>8.68 ± 0.62</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>8.84 ± 0.45</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference in serum calcium levels was noted between the groups </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tzanakis-2008" TYPE="STUDY">Tzanakis 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Magnesium carbonate versus calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>8.97 ± 0.57</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9.72 ± 0.42</P>
</TD>
<TD>
<P>A significant increase in calcium levels from baseline was reported in calcium group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Ferric citrate versus calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9.0 ± 1.0</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9.5 ± 0.7</P>
</TD>
<TD VALIGN="TOP">
<P>A significant increase in calcium levels from baseline was reported in calcium group </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2010-12-23 13:48:58 +1100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-12-16 12:18:25 +1100" MODIFIED_BY="Narelle S Willis">Serum parathyroid hormone (PTH) data from miscellaneous studies not included in the meta-analysis</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH ROWSPAN="2">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Comparison</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>PTH values (pg/mL)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2">
<P>Comment</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>treatment group</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Control group</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Niacinamide versus placebo</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>296 ± 195</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>280 ± 222</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference between the two groups was noted</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Fan-2009" TYPE="STUDY">Fan 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer carbonate powder versus sevelamer hydrochloride</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>390</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>408</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference between the two groups was noted</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Itoh-2008" TYPE="STUDY">Itoh 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Sevelamer hydrochloride and calcium carbonate versus colestimide and calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>161.6 ± 118.4</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>91.4 ± 62.8</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference between the two groups was noted</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Spiegel-2007" TYPE="STUDY">Spiegel 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Magnesium carbonate versus calcium acetate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>322 ± 416</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>373 ± 326</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference between the two groups was noted</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tzanakis-2008" TYPE="STUDY">Tzanakis 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Magnesium carbonate versus calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>251 ± 118</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>212 ± 198</P>
</TD>
<TD>
<P>No significant difference between the two groups was noted</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Ferric citrate versus calcium carbonate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>240 ± 184</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>228 ± 160</P>
</TD>
<TD VALIGN="TOP">
<P>No significant difference between the two groups was noted</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2011-01-17 11:02:59 +1100" MODIFIED_BY="Narelle S Willis" NO="5">
<TITLE MODIFIED="2010-12-15 22:22:36 +1100" MODIFIED_BY="Narelle S Willis">Subgroup analyses to explore the reasons for heterogeneity in studies comparing newer agents with older phosphate binding agents</TITLE>
<TABLE COLS="9" ROWS="44">
<TR>
<TH VALIGN="MIDDLE">
<P>
<B>Variables</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>All-cause mortality</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Treatment-related hypercalcaemia</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>PTH (pg/</B>mL<B>)</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Phosphorus (mg/</B>dL<B>)</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER">
<P>
<B>RR (95% CI); N'</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>P²</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>RR (95% CI); N</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>P</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>MD (95% CI); N</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>P</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>MD (95% CI); N</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>P</P>
</TH>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Older versus newer agents</I> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Calcium carbonate versus sevelamer and lanthanum</P>
</TD>
<TD VALIGN="TOP">
<P>0.75 (0.39 to 1.44); 4</P>
</TD>
<TD VALIGN="TOP">
<P>0.82</P>
</TD>
<TD VALIGN="TOP">
<P>0.45 (0.28 to 0.73); 5</P>
</TD>
<TD VALIGN="TOP">
<P>0.11</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>51.72 (17.66 to 85.78); 5</P>
</TD>
<TD VALIGN="TOP">
<P>0.82</P>
</TD>
<TD VALIGN="TOP">
<P>0.09 (-0.06 to 0.25); 10</P>
</TD>
<TD VALIGN="TOP">
<P>0.15</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Calcium acetate versus sevelamer and lanthanum</P>
</TD>
<TD VALIGN="TOP">
<P>0.64 (0.21 to 1.94); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.20 (0.07 to 0.50); 6</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>62.02 (-21.97 to 146.03); 3</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.41 (0.00 to 0.82); 6</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Baseline PTH</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&lt; 150</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0.61</P>
</TD>
<TD VALIGN="TOP">
<P>0.02 (0.00 to 0.08); 1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>&lt; 0.001</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0.22</P>
</TD>
<TD VALIGN="TOP">
<P>0.10 (-0.13 to 0.33); 1</P>
</TD>
<TD VALIGN="TOP">
<P>0.49</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>150 to 300</P>
</TD>
<TD VALIGN="TOP">
<P>0.44 (0.04 to 4.3); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.30 (0.16 to 0.56); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>42.53 (8.26 to 76.81); 8</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.11 (-0.19 to 0.43); 7</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&gt; 300</P>
</TD>
<TD VALIGN="TOP">
<P>0.81 (0.48 to 1.37); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.42 (0.16 to 0.54); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>118.00 (8.18 to 218.0); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.31 (0.02 to 0.60); 8</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Type of calcium assay</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Corrected calcium</P>
</TD>
<TD VALIGN="TOP">
<P>0.56 (0.29 to 1.07); 4</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0.04</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0.25 (0.11 to 0.55); 7</P>
</TD>
<TD VALIGN="TOP">
<P>0.71</P>
</TD>
<TD VALIGN="TOP">
<P>57.89 (24.55 to 91.24); 8</P>
</TD>
<TD VALIGN="TOP">
<P>0.38</P>
</TD>
<TD VALIGN="TOP">
<P>0.13 (-0.11 to 0.37); 9</P>
</TD>
<TD VALIGN="TOP">
<P>0.42</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Absolute calcium</P>
</TD>
<TD VALIGN="TOP">
<P>1.12 (0.96 to 1.29); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.31 (0.14 to 0.68); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>26.58 (-10.70 to 63.86); 3</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.28 (0.01 to 0.54); 7</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Ionised calcium</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Washout of phosphate binder</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>0.75 (0.44 to 1.27); 5</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>0.27 (0.15 to 0.48); 10</P>
</TD>
<TD VALIGN="TOP">
<P>0.82</P>
</TD>
<TD VALIGN="TOP">
<P>58.16 (27.43 to 88.89); 9</P>
</TD>
<TD VALIGN="TOP">
<P>0.24</P>
</TD>
<TD VALIGN="TOP">
<P>0.18 (0.01 to 0.36); 14</P>
</TD>
<TD VALIGN="TOP">
<P>0.75</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.36 (0.04 to 3.05); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>29.42 (-49.84 to 108.7); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.36 (-0.32 to 1.05); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Study duration</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&lt; 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0.23</P>
</TD>
<TD VALIGN="TOP">
<P>0.24 (0.13 to 0.46); 5</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0.01</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>17.61 (-29.91 to 65.12); 6</P>
</TD>
<TD VALIGN="TOP">
<P>0.61</P>
</TD>
<TD VALIGN="TOP">
<P>0.48 (0.11 to 0.85); 7</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0.008</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6 to 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>0.43 (0.14 to 1.27); 3</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.62 (0.42 to 0.89); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>59.17 (-38.19 to 156.54); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-0.30 (-0.65 to 0.03); 3</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&gt; 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>0.90 (0.53 to 1.53); 3</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.16 (0.04 to 0.62); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>49.95 (11.66 to 88.25); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.11(0.01 to 0.21); 6</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Allocation concealment</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD VALIGN="TOP">
<P>0.57 (0.31 to 1.03); 2</P>
</TD>
<TD VALIGN="TOP">
<P>0.47</P>
</TD>
<TD VALIGN="TOP">
<P>0.41 (0.24 to 0.68); 5</P>
</TD>
<TD VALIGN="TOP">
<P>0.26</P>
</TD>
<TD VALIGN="TOP">
<P>49.95 (11.66 to 88.25); 4</P>
</TD>
<TD VALIGN="TOP">
<P>0.27</P>
</TD>
<TD VALIGN="TOP">
<P>0.19 (-0.02 to 0.40); 7</P>
</TD>
<TD VALIGN="TOP">
<P>0.97</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>0.79 (0.39 to 1.62); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.21 (0.07 to 0.60); 6</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>67.29 (28.73 to 105.86); 6</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.19 (-0.03,0.43); 9</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Blinding</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>0.36 (0.10 to 1.28); 1</P>
</TD>
<TD VALIGN="TOP">
<P>0.69</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>1.30 (0.68 to 1.91); 1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>&lt; 0.001</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>0.88 (0.58 to 1.35); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.27 (0.15 to 0.47); 10</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>47.95 (23.78 to 72.13); 11</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.11 (-0.01 to 0.23); 15</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Intention to treat analysis</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>0.67 (0.35 to 1.26): 5</P>
</TD>
<TD VALIGN="TOP">
<P>0.37</P>
</TD>
<TD VALIGN="TOP">
<P>0.49 (0.37 to 0.66); 6</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0.03</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>NA</P>
</TD>
<TD VALIGN="TOP">
<P>0.22 (0.01 to 0.45); 7</P>
</TD>
<TD VALIGN="TOP">
<P>0.74</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>1.22 (0.38 to 1.34); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.15 (0.04 to 0.44); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>54.78 (25.90 to 83.66); 8</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.16 (-0.13 to 0.46); 9</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Lost to follow-up (%)</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1 to 10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0.37</P>
</TD>
<TD VALIGN="TOP">
<P>0.21 (0.10 to 0.43); 3</P>
</TD>
<TD VALIGN="TOP">
<P>0.07</P>
</TD>
<TD VALIGN="TOP">
<P>30.76 (-7.04 to 68.56); 3</P>
</TD>
<TD VALIGN="TOP">
<P>0.52 </P>
</TD>
<TD VALIGN="TOP">
<P>0.49 (-0.01 to 0.99); 5</P>
</TD>
<TD VALIGN="TOP">
<P>0.26</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10 to 20</P>
</TD>
<TD VALIGN="TOP">
<P>1.22 (0.38, 3.88); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.15 (0.02 to 1.26); 3</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>6.00 (-56.85 to 68.85); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.18 (-0.10 to 0.47); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&gt; 20</P>
</TD>
<TD VALIGN="TOP">
<P>0.67 (0.35 to 1.26); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.49 (0.33 to 0.72); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>58.32 (15.72 to 100.92); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.05 (-0.13 to 0.25); 7</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Number of participants</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1 to 20</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0.74</P>
</TD>
<TD VALIGN="TOP">
<P>0.27 (0.08 to 0.83); 1</P>
</TD>
<TD VALIGN="TOP">
<P>0.97</P>
</TD>
<TD VALIGN="TOP">
<P>51.48 (-32.66 to 135.6); 2</P>
</TD>
<TD VALIGN="TOP">
<P>0.71</P>
</TD>
<TD VALIGN="TOP">
<P>0.80 (0.19 to 1.41); 1</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0.05</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20 to 50</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.35 (0.04 to 0.62); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>40.00 (89.00 to 169.0); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.20 (-0.52 to 0.92); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>50 to 100</P>
</TD>
<TD VALIGN="TOP">
<P>1.00 (0.15 to 6.42); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.31 (0.14 to 0.68); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>27.08 (-7.23 to 61.40); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.44 (0.00 to 0.88); 6</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&gt; 100</P>
</TD>
<TD VALIGN="TOP">
<P>0.72 (0.40 to 1.30); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.24 (0.09 to 0.62); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>71.91 (17.19 to 126.62); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.06 (-0.01 to 0.19); 7</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>Baseline phosphorus</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&lt; 5.5 mg/dL</P>
</TD>
<TD VALIGN="TOP">
<P>0.53 (0.28 to 1.00); 1</P>
</TD>
<TD VALIGN="TOP">
<P>0.61</P>
</TD>
<TD VALIGN="TOP">
<P>0.41 (0.23 to 0.70); 1</P>
</TD>
<TD VALIGN="TOP">
<P>0.1</P>
</TD>
<TD VALIGN="TOP">
<P>55.00 (0.82 to 109.18); 1</P>
</TD>
<TD VALIGN="TOP">
<P>0.19</P>
</TD>
<TD VALIGN="TOP">
<P>0.10 (-0.22 to 0.42); 1</P>
</TD>
<TD VALIGN="TOP">
<P>0.52</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5.5 to 7.0 mg/dL</P>
</TD>
<TD VALIGN="TOP">
<P>0.57 (0.18 to 1.79); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.61 (0.38 to 1.00); 2</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>88.72 (9.69 to 167.25); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.30 (-0.13 to 0.72); 6</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7.0 to 8.0 mg/dL</P>
</TD>
<TD VALIGN="TOP">
<P>1.22 (0.38 to 3.88); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.31 (0.12 to 0.76); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>92.00 (43.91 to 140.90); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.63 (-0.65 to 1.90); 5</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>&gt; 8.0 mg/dL</P>
</TD>
<TD VALIGN="TOP">
<P>1.00 (0.15 to 6.42); 1</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.42 (0.22 to 0.79); 3</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>6.92 (-47.80 to 61.63); 3</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0.52 (-0.09 to 1.14); 4</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Some data are not estimable because no study with the variable of interest reported outcome or because studies in that group reported no events in both treatment and control arms. To convert parathyroid hormone pg/mL to pmol/L, multiply by 0.11. To convert calcium mg/dL to mmol/L, multiply by 0.25. To convert phosphorus mg/dL to mmol/L, multiply by 0.323.</P>
<P>'N - number of studies</P>
<P>²P value for interaction, calculated by analysing each category compared to first (referent) category for categorical variables; P &lt; 0.05 was considered statistically significant.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-12-22 11:01:24 +1100" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2010-12-22 11:00:37 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Calcium salts versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-07 11:09:44 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Calcium salts</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-11-05 02:23:27 +1100" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.0" STUDY_ID="STD-Rudnicki-1994" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-07 16:38:02 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Hypercalcaemia</NAME>
<GROUP_LABEL_1>Calcium salts</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-11-05 02:23:50 +1100" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.0" STUDY_ID="STD-Rudnicki-1994" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-12-03 14:38:35 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Serum phosphorus</NAME>
<GROUP_LABEL_1>Calcium salts</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3977097502525328" CI_START="-1.2422902497474677" EFFECT_SIZE="-0.8200000000000003" ESTIMABLE="YES" MEAN_1="5.21" MEAN_2="6.03" ORDER="3623" SD_1="0.53" SD_2="0.37" SE="0.21545816814923083" STUDY_ID="STD-Rudnicki-1994" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2010-12-22 11:00:37 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Calcium salts</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9119927969080113" CI_START="0.12800720309198965" EFFECT_SIZE="0.5200000000000005" ESTIMABLE="YES" MEAN_1="5.04" MEAN_2="4.52" MODIFIED="2010-12-08 11:19:41 +1100" MODIFIED_BY="Narelle S Willis" ORDER="178" SD_1="0.36" SD_2="0.48" SE="0.19999999999999998" STUDY_ID="STD-Rudnicki-1994" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-12-08 11:44:38 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Calcium acetate versus calcium carbonate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-03 16:35:50 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="35" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3625" O_E="0.0" SE="0.0" STUDY_ID="STD-Almirall-1994" TOTAL_1="4" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.29973378827045" CI_START="0.0736840147571832" EFFECT_SIZE="1.1290322580645162" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.23803942017072" LOG_CI_START="-1.1326267191387138" LOG_EFFECT_SIZE="0.052706350516002996" ORDER="3626" O_E="0.0" SE="1.3925410252170105" STUDY_ID="STD-Caravaca-1992" TOTAL_1="31" TOTAL_2="35" VAR="1.9391705069124425" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4568404730531954" CI_END="10.989480112651755" CI_START="0.10645641871587619" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0816194785331157" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="59.29731657516748" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.0409771474237508" LOG_CI_START="-0.972828147951862" LOG_EFFECT_SIZE="0.03407449973594439" METHOD="MH" MODIFIED="2010-12-07 16:38:14 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.11701418155954091" P_Q="0.0" P_Z="0.9471175189997766" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.8413289568754767" TOTALS="YES" TOTAL_1="41" TOTAL_2="47" WEIGHT="100.0" Z="0.06632696063222338">
<NAME>Hypercalcaemia</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3362415978400985" CI_START="0.1629778463189545" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.1258849874230806" LOG_CI_START="-0.7878714255059294" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="3627" O_E="0.0" SE="0.5367450401216932" STUDY_ID="STD-Caravaca-1992" TOTAL_1="30" TOTAL_2="35" VAR="0.28809523809523807" WEIGHT="65.71249799213938"/>
<DICH_DATA CI_END="101.7702896915023" CI_START="0.2882990494251059" EFFECT_SIZE="5.416666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.007621010748531" LOG_CI_START="-0.5401567895580695" LOG_EFFECT_SIZE="0.7337321105952308" ORDER="3628" O_E="0.0" SE="1.4965772916036075" STUDY_ID="STD-Pflanz-1994" TOTAL_1="11" TOTAL_2="12" VAR="2.2397435897435893" WEIGHT="34.28750200786063"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9072419224363555" CI_END="2.6048689998619596" CI_START="0.605572259363163" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2559603519185905" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.4157858873024781" LOG_CI_START="-0.21783402763189838" LOG_EFFECT_SIZE="0.09897592983528987" METHOD="MH" MODIFIED="2010-12-07 15:10:47 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.9235195862901691" P_Q="0.0" P_Z="0.5403256775756604" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="67" TOTAL_2="69" WEIGHT="300.0" Z="0.6123205828643278">
<NAME>Adverse gastrointestinal events</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.766239014647583" CI_START="0.4148701115152691" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.5759078779346776" LOG_CI_START="-0.38208785191856476" LOG_EFFECT_SIZE="0.09691001300805642" NO="1" P_CHI2="1.0" P_Z="0.6917092902884736" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.39653649660045176">
<NAME>Gastritis</NAME>
<DICH_DATA CI_END="3.766239014647583" CI_START="0.4148701115152691" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5759078779346776" LOG_CI_START="-0.38208785191856476" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="3629" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-d_x0027_Almeida-Filho-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3195576307212885" CI_END="12.558467916798211" CI_START="0.21780235026724507" DF="1" EFFECT_SIZE="1.6538633039143358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="1.0989366604310122" LOG_CI_START="-0.6619374381588097" LOG_EFFECT_SIZE="0.21849961113610122" MODIFIED="2010-10-03 16:36:54 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.5718737403505811" P_Z="0.6266781273014157" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="0.4864077094503533">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="3630" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-d_x0027_Almeida-Filho-2000" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="57.314570507182644"/>
<DICH_DATA CI_END="72.35616493859207" CI_START="0.14597926809642672" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8594755400818401" LOG_CI_START="-0.8357088181240911" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="3631" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Pflanz-1994" TOTAL_1="11" TOTAL_2="12" VAR="2.506410256410256" WEIGHT="42.68542949281736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.496967234329235" CI_END="3.521627590577732" CI_START="0.38362890021372864" DF="1" EFFECT_SIZE="1.1623244467598788" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.5467434277503684" LOG_CI_START="-0.4160886832256401" LOG_EFFECT_SIZE="0.06532737226236415" MODIFIED="2010-12-07 15:10:47 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.48083578332827503" P_Z="0.790267003557045" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="100.0" Z="0.26596391079870235">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="3.2766354889097595" CI_START="0.30519110330845245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5154281307445581" LOG_CI_START="-0.5154281307445581" LOG_EFFECT_SIZE="0.0" ORDER="3632" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-d_x0027_Almeida-Filho-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.3666666666666667" WEIGHT="87.23784024988844"/>
<DICH_DATA CI_END="72.35616493859207" CI_START="0.14597926809642672" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8594755400818401" LOG_CI_START="-0.8357088181240911" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="3633" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Pflanz-1994" TOTAL_1="11" TOTAL_2="12" VAR="2.506410256410256" WEIGHT="12.762159750111561"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-12-07 15:10:47 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Abdominal bloating</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-03 16:41:16 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.127495826258464" CI_END="0.23725560039922985" CI_START="-0.610381846747823" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1865631231742966" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-12-08 11:32:32 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.7123229178434711" P_Q="1.0" P_Z="0.3882653441466607" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="75" UNITS="mg/dL" WEIGHT="100.00000000000003" Z="0.8627674567603077">
<NAME>Serum phosphorus</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8299819922700268" CI_START="-1.1299819922700274" EFFECT_SIZE="-0.15000000000000036" ESTIMABLE="YES" MEAN_1="4.79" MEAN_2="4.94" ORDER="3639" SD_1="0.6" SD_2="0.8" SE="0.5" STUDY_ID="STD-Almirall-1994" TOTAL_1="4" TOTAL_2="4" WEIGHT="18.70355183649077"/>
<CONT_DATA CI_END="1.0889561054404964" CI_START="-0.688956105440496" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.6" ORDER="3640" SD_1="0.9" SD_2="0.9" SE="0.4535573676110727" STUDY_ID="STD-Borrego-2000" TOTAL_1="7" TOTAL_2="9" WEIGHT="22.730010912401976"/>
<CONT_DATA CI_END="0.33095380167382515" CI_START="-1.130953801673824" EFFECT_SIZE="-0.39999999999999947" ESTIMABLE="YES" MEAN_1="5.57" MEAN_2="5.97" ORDER="3641" SD_1="1.54" SD_2="1.48" SE="0.37294246600421993" STUDY_ID="STD-Caravaca-1992" TOTAL_1="31" TOTAL_2="35" WEIGHT="33.61866162286607"/>
<CONT_DATA CI_END="1.0680163677677528" CI_START="-1.008016367767754" EFFECT_SIZE="0.02999999999999936" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="4.57" ORDER="3642" SD_1="1.32" SD_2="1.57" SE="0.5296099193431584" STUDY_ID="STD-d_x0027_Almeida-Filho-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="16.670624720566728"/>
<CONT_DATA CI_END="0.5731253482754399" CI_START="-2.3731253482754404" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="4.67" MEAN_2="5.57" ORDER="3643" SD_1="2.01" SD_2="1.54" SE="0.7516083764269471" STUDY_ID="STD-Pflanz-1994" TOTAL_1="11" TOTAL_2="12" WEIGHT="8.277150907674464"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.995668169556248" CI_END="0.17186248075884547" CI_START="-0.35172120514413485" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.08992936219264469" ESTIMABLE="YES" I2="19.93063061361601" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2010-12-08 11:32:32 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.2877423253274821" P_Q="1.0" P_Z="0.500771367612506" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.01796309303021838" TOTALS="YES" TOTAL_1="68" TOTAL_2="75" UNITS="mg/dL" WEIGHT="100.0" Z="0.6732765584407537">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8529519121748391" CI_START="-0.5329519121748388" EFFECT_SIZE="0.16000000000000014" ESTIMABLE="YES" MEAN_1="10.36" MEAN_2="10.2" ORDER="3634" SD_1="0.5" SD_2="0.5" SE="0.3535533905932738" STUDY_ID="STD-Almirall-1994" TOTAL_1="4" TOTAL_2="4" WEIGHT="12.479353964585865"/>
<CONT_DATA CI_END="0.39141030423149625" CI_START="-0.9914103042314977" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="9.8" ORDER="3635" SD_1="0.7" SD_2="0.7" SE="0.3527668414752787" STUDY_ID="STD-Borrego-2000" TOTAL_1="7" TOTAL_2="9" WEIGHT="12.528038005808076"/>
<CONT_DATA CI_END="0.05721971813333909" CI_START="-0.6972197181333362" EFFECT_SIZE="-0.3199999999999985" ESTIMABLE="YES" MEAN_1="9.88" MEAN_2="10.2" ORDER="3636" SD_1="0.68" SD_2="0.88" SE="0.19246257640895373" STUDY_ID="STD-Caravaca-1992" TOTAL_1="31" TOTAL_2="35" WEIGHT="32.43503511216766"/>
<CONT_DATA CI_END="0.32820673094519515" CI_START="-0.6882067309451946" EFFECT_SIZE="-0.17999999999999972" ESTIMABLE="YES" MEAN_1="9.73" MEAN_2="9.91" ORDER="3637" SD_1="0.62" SD_2="0.79" SE="0.25929391302792537" STUDY_ID="STD-d_x0027_Almeida-Filho-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="20.940867099084944"/>
<CONT_DATA CI_END="0.818037982460966" CI_START="-0.17803798246096547" EFFECT_SIZE="0.3200000000000003" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="9.28" ORDER="3638" SD_1="0.68" SD_2="0.52" SE="0.2541056807111895" STUDY_ID="STD-Pflanz-1994" TOTAL_1="11" TOTAL_2="12" WEIGHT="21.61670581835345"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.2643186154406187" CI_END="0.19436072799746373" CI_START="-10.027086888686924" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.91636308034473" ESTIMABLE="YES" I2="69.36573546252869" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2010-12-08 11:44:38 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.07080249043240139" P_Q="1.0" P_Z="0.0593722666421115" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="10.301678787878824" TOTALS="YES" TOTAL_1="15" TOTAL_2="16" UNITS="mg²/dL²" WEIGHT="100.0" Z="1.8854265919573814">
<NAME>Serum calcium x phosphorus product</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.434803235620008" CI_START="-7.234803235620006" EFFECT_SIZE="-1.3999999999999986" ESTIMABLE="YES" MEAN_1="49.7" MEAN_2="51.1" ORDER="3646" SD_1="2.9" SD_2="5.2" SE="2.9769951293208394" STUDY_ID="STD-Almirall-1994" TOTAL_1="4" TOTAL_2="4" WEIGHT="35.47957650743614"/>
<CONT_DATA CI_END="-5.896557747969758" CI_START="-7.803442252030245" EFFECT_SIZE="-6.850000000000001" ESTIMABLE="YES" MEAN_1="44.83" MEAN_2="51.68" ORDER="3647" SD_1="1.42" SD_2="0.8" SE="0.48645906738637756" STUDY_ID="STD-Pflanz-1994" TOTAL_1="11" TOTAL_2="12" WEIGHT="64.52042349256385"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2010-12-08 11:32:59 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="7" TOTAL_2="9" UNITS="pg/mL" WEIGHT="0.0" Z="0.0">
<NAME>Serum iPTH</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<CONT_DATA CI_END="107.02436997324429" CI_START="-211.0243699732443" EFFECT_SIZE="-52.0" ESTIMABLE="YES" MEAN_1="244.0" MEAN_2="296.0" ORDER="3644" SD_1="84.0" SD_2="224.0" SE="81.1363735393141" STUDY_ID="STD-Borrego-2000" TOTAL_1="7" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2392473816887122" CI_END="1.7383074260991644" CI_START="-1.3167744492720652" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21076648841354956" ESTIMABLE="YES" I2="19.305861381985874" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2010-12-08 11:33:42 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.26561623353638186" P_Q="1.0" P_Z="0.7868285413484155" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.2789696969696956" TOTALS="YES" TOTAL_1="26" TOTAL_2="27" UNITS="mEq/L" WEIGHT="100.0" Z="0.2704311984361072">
<NAME>Serum bicarbonate</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2046261102554394" CI_START="-1.8046261102554337" EFFECT_SIZE="-0.29999999999999716" ESTIMABLE="YES" MEAN_1="18.6" MEAN_2="18.9" ORDER="3652" SD_1="2.0" SD_2="2.2" SE="0.7676804890925217" STUDY_ID="STD-d_x0027_Almeida-Filho-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="69.95491244626194"/>
<CONT_DATA CI_END="3.9873954189266105" CI_START="-1.1873954189266063" EFFECT_SIZE="1.4000000000000021" ESTIMABLE="YES" MEAN_1="21.6" MEAN_2="20.2" ORDER="3653" SD_1="2.7" SD_2="3.6" SE="1.320123961121558" STUDY_ID="STD-Pflanz-1994" TOTAL_1="11" TOTAL_2="12" WEIGHT="30.045087553738053"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.37299762946679577" CI_END="11.824393820689627" CI_START="-8.985142239639922" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4196257905248524" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2010-12-08 11:33:42 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.9457622991428263" P_Q="1.0" P_Z="0.789147848041092" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="38" UNITS="IU/L" WEIGHT="99.99999999999999" Z="0.26741734298028846">
<NAME>Serum alkaline phosphatase</NAME>
<GROUP_LABEL_1>Calcium acetate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium carbonate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium acetate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium carbonate</GRAPH_LABEL_2>
<CONT_DATA CI_END="56.91759145680401" CI_START="-68.91759145680402" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="131.0" MEAN_2="137.0" ORDER="3648" SD_1="51.0" SD_2="39.0" SE="32.101401838549044" STUDY_ID="STD-Almirall-1994" TOTAL_1="4" TOTAL_2="4" WEIGHT="2.73476886166047"/>
<CONT_DATA CI_END="60.86370874883541" CI_START="-104.8637087488354" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="174.0" MEAN_2="196.0" ORDER="3649" SD_1="77.0" SD_2="92.0" SE="42.278179294341" STUDY_ID="STD-Borrego-2000" TOTAL_1="7" TOTAL_2="9" WEIGHT="1.5766528132945876"/>
<CONT_DATA CI_END="12.73123184701714" CI_START="-8.73123184701714" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="90.0" MEAN_2="88.0" ORDER="3650" SD_1="12.0" SD_2="16.0" SE="5.4752188977265535" STUDY_ID="STD-Janssen-1996" TOTAL_1="14" TOTAL_2="13" WEIGHT="94.0081808602058"/>
<CONT_DATA CI_END="83.26503389293002" CI_START="-77.26503389293002" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="117.0" MEAN_2="114.0" ORDER="3651" SD_1="100.0" SD_2="96.0" SE="40.952300412686334" STUDY_ID="STD-Pflanz-1994" TOTAL_1="11" TOTAL_2="12" WEIGHT="1.6803974648391296"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-12-22 11:01:02 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Calcium ketoglutarate versus other calcium salts</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-22 11:01:02 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Calcium ketoglutarate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca ketoglutarate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other Ca salts</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-08 10:59:23 +1100" MODIFIED_BY="Narelle S Willis" ORDER="177" O_E="0.0" SE="0.0" STUDY_ID="STD-Birck-1999" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3654" O_E="0.0" SE="0.0" STUDY_ID="STD-Bro-1998" TOTAL_1="17" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-03 16:41:03 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Adverse gastrointestinal events</NAME>
<GROUP_LABEL_1>Calcium ketoglutarate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca ketoglutarate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other Ca salts</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gastritis</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-03 16:40:42 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhoea</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gastroparesis</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="38.41737465163205" CI_START="0.6507472263968965" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5845276829289354" LOG_CI_START="-0.18658767425689776" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="3655" O_E="0.0" SE="1.0403619279733713" STUDY_ID="STD-Bro-1998" TOTAL_1="17" TOTAL_2="17" VAR="1.0823529411764705" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.018901039557175515" CI_END="0.12316485321856648" CI_START="-0.3182505829337001" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09754286485756682" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2010-12-08 11:55:05 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.8906505761344369" P_Q="1.0" P_Z="0.38637186550522673" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="24" UNITS="mg/dL" WEIGHT="100.0" Z="0.86621575238135">
<NAME>Serum phosphorus</NAME>
<GROUP_LABEL_1>Calcium ketoglutarate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca ketoglutarate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other Ca salts</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4080011155513807" CI_START="-1.4080011155513807" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.0" ORDER="1" SD_1="1.95" SD_2="1.85" SE="0.7183811165192391" STUDY_ID="STD-Birck-1999" TOTAL_1="14" TOTAL_2="14" WEIGHT="2.457135142432834"/>
<CONT_DATA CI_END="0.12347027692519605" CI_START="-0.32347027692519537" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="4.6" ORDER="3658" SD_1="0.3" SD_2="0.2" SE="0.1140175425099138" STUDY_ID="STD-Bro-1998" TOTAL_1="10" TOTAL_2="10" WEIGHT="97.54286485756717"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2010-12-08 11:55:05 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Calcium ketoglutarate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca ketoglutarate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other Ca salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Total calcium</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Ionised calcium</NAME>
<CONT_DATA CI_END="-0.31234774594234216" CI_START="-0.48765225405765855" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="5.2" ORDER="3656" SD_1="0.1" SD_2="0.1" SE="0.0447213595499958" STUDY_ID="STD-Bro-1998" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2010-12-08 11:56:35 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="mg²/dL²" WEIGHT="0.0" Z="0.0">
<NAME>Serum calcium x phosphorus product</NAME>
<GROUP_LABEL_1>Calcium ketoglutarate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca ketoglutarate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other Ca salts</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.3471145972126424" CI_START="-5.652885402787358" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="21.8" MEAN_2="26.3" ORDER="3660" SD_1="1.5" SD_2="1.1" SE="0.5882176467941097" STUDY_ID="STD-Bro-1998" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2010-12-08 11:56:35 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="pg/mL" WEIGHT="0.0" Z="0.0">
<NAME>Serum iPTH</NAME>
<GROUP_LABEL_1>Calcium ketoglutarate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca ketoglutarate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other Ca salts</GRAPH_LABEL_2>
<CONT_DATA CI_END="85.06919175285135" CI_START="-155.06919175285134" EFFECT_SIZE="-35.0" ESTIMABLE="YES" MEAN_1="266.0" MEAN_2="301.0" ORDER="3659" SD_1="125.0" SD_2="148.0" SE="61.26091739437143" STUDY_ID="STD-Bro-1998" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.13115205786120337" CI_END="2.291690360787537" CI_START="1.0338615593089036" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6627759600482204" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2010-10-03 17:02:32 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.7172406095329447" P_Q="1.0" P_Z="2.19619246666879E-7" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="31" UNITS="mEq/L" WEIGHT="100.00000000000001" Z="5.181915046344059">
<NAME>Serum bicarbonate</NAME>
<GROUP_LABEL_1>Calcium ketoglutarate</GROUP_LABEL_1>
<GROUP_LABEL_2>Other calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ca ketoglutarate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other Ca salts</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.3616255225385356" CI_START="-0.7616255225385342" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="22.5" MEAN_2="21.2" ORDER="3661" SD_1="3.5" SD_2="1.8" SE="1.051869084738482" STUDY_ID="STD-Birck-1999" TOTAL_1="14" TOTAL_2="14" WEIGHT="9.30600998794558"/>
<CONT_DATA CI_END="2.360392731813236" CI_START="1.0396072681867696" EFFECT_SIZE="1.7000000000000028" ESTIMABLE="YES" MEAN_1="24.1" MEAN_2="22.4" ORDER="3662" SD_1="0.7" SD_2="1.2" SE="0.33694125862634555" STUDY_ID="STD-Bro-1998" TOTAL_1="17" TOTAL_2="17" WEIGHT="90.69399001205443"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-12-22 11:01:14 +1100" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Sevelamer versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-07 11:12:28 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3663" O_E="0.0" SE="0.0" STUDY_ID="STD-Chertow-1997" TOTAL_1="24" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7874455850735969" CI_END="3.4502415174323384" CI_START="0.08488839798976794" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5411889458337238" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.5378494968173075" LOG_CI_START="-1.071151662327722" LOG_EFFECT_SIZE="-0.2666510827552072" METHOD="MH" MODIFIED="2010-12-22 11:01:14 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.3748736901490516" P_Q="0.0" P_Z="0.5159322118759732" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="24" WEIGHT="200.0" Z="0.649628517255416">
<NAME>Adverse gastrointestinal events</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.956857307626873" CI_START="0.10043329628054506" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.9981222832702461" LOG_CI_START="-0.9981222832702461" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Gastritis</NAME>
<DICH_DATA CI_END="9.956857307626873" CI_START="0.10043329628054506" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9981222832702461" LOG_CI_START="-0.9981222832702461" LOG_EFFECT_SIZE="0.0" ORDER="3664" O_E="0.0" SE="1.1726039399558574" STUDY_ID="STD-Chertow-1997" TOTAL_1="24" TOTAL_2="12" VAR="1.375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9634520633724324" CI_START="0.007580372857816312" DF="0" EFFECT_SIZE="0.17333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.5980736099146257" LOG_CI_START="-2.120309432084352" LOG_EFFECT_SIZE="-0.7611179110848633" MODIFIED="2010-10-03 16:43:45 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.27240650490053697" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="100.0" Z="1.0975375218775016">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="3.9634520633724324" CI_START="0.007580372857816312" EFFECT_SIZE="0.17333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5980736099146257" LOG_CI_START="-2.120309432084352" LOG_EFFECT_SIZE="-0.7611179110848633" ORDER="3665" O_E="0.0" SE="1.5967916550832766" STUDY_ID="STD-Chertow-1997" TOTAL_1="24" TOTAL_2="12" VAR="2.5497435897435894" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gastroparesis</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2010-12-08 12:02:22 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="12" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Serum phosphorus</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2812913708487621" CI_START="-3.3187086291512378" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="7.2" ORDER="3667" SD_1="1.7" SD_2="2.4" SE="0.7748655797405551" STUDY_ID="STD-Chertow-1997" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2010-12-08 12:02:22 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="12" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Total calcium</NAME>
<CONT_DATA CI_END="0.31577114730490374" CI_START="-0.515771147304903" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="9.4" ORDER="3666" SD_1="0.6" SD_2="0.6" SE="0.21213203435596426" STUDY_ID="STD-Chertow-1997" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Ionised calcium</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2010-10-03 17:03:13 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="12" UNITS="mEq/L" WEIGHT="0.0" Z="0.0">
<NAME>Serum bicarbonate</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5254278310848144" CI_START="-2.5254278310848144" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="20.4" MEAN_2="20.9" ORDER="3668" SD_1="4.1" SD_2="2.1" SE="1.033400535449187" STUDY_ID="STD-Chertow-1997" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2010-10-03 17:03:28 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="12" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Serum total cholesterol</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.41926285512951" CI_START="-51.58073714487049" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="149.0" MEAN_2="177.0" ORDER="3669" SD_1="32.0" SD_2="35.0" SE="12.031209415515965" STUDY_ID="STD-Chertow-1997" TOTAL_1="24" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-12-22 11:01:24 +1100" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Sevelamer versus calcium salts</NAME>
<DICH_OUTCOME CHI2="8.80635455108119" CI_END="1.1613257052468537" CI_START="0.46263966801056755" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.732990681201025" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="320" I2="43.22281744395437" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.06495403899247383" LOG_CI_START="-0.3347571323533255" LOG_EFFECT_SIZE="-0.13490154668042584" METHOD="MH" MODIFIED="2010-08-10 08:16:13 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.11704191085969406" P_Q="0.0" P_Z="0.18584663797414863" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1200707949736022" TOTALS="YES" TOTAL_1="1532" TOTAL_2="1547" WEIGHT="100.00000000000001" Z="1.322966141087126">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8747200456814275" CI_END="1.3793809719879058" CI_START="0.13097179499724687" DF="2" EFFECT_SIZE="0.4250411766950387" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="30.42800800709214" ID="CMP-005.01.01" LOG_CI_END="0.13968423077453243" LOG_CI_START="-0.8828222203435837" LOG_EFFECT_SIZE="-0.37156899478452565" MODIFIED="2010-07-14 00:52:14 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23755443420603806" P_Z="0.1543121805095718" STUDIES="6" TAU2="0.33714483735045814" TOTAL_1="304" TOTAL_2="309" WEIGHT="19.54444682411848" Z="1.4244640642669069">
<NAME>Sevelamer versus calcium acetate</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3671" O_E="0.0" SE="0.0" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9075909694158217" CI_START="0.0152867559717213" EFFECT_SIZE="0.11778846153846154" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.042109834021553647" LOG_CI_START="-1.8156846671749045" LOG_EFFECT_SIZE="-0.9288972505982291" MODIFIED="2009-04-20 00:59:23 +1000" MODIFIED_BY="[Empty name]" ORDER="1376" O_E="0.0" SE="1.041806636331294" STUDY_ID="STD-BRiC-Study-2008" TOTAL_1="52" TOTAL_2="49" VAR="1.0853610675039247" WEIGHT="4.573251757527979"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3673" O_E="0.0" SE="0.0" STUDY_ID="STD-CARE-Study-2004" TOTAL_1="50" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6594394780534443" CI_START="0.11742470047900938" EFFECT_SIZE="0.44142857142857145" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.21996141774086875" LOG_CI_START="-0.9302405389197131" LOG_EFFECT_SIZE="-0.35513956058942214" MODIFIED="2009-04-20 01:14:07 +1000" MODIFIED_BY="[Empty name]" ORDER="650" O_E="0.0" SE="0.6756343229339363" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="100" TOTAL_2="103" VAR="0.4564817383263985" WEIGHT="9.561563023758497"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-09 03:15:33 +1000" MODIFIED_BY="[Empty name]" ORDER="1375" O_E="0.0" SE="0.0" STUDY_ID="STD-Ferreira-2008" TOTAL_1="44" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.838222396101608" CI_START="0.19058239036912145" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8942175816771042" LOG_CI_START="-0.7199172302393039" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2009-04-20 01:10:26 +1000" MODIFIED_BY="[Empty name]" ORDER="3672" O_E="0.0" SE="0.9481507786158797" STUDY_ID="STD-Hervas-2003" TOTAL_1="18" TOTAL_2="22" VAR="0.898989898989899" WEIGHT="5.409632042832005"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-04-13 22:44:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Sevelamer versus calcium carbonate</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3674" O_E="0.0" SE="0.0" STUDY_ID="STD-Koiwa-2005a" TOTAL_1="16" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4684825669608705" CI_END="1.2743173697379255" CI_START="0.5673769420481609" DF="2" EFFECT_SIZE="0.8503048232491451" ESTIMABLE="YES" EVENTS_1="284" EVENTS_2="303" I2="42.33789672028175" ID="CMP-005.01.03" LOG_CI_END="0.1052776028509051" LOG_CI_START="-0.24612831772015603" LOG_EFFECT_SIZE="-0.07042535743462543" MODIFIED="2010-08-10 08:16:13 +1000" MODIFIED_BY="Narelle S Willis" NO="3" NOTES="&lt;p&gt;Replaced Block 2007 with Block 2005&lt;/p&gt;" NOTES_MODIFIED="2010-08-10 08:16:13 +1000" NOTES_MODIFIED_BY="Narelle S Willis" P_CHI2="0.17653440307433033" P_Z="0.43210547831345303" STUDIES="3" TAU2="0.06148816583417314" TOTAL_1="1212" TOTAL_2="1218" WEIGHT="80.45555317588153" Z="0.7855938451231269">
<NAME>Sevelamer versus calcium salts (calcium acetate and calcium carbonate)</NAME>
<DICH_DATA CI_END="1.0011477017418708" CI_START="0.28489094656849684" EFFECT_SIZE="0.5340579710144927" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" LOG_CI_END="4.98154721494695E-4" LOG_CI_START="-0.5453213518058648" LOG_EFFECT_SIZE="-0.27241159854218505" MODIFIED="2010-08-09 16:33:30 +1000" MODIFIED_BY="Narelle S Willis" ORDER="175" O_E="0.0" SE="0.3206170799843032" STUDY_ID="STD-Block-2005" TOTAL_1="60" TOTAL_2="67" VAR="0.1027953119776611" WEIGHT="24.73567407385597"/>
<DICH_DATA CI_END="3.881860085359043" CI_START="0.38609570678958227" EFFECT_SIZE="1.2242424242424241" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5890398779736322" LOG_CI_START="-0.41330502750819725" LOG_EFFECT_SIZE="0.08786742523271744" ORDER="3675" O_E="0.0" SE="0.5887823591673299" STUDY_ID="STD-Chertow-2002" TOTAL_1="99" TOTAL_2="101" VAR="0.3466646664666467" WEIGHT="11.811280348496325"/>
<DICH_DATA CI_END="1.1193072151339631" CI_START="0.8373936968256712" EFFECT_SIZE="0.9681429681429682" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="275" LOG_CI_END="0.04894930326265092" LOG_CI_START="-0.07707031242512265" LOG_EFFECT_SIZE="-0.014060504581235854" MODIFIED="2009-04-21 23:05:25 +1000" MODIFIED_BY="[Empty name]" ORDER="3677" O_E="0.0" SE="0.07402454606215647" STUDY_ID="STD-DCOR-Study-2007" TOTAL_1="1053" TOTAL_2="1050" VAR="0.005479633419708325" WEIGHT="43.90859875352923"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.051023377944668" CI_END="0.5876227501653077" CI_START="0.3521453315949862" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4548940626230683" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="139" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.23090139858635433" LOG_CI_START="-0.45327806469313453" LOG_EFFECT_SIZE="-0.3420897316397445" METHOD="MH" MODIFIED="2010-12-07 16:38:32 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.5272682966650313" P_Q="0.0" P_Z="1.6379638158624956E-9" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="597" TOTAL_2="547" WEIGHT="99.99999999999999" Z="6.030161034727631">
<NAME>Hypercalcaemia</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.822300034908532" CI_END="0.661584133306139" CI_START="0.2730317818487252" DF="5" EFFECT_SIZE="0.4250099937171121" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="86" I2="36.08018130618195" ID="CMP-005.02.01" LOG_CI_END="-0.1794149189637021" LOG_CI_START="-0.5637867966290067" LOG_EFFECT_SIZE="-0.3716008577963543" MODIFIED="2010-05-26 02:01:14 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1663048529194988" P_Z="1.5083803419680542E-4" STUDIES="6" TAU2="0.102133387523349" TOTAL_1="344" TOTAL_2="290" WEIGHT="66.27228843941384" Z="3.789685667582789">
<NAME>Sevelamer versus calcium acetate</NAME>
<DICH_DATA CI_END="0.964717167323624" CI_START="0.0511888019847135" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.015599993054897914" LOG_CI_START="-1.2908250344957894" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="3682" O_E="0.0" SE="0.749073501808141" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" VAR="0.5611111111111111" WEIGHT="3.0409183917565996"/>
<DICH_DATA CI_END="1.2773205757457686" CI_START="0.10146239124374282" EFFECT_SIZE="0.36" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.10629990807393946" LOG_CI_START="-0.9936949065393649" LOG_EFFECT_SIZE="-0.44369749923271273" ORDER="3684" O_E="0.0" SE="0.6461423991660042" STUDY_ID="STD-CARE-Study-2004" TOTAL_1="50" TOTAL_2="48" VAR="0.4175" WEIGHT="4.086929575082057"/>
<DICH_DATA CI_END="1.0412273794865832" CI_START="0.38274778327523834" EFFECT_SIZE="0.6312903225806452" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="31" LOG_CI_END="0.017545579532859783" LOG_CI_START="-0.41708731588540277" LOG_EFFECT_SIZE="-0.1997708681762715" ORDER="3685" O_E="0.0" SE="0.25530551423621817" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="100" TOTAL_2="103" VAR="0.06518090559941979" WEIGHT="26.177805937264356"/>
<DICH_DATA CI_END="0.5362654402608498" CI_START="0.02621032478337564" EFFECT_SIZE="0.11855670103092783" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.2706201903343979" LOG_CI_START="-1.5815275974908687" LOG_EFFECT_SIZE="-0.9260738939126332" MODIFIED="2009-04-09 04:06:28 +1000" MODIFIED_BY="[Empty name]" ORDER="1396" O_E="0.0" SE="0.7700335000600311" STUDY_ID="STD-Evenepoel-2009" TOTAL_1="97" TOTAL_2="46" VAR="0.592951591214702" WEIGHT="2.8776263068985117"/>
<DICH_DATA CI_END="1.0364301040210335" CI_START="0.3473461438483015" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.015540018960972728" LOG_CI_START="-0.45923751819368547" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="3683" O_E="0.0" SE="0.2788866755113585" STUDY_ID="STD-Hervas-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.07777777777777777" WEIGHT="21.93805411195833"/>
<DICH_DATA CI_END="0.7288596507754739" CI_START="0.1212657099158105" EFFECT_SIZE="0.2972972972972973" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.13735609138287516" LOG_CI_START="-0.9162619864346648" LOG_EFFECT_SIZE="-0.52680903890877" MODIFIED="2010-05-26 02:01:14 +1000" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.4575331783997848" STUDY_ID="STD-Liu-2006" TOTAL_1="37" TOTAL_2="33" VAR="0.20933660933660933" WEIGHT="8.150954116453999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.28235892227588116" CI_END="0.7207038020550012" CI_START="0.2570174002196873" DF="1" EFFECT_SIZE="0.43038752018688986" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="35" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-0.14224318682476558" LOG_CI_START="-0.5900374736975463" LOG_EFFECT_SIZE="-0.36614033026115594" NO="2" P_CHI2="0.5951593124418333" P_Z="0.0013499644452599846" STUDIES="2" TAU2="0.0" TOTAL_1="153" TOTAL_2="156" WEIGHT="24.6616047544586" Z="3.2051407605534923">
<NAME>Sevelamer versus calcium salts (calcium acetate and calcium carbonate)</NAME>
<DICH_DATA CI_END="0.7091439544703186" CI_START="0.2340579716771348" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.14926559516092308" LOG_CI_START="-0.6306765628406016" LOG_EFFECT_SIZE="-0.3899710790007623" ORDER="3686" O_E="0.0" SE="0.28278318543776604" STUDY_ID="STD-Block-2005" TOTAL_1="54" TOTAL_2="55" VAR="0.07996632996632996" WEIGHT="21.337644209946834"/>
<DICH_DATA CI_END="2.4928665502507217" CI_START="0.15030583096839137" EFFECT_SIZE="0.6121212121212121" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3966990301921098" LOG_CI_START="-0.8230241710546373" LOG_EFFECT_SIZE="-0.21316257043126374" ORDER="3687" O_E="0.0" SE="0.7164714461395606" STUDY_ID="STD-Chertow-2002" TOTAL_1="99" TOTAL_2="101" VAR="0.5133313331333134" WEIGHT="3.3239605445117655"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3581876637431907" CI_END="0.7803774890784346" CI_START="0.14248088663466726" DF="2" EFFECT_SIZE="0.3334499610940609" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="18" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="-0.10769526684033677" LOG_CI_START="-0.8462433909946628" LOG_EFFECT_SIZE="-0.4769693289174999" MODIFIED="2010-05-26 01:56:18 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8360274890141848" P_Z="0.011355352729650296" STUDIES="4" TAU2="0.0" TOTAL_1="100" TOTAL_2="101" WEIGHT="9.066106806127543" Z="2.5315688330506005">
<NAME>Sevelamer versus calcium carbonate</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3689" O_E="0.0" SE="0.0" STUDY_ID="STD-De-Santo-2006" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.6222981337738407" CI_START="0.09533622313196566" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4186820658789642" LOG_CI_START="-1.0207420572069266" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-05-26 01:56:18 +1000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.8455248551649763" STUDY_ID="STD-Gallieni-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.7149122807017543" WEIGHT="2.386716725472767"/>
<DICH_DATA CI_END="3.054706337101762" CI_START="0.04138523940941702" EFFECT_SIZE="0.35555555555555557" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48496946586945155" LOG_CI_START="-1.3831545281082893" LOG_EFFECT_SIZE="-0.4490925311194189" ORDER="3688" O_E="0.0" SE="1.0973452814254347" STUDY_ID="STD-Sadek-2003" TOTAL_1="15" TOTAL_2="16" VAR="1.2041666666666666" WEIGHT="1.4169908076928102"/>
<DICH_DATA CI_END="0.8325727832412549" CI_START="0.08933773333268213" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.07957779028005475" LOG_CI_START="-1.0489650705970706" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="3690" O_E="0.0" SE="0.5694228870026425" STUDY_ID="STD-Shaheen-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.3242424242424242" WEIGHT="5.262399272961966"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.355558559969811" CI_END="1.8925507288820032" CI_START="1.1411907168833886" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4696126438728787" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="80" I2="3.800505952591232" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.27704752937594435" LOG_CI_START="0.057358230192612464" LOG_EFFECT_SIZE="0.1672028797842784" METHOD="MH" MODIFIED="2010-12-22 11:01:24 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.40512126871332366" P_Q="0.0" P_Z="0.00285055887116968" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.006837864863131327" TOTALS="SUB" TOTAL_1="633" TOTAL_2="586" WEIGHT="500.0" Z="2.983409967684307">
<NAME>Gastrointestinal adverse events</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8628569275251436" CI_START="0.5695015995723486" DF="0" EFFECT_SIZE="1.03" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.2701795011805302" LOG_CI_START="-0.24450505177018583" LOG_EFFECT_SIZE="0.012837224705172217" MODIFIED="2010-12-07 16:43:08 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.9221144863094562" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="103" WEIGHT="100.0" Z="0.0977705584492046">
<NAME>Nausea/vomiting</NAME>
<DICH_DATA CI_END="1.8628569275251436" CI_START="0.5695015995723486" EFFECT_SIZE="1.03" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.2701795011805302" LOG_CI_START="-0.24450505177018583" LOG_EFFECT_SIZE="0.012837224705172217" MODIFIED="2009-06-07 01:39:20 +1000" MODIFIED_BY="[Empty name]" ORDER="671" O_E="0.0" SE="0.30232825413287695" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="100" TOTAL_2="103" VAR="0.09140237324703344" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.945540774362923" CI_START="0.5452982605041505" DF="0" EFFECT_SIZE="1.03" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.2890403371162494" LOG_CI_START="-0.263365887705905" LOG_EFFECT_SIZE="0.012837224705172217" MODIFIED="2010-10-03 16:45:32 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.927417751225987" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="103" WEIGHT="100.0" Z="0.09109418740415427">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="1.945540774362923" CI_START="0.5452982605041505" EFFECT_SIZE="1.03" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.2890403371162494" LOG_CI_START="-0.263365887705905" LOG_EFFECT_SIZE="0.012837224705172217" MODIFIED="2009-06-07 01:37:51 +1000" MODIFIED_BY="[Empty name]" ORDER="651" O_E="0.0" SE="0.32448615091544714" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="100" TOTAL_2="103" VAR="0.10529126213592234" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.008056200082498" CI_START="0.49215387822006895" DF="0" EFFECT_SIZE="2.3275862068965516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="1.041710638126484" LOG_CI_START="-0.30789908826234635" LOG_EFFECT_SIZE="0.36690577493206883" MODIFIED="2009-04-13 22:44:01 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.28657097914481855" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="27" WEIGHT="100.0" Z="1.065674158278007">
<NAME>Abdominal bloating</NAME>
<DICH_DATA CI_END="11.008056200082498" CI_START="0.492153878220069" EFFECT_SIZE="2.3275862068965516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.041710638126484" LOG_CI_START="-0.3078990882623463" LOG_EFFECT_SIZE="0.36690577493206883" ORDER="3691" O_E="0.0" SE="0.792767433956689" STUDY_ID="STD-Koiwa-2005a" TOTAL_1="29" TOTAL_2="27" VAR="0.6284802043422733" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.39700884465180347" CI_END="5.352396655331047" CI_START="1.2875548714289633" DF="1" EFFECT_SIZE="2.6251674970164443" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" I2="0.0" ID="CMP-005.03.04" LOG_CI_END="0.7285482906413473" LOG_CI_START="0.10976574633537949" LOG_EFFECT_SIZE="0.4191570184883635" MODIFIED="2009-06-07 01:37:53 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5286384744972672" P_Z="0.007923333765434467" STUDIES="2" TAU2="0.0" TOTAL_1="129" TOTAL_2="130" WEIGHT="100.0" Z="2.6553194419077237">
<NAME>Constipation</NAME>
<DICH_DATA CI_END="5.814534400459255" CI_START="0.7298262780360923" EFFECT_SIZE="2.06" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7645149442739266" LOG_CI_START="-0.13678050353561985" LOG_EFFECT_SIZE="0.31386722036915343" MODIFIED="2009-06-07 01:37:53 +1000" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="0.5294254075277482" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="100" TOTAL_2="103" VAR="0.28029126213592237" WEIGHT="47.1348091104418"/>
<DICH_DATA CI_END="8.680743522397217" CI_START="1.2232372459400096" EFFECT_SIZE="3.2586206896551726" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9385569249282264" LOG_CI_START="0.0875106962923872" LOG_EFFECT_SIZE="0.5130338106103068" ORDER="3692" O_E="0.0" SE="0.49990876744746604" STUDY_ID="STD-Koiwa-2005a" TOTAL_1="29" TOTAL_2="27" VAR="0.2499087757708447" WEIGHT="52.86519088955821"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.344805269409427" CI_END="2.249055622704464" CI_START="1.1053360916422021" DF="4" EFFECT_SIZE="1.5766934869802915" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="35" I2="0.0" ID="CMP-005.03.05" LOG_CI_END="0.3520001963582195" LOG_CI_START="0.04349435091927294" LOG_EFFECT_SIZE="0.19774727363874617" MODIFIED="2010-05-26 01:59:53 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5018649219974214" P_Z="0.01198415210774817" STUDIES="5" TAU2="0.0" TOTAL_1="275" TOTAL_2="223" WEIGHT="100.0" Z="2.5126106367383643">
<NAME>Combined</NAME>
<DICH_DATA CI_END="2.3160076316098115" CI_START="0.6030611453146286" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.3647399861264558" LOG_CI_START="-0.21963865182923223" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="3693" O_E="0.0" SE="0.34326690465608223" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" VAR="0.11783216783216785" WEIGHT="27.87007457737686"/>
<DICH_DATA CI_END="4.644429572440226" CI_START="0.9092514626117464" EFFECT_SIZE="2.0549828178694156" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="6" LOG_CI_END="0.6669323816764431" LOG_CI_START="-0.04131599167143609" LOG_EFFECT_SIZE="0.3128081950025035" MODIFIED="2009-04-09 04:24:15 +1000" MODIFIED_BY="[Empty name]" ORDER="1407" O_E="0.0" SE="0.4160286003905345" STUDY_ID="STD-Evenepoel-2009" TOTAL_1="97" TOTAL_2="46" VAR="0.17307979634290704" WEIGHT="18.973856998249726"/>
<DICH_DATA CI_END="7.259520829004249" CI_START="0.15717461573158975" EFFECT_SIZE="1.0681818181818181" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8609079556605419" LOG_CI_START="-0.8036175927614819" LOG_EFFECT_SIZE="0.02864518144953001" MODIFIED="2009-04-09 04:22:59 +1000" MODIFIED_BY="[Empty name]" ORDER="1406" O_E="0.0" SE="0.977750546677447" STUDY_ID="STD-Ferreira-2008" TOTAL_1="44" TOTAL_2="47" VAR="0.9559961315280464" WEIGHT="3.4351512488313465"/>
<DICH_DATA CI_END="7.7044563123624386" CI_START="1.168155108564735" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8867419968672938" LOG_CI_START="0.06750051257203113" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-05-26 01:52:23 +1000" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.4812265031857878" STUDY_ID="STD-Gallieni-2005" TOTAL_1="57" TOTAL_2="57" VAR="0.23157894736842105" WEIGHT="14.180871544734906"/>
<DICH_DATA CI_END="2.501007007891188" CI_START="0.7596647862186511" EFFECT_SIZE="1.3783783783783783" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.39811490863742327" LOG_CI_START="-0.11937800457554064" LOG_EFFECT_SIZE="0.13936845203094134" MODIFIED="2010-05-26 01:59:53 +1000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.30397789885252885" STUDY_ID="STD-Liu-2006" TOTAL_1="37" TOTAL_2="33" VAR="0.09240256299079827" WEIGHT="35.54004563080717"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="32.31640358834806" CI_END="0.41693062197220665" CI_START="0.03806374274053417" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2274971823563704" ESTIMABLE="YES" I2="56.678347695076404" I2_Q="64.40447727976102" ID="CMP-005.04" MODIFIED="2010-12-08 12:02:28 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.003611093846184965" P_Q="0.06024466704108433" P_Z="0.018583172606994745" Q="5.618684169126798" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0629178170521155" TOTALS="YES" TOTAL_1="1593" TOTAL_2="1533" UNITS="mg/dL" WEIGHT="99.99999999999999" Z="2.353788670612049">
<NAME>Serum phosphorus</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="23.793711425152345" CI_END="0.7058238105455272" CI_START="-0.20286248191580158" DF="6" EFFECT_SIZE="0.2514806643148628" ESTIMABLE="YES" I2="74.78325305039466" ID="CMP-005.04.01" MODIFIED="2010-07-14 00:52:26 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.699059413800667E-4" P_Z="0.27798920223514223" STUDIES="7" TAU2="0.2757717011989987" TOTAL_1="341" TOTAL_2="271" WEIGHT="41.1427199403678" Z="1.0848475407948657">
<NAME>Sevelamer versus calcium acetate</NAME>
<CONT_DATA CI_END="1.2450441594900945" CI_START="-0.2450441594900944" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="5.9" ORDER="3706" SD_1="1.7" SD_2="1.7" SE="0.38013155617496425" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" WEIGHT="4.5037165409075275"/>
<CONT_DATA CI_END="-0.05677597098907827" CI_START="-0.9232240290109222" EFFECT_SIZE="-0.4900000000000002" ESTIMABLE="YES" MEAN_1="5.29" MEAN_2="5.78" MODIFIED="2009-04-09 03:29:31 +1000" MODIFIED_BY="[Empty name]" ORDER="1377" SD_1="0.92" SD_2="0.92" SE="0.22103672946448905" STUDY_ID="STD-BRiC-Study-2008" TOTAL_1="41" TOTAL_2="30" WEIGHT="8.357419924493302"/>
<CONT_DATA CI_END="1.9138005163239733" CI_START="0.6861994836760263" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="5.5" ORDER="3708" SD_1="1.6" SD_2="1.5" SE="0.31316928329579197" STUDY_ID="STD-CARE-Study-2004" TOTAL_1="50" TOTAL_2="48" WEIGHT="5.802439330160594"/>
<CONT_DATA CI_END="0.986928370885399" CI_START="-0.18692837088539827" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="5.0" ORDER="3709" SD_1="1.8" SD_2="1.6" SE="0.29945875307659464" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="70" TOTAL_2="59" WEIGHT="6.121832838819312"/>
<CONT_DATA CI_END="0.678040394374147" CI_START="-0.39804039437414585" EFFECT_SIZE="0.14000000000000057" ESTIMABLE="YES" MEAN_1="5.91" MEAN_2="5.77" MODIFIED="2009-04-09 03:37:13 +1000" MODIFIED_BY="[Empty name]" ORDER="1381" SD_1="1.25" SD_2="1.61" SE="0.27451544957873736" STUDY_ID="STD-Evenepoel-2009" TOTAL_1="95" TOTAL_2="44" WEIGHT="6.755672307070544"/>
<CONT_DATA CI_END="0.6813964923405756" CI_START="-0.8813964923405767" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.9" ORDER="3707" SD_1="1.01" SD_2="1.5" SE="0.3986790055858842" STUDY_ID="STD-Hervas-2003" TOTAL_1="18" TOTAL_2="22" WEIGHT="4.210490421962611"/>
<CONT_DATA CI_END="0.7511009290848637" CI_START="-0.5511009290848644" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.7" MODIFIED="2009-04-09 04:52:47 +1000" MODIFIED_BY="[Empty name]" ORDER="1382" SD_1="0.9" SD_2="1.5" SE="0.33220045583524244" STUDY_ID="STD-Russo-2007" TOTAL_1="27" TOTAL_2="28" WEIGHT="5.39114857695391"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.636887659748031" CI_END="0.7425666015669563" CI_START="0.17289082698685304" DF="4" EFFECT_SIZE="0.45772871427690465" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" MODIFIED="2010-05-26 01:49:25 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6203028958745138" P_Z="0.001634816016776918" STUDIES="6" TAU2="0.0" TOTAL_1="256" TOTAL_2="263" WEIGHT="24.825030359625476" Z="3.1496224157813844">
<NAME>Sevelamer versus calcium carbonate</NAME>
<CONT_DATA CI_END="0.8901761896840756" CI_START="-0.6901761896840746" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="5.3" MODIFIED="2009-04-14 00:35:58 +1000" MODIFIED_BY="[Empty name]" ORDER="1378" SD_1="1.4" SD_2="1.9" SE="0.403158525318263" STUDY_ID="STD-Ferreira-2008" TOTAL_1="33" TOTAL_2="35" WEIGHT="4.143410678833347"/>
<CONT_DATA CI_END="0.8422387011263693" CI_START="0.017761298873630094" EFFECT_SIZE="0.4299999999999997" ESTIMABLE="YES" MEAN_1="5.25" MEAN_2="4.82" MODIFIED="2010-05-26 01:49:25 +1000" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="1.2" SD_2="1.04" SE="0.21032973277981426" STUDY_ID="STD-Gallieni-2005" TOTAL_1="57" TOTAL_2="57" WEIGHT="8.717640154676232"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="5.62" MEAN_2="5.59" ORDER="3711" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Kinugasa-2001" TOTAL_1="115" TOTAL_2="115" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.086087858148654" CI_START="-0.8860878581486547" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="6.0" ORDER="3710" SD_1="1.5" SD_2="1.5" SE="0.5031152949374527" STUDY_ID="STD-Koiwa-2005a" TOTAL_1="16" TOTAL_2="20" WEIGHT="2.955773721579322"/>
<CONT_DATA CI_END="1.5676684285107194" CI_START="-0.3276684285107192" EFFECT_SIZE="0.6200000000000001" ESTIMABLE="YES" MEAN_1="5.71" MEAN_2="5.09" ORDER="3712" SD_1="1.08" SD_2="1.58" SE="0.48351318492880835" STUDY_ID="STD-Sadek-2003" TOTAL_1="15" TOTAL_2="16" WEIGHT="3.148440122064838"/>
<CONT_DATA CI_END="1.4088520150225199" CI_START="0.19114798497747976" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="4.9" ORDER="3713" SD_1="1.2" SD_2="0.7" SE="0.3106444913401813" STUDY_ID="STD-Shaheen-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.859765682471736"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.267120334320886" CI_END="0.20087711328081387" CI_START="-0.019494952874264032" DF="2" EFFECT_SIZE="0.09069108020327492" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.03" NO="3" P_CHI2="0.8749748296751749" P_Z="0.10670275396351618" STUDIES="3" TAU2="0.0" TOTAL_1="996" TOTAL_2="999" WEIGHT="34.032249700006716" Z="1.6131922164070205">
<NAME>Sevelamer versus calcium salts (calcium acetate and calcium carbonate)</NAME>
<CONT_DATA CI_END="0.4198788740165966" CI_START="-0.21987887401659556" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="5.1" ORDER="3714" SD_1="0.9" SD_2="0.8" SE="0.16320650610917334" STUDY_ID="STD-Block-2005" TOTAL_1="54" TOTAL_2="55" WEIGHT="10.431127238895275"/>
<CONT_DATA CI_END="0.36114108923460586" CI_START="-0.36114108923460586" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="5.1" ORDER="3715" SD_1="1.2" SD_2="1.4" SE="0.18425904357592315" STUDY_ID="STD-Chertow-2002" TOTAL_1="99" TOTAL_2="101" WEIGHT="9.64342573250807"/>
<CONT_DATA CI_END="0.22410596443363412" CI_START="-0.024105964433634844" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.7" ORDER="3716" SD_1="1.3" SD_2="1.3" SE="0.0633205331386528" STUDY_ID="STD-DCOR-Study-2007" TOTAL_1="843" TOTAL_2="843" WEIGHT="13.957696728603374"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="29.13152952609507" CI_END="-0.23909049635509794" CI_START="-0.4499464980231753" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.34451849718913663" ESTIMABLE="YES" I2="55.3748113762615" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2010-12-08 12:02:28 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0062703951215673515" P_Q="0.4220424751197148" P_Z="1.505798494095885E-10" Q="1.7253002306133034" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.01767899046969197" TOTALS="YES" TOTAL_1="1544" TOTAL_2="1495" UNITS="mg/dL" WEIGHT="100.0" Z="6.404786595180901">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.777953268363827" CI_END="-0.19548732293198526" CI_START="-0.5256877133228759" DF="5" EFFECT_SIZE="-0.36058751812743056" ESTIMABLE="YES" I2="43.039113479673624" ID="CMP-005.05.01" MODIFIED="2010-07-14 00:34:46 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11825551554609814" P_Z="1.863360705406938E-5" STUDIES="6" TAU2="0.017840835900347594" TOTAL_1="300" TOTAL_2="241" WEIGHT="40.94396419275034" Z="4.2806645259735285">
<NAME>Sevelamer versus calcium acetate</NAME>
<CONT_DATA CI_END="-0.09010248384771774" CI_START="-0.7098975161522794" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="9.7" ORDER="3695" SD_1="0.6" SD_2="0.8" SE="0.15811388300841897" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" WEIGHT="6.779561778498536"/>
<CONT_DATA CI_END="-0.3582931812476322" CI_START="-0.8417068187523671" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="9.5" ORDER="3696" SD_1="0.5" SD_2="0.7" SE="0.12332207155790617" STUDY_ID="STD-CARE-Study-2004" TOTAL_1="50" TOTAL_2="48" WEIGHT="8.798066217434517"/>
<CONT_DATA CI_END="-0.15752556258838107" CI_START="-0.6424744374116196" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="9.4" ORDER="3698" SD_1="0.7" SD_2="0.7" SE="0.1237137209276429" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="70" TOTAL_2="59" WEIGHT="8.77225905662665"/>
<CONT_DATA CI_END="-0.09655247172753767" CI_START="-0.7234475282724626" EFFECT_SIZE="-0.41000000000000014" ESTIMABLE="YES" MEAN_1="9.59" MEAN_2="10.0" MODIFIED="2009-04-09 03:47:04 +1000" MODIFIED_BY="[Empty name]" ORDER="1386" SD_1="0.56" SD_2="0.99" SE="0.15992514696438126" STUDY_ID="STD-Evenepoel-2009" TOTAL_1="95" TOTAL_2="44" WEIGHT="6.689274401040314"/>
<CONT_DATA CI_END="0.5576571399811477" CI_START="-0.4776571399811459" EFFECT_SIZE="0.040000000000000924" ESTIMABLE="YES" MEAN_1="10.22" MEAN_2="10.18" ORDER="3697" SD_1="0.77" SD_2="0.9" SE="0.2641156388915104" STUDY_ID="STD-Hervas-2003" TOTAL_1="18" TOTAL_2="22" WEIGHT="3.3092164564490276"/>
<CONT_DATA CI_END="0.217190220183543" CI_START="-0.4171902201835423" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="9.1" MODIFIED="2009-04-09 03:47:40 +1000" MODIFIED_BY="[Empty name]" ORDER="1387" SD_1="0.3" SD_2="0.8" SE="0.16183471874253744" STUDY_ID="STD-Russo-2007" TOTAL_1="27" TOTAL_2="28" WEIGHT="6.595586282701296"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.715615885202464" CI_END="0.007121671154626752" CI_START="-0.7354182111738179" DF="4" EFFECT_SIZE="-0.3641482700095956" ESTIMABLE="YES" I2="72.81799123322955" ID="CMP-005.05.02" MODIFIED="2010-05-26 01:57:36 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005328912953515452" P_Z="0.054559455598147365" STUDIES="6" TAU2="0.12512639258833724" TOTAL_1="256" TOTAL_2="263" WEIGHT="22.404318907418507" Z="1.9223681077259058">
<NAME>Sevelamer versus calcium carbonate</NAME>
<CONT_DATA CI_END="0.2411733373424042" CI_START="-0.6411733373424063" EFFECT_SIZE="-0.20000000000000107" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="9.3" MODIFIED="2009-04-09 03:46:30 +1000" MODIFIED_BY="[Empty name]" ORDER="1383" SD_1="1.1" SD_2="0.7" SE="0.2250925735484551" STUDY_ID="STD-Ferreira-2008" TOTAL_1="33" TOTAL_2="35" WEIGHT="4.233551401165777"/>
<CONT_DATA CI_END="0.18940535743081566" CI_START="-0.5894053574308142" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.6" MODIFIED="2010-05-26 01:57:36 +1000" MODIFIED_BY="[Empty name]" ORDER="169" SD_1="0.9" SD_2="1.2" SE="0.19867985355975656" STUDY_ID="STD-Gallieni-2005" TOTAL_1="57" TOTAL_2="57" WEIGHT="5.062665118512383"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="9.13" MEAN_2="9.65" ORDER="3700" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Kinugasa-2001" TOTAL_1="115" TOTAL_2="115" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.5095192576196598" CI_START="-1.4904807423803401" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="9.7" ORDER="3699" SD_1="0.7" SD_2="0.8" SE="0.250249875124844" STUDY_ID="STD-Koiwa-2005a" TOTAL_1="16" TOTAL_2="20" WEIGHT="3.603119232816088"/>
<CONT_DATA CI_END="0.32176257551529525" CI_START="-0.2417625755152934" EFFECT_SIZE="0.040000000000000924" ESTIMABLE="YES" MEAN_1="9.64" MEAN_2="9.6" ORDER="3701" SD_1="0.4" SD_2="0.4" SE="0.14375905768565217" STUDY_ID="STD-Sadek-2003" TOTAL_1="15" TOTAL_2="16" WEIGHT="7.5457007166236725"/>
<CONT_DATA CI_END="0.006675064432188238" CI_START="-1.4066750644321868" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="10.0" ORDER="3702" SD_1="0.8" SD_2="1.4" SE="0.36055512754639896" STUDY_ID="STD-Shaheen-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.9592824383005856"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.912660141915475" CI_END="-0.23243332313599857" CI_START="-0.4630349777340543" DF="2" EFFECT_SIZE="-0.3477341504350264" ESTIMABLE="YES" I2="48.88388136310547" ID="CMP-005.05.03" NO="3" P_CHI2="0.14137647304697343" P_Z="3.3997936467192584E-9" STUDIES="3" TAU2="0.005324964596753031" TOTAL_1="988" TOTAL_2="991" WEIGHT="36.65171689983116" Z="5.911027934602091">
<NAME>Sevelamer versus calcium salts (calcium acetate and calcium carbonate)</NAME>
<CONT_DATA CI_END="-0.3122615968029232" CI_START="-0.6877384031970768" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="9.6" ORDER="3703" SD_1="0.5" SD_2="0.5" SE="0.09578665969269506" STUDY_ID="STD-Block-2005" TOTAL_1="54" TOTAL_2="55" WEIGHT="10.774709475588372"/>
<CONT_DATA CI_END="-0.10596376253661347" CI_START="-0.49403623746338443" EFFECT_SIZE="-0.29999999999999893" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.7" ORDER="3704" SD_1="0.7" SD_2="0.7" SE="0.09899989948484694" STUDY_ID="STD-Chertow-2002" TOTAL_1="99" TOTAL_2="101" WEIGHT="10.529299943039414"/>
<CONT_DATA CI_END="-0.23285434864308852" CI_START="-0.3671456513569129" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="9.5" ORDER="3705" SD_1="0.7" SD_2="0.7" SE="0.03425861489626775" STUDY_ID="STD-DCOR-Study-2007" TOTAL_1="835" TOTAL_2="835" WEIGHT="15.347707481203376"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.020261040137129" CI_END="2.3994308928381027" CI_START="-0.6862160962474685" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8566073982953172" ESTIMABLE="YES" I2="33.42326093216351" I2_Q="73.73996587996425" ID="CMP-005.06" MODIFIED="2010-12-08 12:02:31 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.1313250288964788" P_Q="0.022191031164584873" P_Z="0.27650137103285954" Q="7.616136334240517" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.8912077905434153" TOTALS="YES" TOTAL_1="1367" TOTAL_2="1307" UNITS="mg²/dL²" WEIGHT="100.0" Z="1.088212394669894">
<NAME>Serum calcium x phosphorus product</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.292488324921131" CI_END="5.842862529767091" CI_START="-0.7179036462545909" DF="4" EFFECT_SIZE="2.56247944175625" ESTIMABLE="YES" I2="24.421184243999104" ID="CMP-005.06.01" MODIFIED="2009-04-09 04:13:00 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2585810813254059" P_Z="0.12576179023301262" STUDIES="5" TAU2="3.4110487603108237" TOTAL_1="275" TOTAL_2="211" WEIGHT="25.19321817917973" Z="1.5310307614139107">
<NAME>Sevelamer versus calcium acetate</NAME>
<CONT_DATA CI_END="9.977953436225564" CI_START="-4.177953436225566" EFFECT_SIZE="2.8999999999999986" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="57.1" ORDER="3729" SD_1="16.1" SD_2="16.2" SE="3.6112670906483784" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" WEIGHT="4.149588293196086"/>
<CONT_DATA CI_END="13.304617455762987" CI_START="2.0953825442370055" EFFECT_SIZE="7.699999999999996" ESTIMABLE="YES" MEAN_1="60.4" MEAN_2="52.7" ORDER="3731" SD_1="14.1" SD_2="14.2" SE="2.859551246845094" STUDY_ID="STD-CARE-Study-2004" TOTAL_1="50" TOTAL_2="48" WEIGHT="6.154357178567924"/>
<CONT_DATA CI_END="7.204264423430344" CI_START="-3.2042644234303443" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="46.0" ORDER="3732" SD_1="15.4" SD_2="14.7" SE="2.655285742228387" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="70" TOTAL_2="59" WEIGHT="6.92968947955386"/>
<CONT_DATA CI_END="4.431542887653256" CI_START="-6.831542887653248" EFFECT_SIZE="-1.1999999999999957" ESTIMABLE="YES" MEAN_1="56.1" MEAN_2="57.3" MODIFIED="2009-04-09 04:13:00 +1000" MODIFIED_BY="[Empty name]" ORDER="1401" SD_1="16.5" SD_2="15.4" SE="2.8732889645290136" STUDY_ID="STD-Evenepoel-2009" TOTAL_1="95" TOTAL_2="44" WEIGHT="6.1065900012342444"/>
<CONT_DATA CI_END="10.508735785941482" CI_START="-11.508735785941482" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="58.7" MEAN_2="59.2" ORDER="3730" SD_1="17.1" SD_2="18.4" SE="5.61680514171535" STUDY_ID="STD-Hervas-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.8529932266276157"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.34701492754136914" CI_END="6.020518538005225" CI_START="0.15263068181779937" DF="2" EFFECT_SIZE="3.086574609911512" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.02" MODIFIED="2010-05-26 01:58:38 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8407109089307396" P_Z="0.039214788138804364" STUDIES="3" TAU2="0.0" TOTAL_1="104" TOTAL_2="105" WEIGHT="20.106637710172052" Z="2.0619259329038897">
<NAME>Sevelamer versus calcium carbonate</NAME>
<CONT_DATA CI_END="6.559325048368461" CI_START="-0.9593250483684521" EFFECT_SIZE="2.8000000000000043" ESTIMABLE="YES" MEAN_1="49.6" MEAN_2="46.8" MODIFIED="2010-05-26 01:58:38 +1000" MODIFIED_BY="[Empty name]" ORDER="170" SD_1="11.1" SD_2="9.3" SE="1.9180582286315118" STUDY_ID="STD-Gallieni-2005" TOTAL_1="57" TOTAL_2="57" WEIGHT="11.124205747942419"/>
<CONT_DATA CI_END="8.19833662531596" CI_START="-2.5983366253159526" EFFECT_SIZE="2.8000000000000043" ESTIMABLE="YES" MEAN_1="43.1" MEAN_2="40.3" MODIFIED="2009-04-09 04:11:45 +1000" MODIFIED_BY="[Empty name]" ORDER="1400" SD_1="8.4" SD_2="11.8" SE="2.7543039912454246" STUDY_ID="STD-Russo-2007" TOTAL_1="27" TOTAL_2="28" WEIGHT="6.538033993335343"/>
<CONT_DATA CI_END="15.292783628411783" CI_START="-3.6927836284117888" EFFECT_SIZE="5.799999999999997" ESTIMABLE="YES" MEAN_1="50.8" MEAN_2="45.0" ORDER="3733" SD_1="16.0" SD_2="14.6" SE="4.843345950889736" STUDY_ID="STD-Shaheen-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.4443979688942905"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7646214534341118" CI_END="0.6902631057641502" CI_START="-1.4223652889354228" DF="2" EFFECT_SIZE="-0.36605109158563626" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.03" NO="3" P_CHI2="0.4138256036565926" P_Z="0.4970121395312037" STUDIES="3" TAU2="0.0" TOTAL_1="988" TOTAL_2="991" WEIGHT="54.70014411064821" Z="0.6791984409652364">
<NAME>Sevelamer versus calcium salts (calcium acetate and calcium carbonate)</NAME>
<CONT_DATA CI_END="0.8206079774260941" CI_START="-4.820607977426095" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="49.0" ORDER="3734" SD_1="7.0" SD_2="8.0" SE="1.4391121467918235" STUDY_ID="STD-Block-2005" TOTAL_1="54" TOTAL_2="55" WEIGHT="15.63846996414899"/>
<CONT_DATA CI_END="2.611410892346058" CI_START="-4.611410892346058" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="49.0" ORDER="3735" SD_1="12.0" SD_2="14.0" SE="1.8425904357592315" STUDY_ID="STD-Chertow-2002" TOTAL_1="99" TOTAL_2="101" WEIGHT="11.721430406889468"/>
<CONT_DATA CI_END="1.2005134483352073" CI_START="-1.2005134483352073" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="53.65" MEAN_2="53.65" ORDER="3736" SD_1="12.14" SD_2="12.88" SE="0.612518116559643" STUDY_ID="STD-DCOR-Study-2007" TOTAL_1="835" TOTAL_2="835" WEIGHT="27.340243739609754"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.164942571198926" CI_END="92.01846737234422" CI_START="27.46528129976" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="59.741874336052106" ESTIMABLE="YES" I2="21.29812889777672" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2010-12-08 12:02:31 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.25363959750912723" P_Q="0.5754767838200239" P_Z="2.8588434340708914E-4" Q="1.1051132440896598" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="494.3251145264656" TOTALS="YES" TOTAL_1="546" TOTAL_2="534" UNITS="pg/mL" WEIGHT="100.0" Z="3.627765852979608">
<NAME>Serum iPTH</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.010438444696398" CI_END="167.44326948655856" CI_START="12.367105258616178" DF="3" EFFECT_SIZE="89.90518737258736" ESTIMABLE="YES" I2="25.19521141217493" ID="CMP-005.07.01" MODIFIED="2010-10-03 16:52:16 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.2603392514283508" P_Z="0.023051941834556867" STUDIES="5" TAU2="1598.0995144989167" TOTAL_1="219" TOTAL_2="199" WEIGHT="21.59653121997929" Z="2.2725727083962264">
<NAME>Sevelamer versus calcium acetate</NAME>
<CONT_DATA CI_END="233.0585613711933" CI_START="-128.65856137119331" EFFECT_SIZE="52.19999999999999" ESTIMABLE="YES" MEAN_1="381.9" MEAN_2="329.7" ORDER="3717" SD_1="417.0" SD_2="408.3" SE="92.2764718116162" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" WEIGHT="3.010159264263193"/>
<CONT_DATA CI_END="308.8973056477695" CI_START="35.10269435223054" EFFECT_SIZE="172.0" ESTIMABLE="YES" MEAN_1="498.0" MEAN_2="326.0" MODIFIED="2010-10-03 16:52:16 +1100" MODIFIED_BY="Narelle S Willis" ORDER="1388" SD_1="352.0" SD_2="236.0" SE="69.8468475582194" STUDY_ID="STD-BRiC-Study-2008" TOTAL_1="41" TOTAL_2="30" WEIGHT="5.047424703197425"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="131.0" MEAN_2="158.0" ORDER="3719" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-CARE-Study-2004" TOTAL_1="50" TOTAL_2="48" WEIGHT="0.0"/>
<CONT_DATA CI_END="217.99504705474152" CI_START="18.00495294525848" EFFECT_SIZE="118.0" ESTIMABLE="YES" MEAN_1="434.0" MEAN_2="316.0" ORDER="3720" SD_1="359.0" SD_2="212.0" SE="51.0188186331431" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="70" TOTAL_2="59" WEIGHT="8.755957291597134"/>
<CONT_DATA CI_END="125.00345584590829" CI_START="-157.0034558459083" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="330.0" MEAN_2="346.0" ORDER="3718" SD_1="205.0" SD_2="250.0" SE="71.94186064546366" STUDY_ID="STD-Hervas-2003" TOTAL_1="18" TOTAL_2="22" WEIGHT="4.7829899609215385"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.049390882412869" CI_END="96.2923528664449" CI_START="-2.3892181264867105" DF="3" EFFECT_SIZE="46.951567369979095" ESTIMABLE="YES" I2="40.58689315479494" ID="CMP-005.07.02" MODIFIED="2009-04-17 00:58:50 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.16821621543869325" P_Z="0.06217340450794893" STUDIES="5" TAU2="1003.4770457964254" TOTAL_1="174" TOTAL_2="179" WEIGHT="56.85397578065583" Z="1.8650570747289075">
<NAME>Sevelamer versus calcium carbonate</NAME>
<CONT_DATA CI_END="140.09405776611547" CI_START="43.90594223388454" EFFECT_SIZE="92.0" ESTIMABLE="YES" MEAN_1="210.0" MEAN_2="118.0" ORDER="3724" SD_1="41.0" SD_2="56.0" SE="24.538235470383768" STUDY_ID="STD-De-Santo-2006" TOTAL_1="8" TOTAL_2="8" WEIGHT="24.733769747529276"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="213.0" MEAN_2="147.0" ORDER="3722" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Kinugasa-2001" TOTAL_1="115" TOTAL_2="115" WEIGHT="0.0"/>
<CONT_DATA CI_END="123.44911028312023" CI_START="-77.44911028312023" EFFECT_SIZE="23.0" ESTIMABLE="YES" MEAN_1="194.0" MEAN_2="171.0" ORDER="3721" SD_1="163.0" SD_2="139.0" SE="51.25048780255658" STUDY_ID="STD-Koiwa-2005a" TOTAL_1="16" TOTAL_2="20" WEIGHT="8.6894863088971"/>
<CONT_DATA CI_END="168.99854027245368" CI_START="-88.99854027245368" EFFECT_SIZE="40.0" ESTIMABLE="YES" MEAN_1="239.0" MEAN_2="199.0" ORDER="3723" SD_1="168.0" SD_2="198.0" SE="65.81679117064277" STUDY_ID="STD-Sadek-2003" TOTAL_1="15" TOTAL_2="16" WEIGHT="5.619221024683145"/>
<CONT_DATA CI_END="68.84886659581647" CI_START="-56.848866595816475" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="91.0" ORDER="3725" SD_1="114.0" SD_2="87.0" SE="32.06633748964793" STUDY_ID="STD-Shaheen-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="17.811498699546302"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.607024304183201E-32" CI_END="109.17954364234836" CI_START="0.8204563576516151" DF="0" EFFECT_SIZE="54.99999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-005.07.03" MODIFIED="2009-07-23 00:09:14 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.04663013460916812" STUDIES="2" TAU2="0.0" TOTAL_1="153" TOTAL_2="156" WEIGHT="21.54949299936489" Z="1.9896442808987553">
<NAME>Sevelamer versus calcium salts (calcium acetate and calcium carbonate)</NAME>
<CONT_DATA CI_END="109.17954364234838" CI_START="0.8204563576516222" EFFECT_SIZE="55.0" ESTIMABLE="YES" MEAN_1="298.0" MEAN_2="243.0" ORDER="3726" SD_1="152.0" SD_2="136.0" SE="27.64313225636272" STUDY_ID="STD-Block-2005" TOTAL_1="54" TOTAL_2="55" WEIGHT="21.54949299936489"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="224.0" MEAN_2="138.0" ORDER="3727" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Chertow-2002" TOTAL_1="99" TOTAL_2="101" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.745255657612737" CI_END="-0.7934196330331684" CI_START="-2.074857930647215" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4341387818401918" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.08" MODIFIED="2010-12-08 12:21:01 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.7824814308104019" P_Q="0.4855696999714141" P_Z="1.149038076079655E-5" Q="0.48632851762801055" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="186" UNITS="mEq/L" WEIGHT="100.0" Z="4.387039729454876">
<NAME>Serum bicarbonate</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours calcium salts</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sevelamer</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.04946988071829513" CI_END="-0.7860347014486299" CI_START="-2.4721681304524945" DF="1" EFFECT_SIZE="-1.6291014159505621" ESTIMABLE="YES" I2="0.0" ID="CMP-005.08.01" NO="1" P_CHI2="0.8239883023840775" P_Z="1.5226881142134776E-4" STUDIES="2" TAU2="0.0" TOTAL_1="120" TOTAL_2="107" WEIGHT="57.7579168614649" Z="3.787339776915116">
<NAME>Sevelamer versus calcium acetate</NAME>
<CONT_DATA CI_END="-0.6506715735108028" CI_START="-2.7493284264891957" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="21.0" ORDER="3741" SD_1="2.7" SD_2="2.6" SE="0.5353814839283605" STUDY_ID="STD-CARE-Study-2004" TOTAL_1="50" TOTAL_2="48" WEIGHT="37.28314424585004"/>
<CONT_DATA CI_END="-0.08401660653261378" CI_START="-2.9159833934673864" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="21.6" MEAN_2="23.1" ORDER="3742" SD_1="4.3" SD_2="3.9" SE="0.7224537821288975" STUDY_ID="STD-CARE_x002d_2-Study-2008" TOTAL_1="70" TOTAL_2="59" WEIGHT="20.47477261561486"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2094572592664312" CI_END="-0.18175077775302062" CI_START="-2.153379044367879" DF="2" EFFECT_SIZE="-1.1675649110604498" ESTIMABLE="YES" I2="0.0" ID="CMP-005.08.02" MODIFIED="2009-04-09 04:10:54 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5462228947761515" P_Z="0.020269847045142748" STUDIES="3" TAU2="0.0" TOTAL_1="75" TOTAL_2="79" WEIGHT="42.242083138535094" Z="2.321315041014484">
<NAME>Sevelamer versus calcium carbonate</NAME>
<CONT_DATA CI_END="0.9642786640509189" CI_START="-2.5642786640509203" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="20.4" MEAN_2="21.2" MODIFIED="2009-04-09 04:07:55 +1000" MODIFIED_BY="[Empty name]" ORDER="1397" SD_1="3.3" SD_2="4.1" SE="0.9001587161638298" STUDY_ID="STD-Ferreira-2008" TOTAL_1="33" TOTAL_2="35" WEIGHT="13.188671259934484"/>
<CONT_DATA CI_END="-0.21877558028526" CI_START="-3.78122441971474" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="23.2" MODIFIED="2009-04-09 04:09:10 +1000" MODIFIED_BY="[Empty name]" ORDER="1398" SD_1="2.3" SD_2="4.2" SE="0.9088046687412681" STUDY_ID="STD-Russo-2007" TOTAL_1="27" TOTAL_2="28" WEIGHT="12.938922943186459"/>
<CONT_DATA CI_END="0.7960975663338961" CI_START="-2.3960975663338973" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="22.2" MEAN_2="23.0" ORDER="3743" SD_1="1.9" SD_2="2.6" SE="0.8143504569082446" STUDY_ID="STD-Sadek-2003" TOTAL_1="15" TOTAL_2="16" WEIGHT="16.11448893541415"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5932680529337904" CI_END="31.528287335231674" CI_START="-11.277348266939962" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="10.125469534145855" ESTIMABLE="YES" I2="0.0" I2_Q="13.104294141772435" ID="CMP-005.09" MODIFIED="2010-12-08 12:21:01 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.6609172547601596" P_Q="0.28338077483227964" P_Z="0.35380178397284634" Q="1.1508048529250963" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="93" TOTAL_2="94" UNITS="IU/L" WEIGHT="99.99999999999999" Z="0.9272403193787233">
<NAME>Serum alkaline phosphatase</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4424632000086941" CI_END="37.17851262809803" CI_START="-8.384228978999444" DF="2" EFFECT_SIZE="14.397141824549292" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.01" MODIFIED="2010-08-10 08:16:46 +1000" MODIFIED_BY="Narelle S Willis" NO="1" NOTES="&lt;p&gt;Replaced Peres 2009 with Barret 2008&lt;/p&gt;" NOTES_MODIFIED="2010-08-10 08:16:46 +1000" NOTES_MODIFIED_BY="Narelle S Willis" P_CHI2="0.8015311589633785" P_Z="0.21547948422359087" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="74" WEIGHT="88.26371501642949" Z="1.2386383462068182">
<NAME>Sevelamer versus calcium acetate</NAME>
<CONT_DATA CI_END="45.42023938043499" CI_START="-9.420239380434989" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="96.0" ORDER="3738" SD_1="73.0" SD_2="50.0" SE="13.990175123993266" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" WEIGHT="60.925545318977164"/>
<CONT_DATA CI_END="53.142367104793244" CI_START="-59.142367104793244" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="195.0" MEAN_2="198.0" MODIFIED="2010-08-09 16:35:40 +1000" MODIFIED_BY="Narelle S Willis" ORDER="177" SD_1="81.0" SD_2="78.0" SE="28.644591200469534" STUDY_ID="STD-BRiC-Study-2008" TOTAL_1="17" TOTAL_2="14" WEIGHT="14.533173877257095"/>
<CONT_DATA CI_END="76.811023455308" CI_START="-42.81102345530801" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="243.0" MEAN_2="226.0" ORDER="3739" SD_1="65.0" SD_2="120.0" SE="30.516389039334257" STUDY_ID="STD-Hervas-2003" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.804995820195227"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="40.47490884160029" CI_START="-84.4749088416003" DF="0" EFFECT_SIZE="-22.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.02" NO="2" P_CHI2="1.0" P_Z="0.490078235196049" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="20" WEIGHT="11.7362849835705" Z="0.6901844029769808">
<NAME>Sevelamer versus calcium carbonate</NAME>
<CONT_DATA CI_END="40.47490884160029" CI_START="-84.4749088416003" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="211.0" MEAN_2="233.0" ORDER="3740" SD_1="80.0" SD_2="111.0" SE="31.87553921112551" STUDY_ID="STD-Koiwa-2005a" TOTAL_1="16" TOTAL_2="20" WEIGHT="11.7362849835705"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="24.817264500983878" CI_END="-10.89545026235529" CI_START="-27.415194185018024" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-19.155322223686657" ESTIMABLE="YES" I2="63.734923324675066" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2010-12-08 12:02:40 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.00318011847692512" P_Q="0.5563555918121843" P_Z="5.485247208891401E-6" Q="1.1726960120577168" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="93.11384818706401" TOTALS="YES" TOTAL_1="845" TOTAL_2="860" UNITS="mg/dL" WEIGHT="100.0" Z="4.5453176328212805">
<NAME>Serum total cholesterol</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7648576286004882" CI_END="-0.975088697036453" CI_START="-27.6133684653052" DF="2" EFFECT_SIZE="-14.294228581170827" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.01" MODIFIED="2010-08-10 08:17:14 +1000" MODIFIED_BY="Narelle S Willis" NO="1" NOTES="&lt;p&gt;Replaced Peres 2009 with Barreto 2008&lt;/p&gt;" NOTES_MODIFIED="2010-08-10 08:17:14 +1000" NOTES_MODIFIED_BY="Narelle S Willis" P_CHI2="0.4137767389242576" P_Z="0.03542626532077435" STUDIES="3" TAU2="0.0" TOTAL_1="75" TOTAL_2="76" WEIGHT="22.812830422141452" Z="2.103452133515805">
<NAME>Sevelamer versus calcium acetate</NAME>
<CONT_DATA CI_END="-2.372048779473289" CI_START="-43.8279512205267" EFFECT_SIZE="-23.099999999999994" ESTIMABLE="YES" MEAN_1="146.8" MEAN_2="169.9" ORDER="3744" SD_1="42.8" SD_2="51.4" SE="10.57567964719053" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" WEIGHT="8.665303466028933"/>
<CONT_DATA CI_END="21.38881460299918" CI_START="-25.38881460299918" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="139.0" MEAN_2="141.0" MODIFIED="2010-08-09 16:38:26 +1000" MODIFIED_BY="Narelle S Willis" ORDER="178" SD_1="40.0" SD_2="26.0" SE="11.933287951966038" STUDY_ID="STD-BRiC-Study-2008" TOTAL_1="17" TOTAL_2="14" WEIGHT="7.54098021592921"/>
<CONT_DATA CI_END="10.350802371919272" CI_START="-41.61080237191926" EFFECT_SIZE="-15.629999999999995" ESTIMABLE="YES" MEAN_1="154.62" MEAN_2="170.25" ORDER="3745" SD_1="49.79" SD_2="28.91" SE="13.255754991853177" STUDY_ID="STD-Hervas-2003" TOTAL_1="18" TOTAL_2="22" WEIGHT="6.606546740183312"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.4869638747022065" CI_END="-2.9900946592028337" CI_START="-25.1382727876519" DF="3" EFFECT_SIZE="-14.064183723427366" ESTIMABLE="YES" I2="13.965268703674028" ID="CMP-005.10.02" MODIFIED="2009-04-13 22:44:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32245692465448317" P_Z="0.012804161742134114" STUDIES="4" TAU2="18.346322145999743" TOTAL_1="91" TOTAL_2="99" WEIGHT="33.832917135632734" Z="2.489170297439932">
<NAME>Sevelamer versus calcium carbonate</NAME>
<CONT_DATA CI_END="-8.137546475162786" CI_START="-43.862453524837214" EFFECT_SIZE="-26.0" ESTIMABLE="YES" MEAN_1="140.0" MEAN_2="166.0" MODIFIED="2009-04-09 04:15:06 +1000" MODIFIED_BY="[Empty name]" ORDER="1402" SD_1="34.0" SD_2="41.0" SE="9.113664162063165" STUDY_ID="STD-Ferreira-2008" TOTAL_1="33" TOTAL_2="35" WEIGHT="10.081189590048085"/>
<CONT_DATA CI_END="1.6827363330866518" CI_START="-31.682736333086652" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="156.0" MEAN_2="171.0" ORDER="3746" SD_1="30.0" SD_2="18.0" SE="8.511756575466665" STUDY_ID="STD-Koiwa-2005a" TOTAL_1="16" TOTAL_2="20" WEIGHT="10.727164396311911"/>
<CONT_DATA CI_END="19.13871470886933" CI_START="-24.538714708869307" EFFECT_SIZE="-2.6999999999999886" ESTIMABLE="YES" MEAN_1="181.3" MEAN_2="184.0" MODIFIED="2009-04-09 04:15:47 +1000" MODIFIED_BY="[Empty name]" ORDER="1403" SD_1="53.1" SD_2="23.5" SE="11.142406126403502" STUDY_ID="STD-Russo-2007" TOTAL_1="27" TOTAL_2="28" WEIGHT="8.174412620924468"/>
<CONT_DATA CI_END="32.3878735841705" CI_START="-32.3878735841705" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="180.0" MEAN_2="180.0" ORDER="3747" SD_1="44.0" SD_2="48.0" SE="16.52472894381831" STUDY_ID="STD-Sadek-2003" TOTAL_1="15" TOTAL_2="16" WEIGHT="4.85015052834827"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="18.392746985623468" CI_END="-9.595140458186709" CI_START="-44.594165460952865" DF="2" EFFECT_SIZE="-27.09465295956979" ESTIMABLE="YES" I2="89.12614846731006" ID="CMP-005.10.03" NO="3" P_CHI2="1.0140749193898735E-4" P_Z="0.0024083101457308743" STUDIES="3" TAU2="206.90578174050003" TOTAL_1="679" TOTAL_2="685" WEIGHT="43.354252442225814" Z="3.034629905842876">
<NAME>Sevelamer versus calcium salts (calcium acetate and calcium carbonate)</NAME>
<CONT_DATA CI_END="-9.755663377327945" CI_START="-42.24433662267205" EFFECT_SIZE="-26.0" ESTIMABLE="YES" MEAN_1="134.0" MEAN_2="160.0" ORDER="3748" SD_1="52.0" SD_2="32.0" SE="8.288079143701266" STUDY_ID="STD-Block-2005" TOTAL_1="54" TOTAL_2="55" WEIGHT="10.976289353818354"/>
<CONT_DATA CI_END="-29.966348125159506" CI_START="-52.033651874840494" EFFECT_SIZE="-41.0" ESTIMABLE="YES" MEAN_1="141.0" MEAN_2="182.0" ORDER="3749" SD_1="28.0" SD_2="49.0" SE="5.629517665565558" STUDY_ID="STD-Chertow-2002" TOTAL_1="99" TOTAL_2="101" WEIGHT="14.230408251244699"/>
<CONT_DATA CI_END="-11.327340146702529" CI_START="-19.87265985329746" EFFECT_SIZE="-15.599999999999994" ESTIMABLE="YES" MEAN_1="150.8" MEAN_2="166.4" ORDER="3750" SD_1="34.8" SD_2="36.0" SE="2.179968554014084" STUDY_ID="STD-DCOR-Study-2007" TOTAL_1="526" TOTAL_2="529" WEIGHT="18.147554837162765"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.11" MODIFIED="2010-12-08 12:02:40 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum 1, 25 dihydroxyvitamin D</NAME>
<GROUP_LABEL_1>Sevelamer</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sevelamer</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.11.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Sevelamer versus calcium acetate</NAME>
<CONT_DATA CI_END="6.8345759238624995" CI_START="-8.354575923862502" EFFECT_SIZE="-0.7600000000000016" ESTIMABLE="YES" MEAN_1="22.4" MEAN_2="23.16" ORDER="3737" SD_1="18.3" SD_2="16.3" SE="3.8748548359906336" STUDY_ID="STD-Bleyer-1999" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-12-08 12:02:53 +1100" MODIFIED_BY="Narelle S Willis" NO="6">
<NAME>Lanthanum carbonate versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-07-07 11:12:54 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="79" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4209" O_E="0.0" SE="0.0" STUDY_ID="STD-Chiang-2005" TOTAL_1="30" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4210" O_E="0.0" SE="0.0" STUDY_ID="STD-Joy-2003" TOTAL_1="49" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3011463056558571" CI_END="2.445236422466101" CI_START="0.44736547786037195" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0459036096209506" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.38832085610115386" LOG_CI_START="-0.34933753242805166" LOG_EFFECT_SIZE="0.019491661836551148" METHOD="MH" MODIFIED="2010-10-03 16:48:03 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.5831647728503745" P_Q="0.0" P_Z="0.9175034620133472" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="79" TOTAL_2="75" WEIGHT="100.0" Z="0.10357898938733878">
<NAME>Adverse gastrointestinal events</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gastritis</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-03 16:47:55 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhoea</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gastroparesis</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3011463056558571" CI_END="2.445236422466101" CI_START="0.44736547786037195" DF="1" EFFECT_SIZE="1.0459036096209506" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" ID="CMP-006.02.04" LOG_CI_END="0.38832085610115386" LOG_CI_START="-0.34933753242805166" LOG_EFFECT_SIZE="0.019491661836551148" NO="4" P_CHI2="0.5831647728503745" P_Z="0.9175034620133472" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="75" WEIGHT="100.0" Z="0.10357898938733878">
<NAME>Combined</NAME>
<DICH_DATA CI_END="3.836891327997325" CI_START="0.12368552055975736" EFFECT_SIZE="0.6888888888888889" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5839794988805024" LOG_CI_START="-0.9076811387626443" LOG_EFFECT_SIZE="-0.161850819941071" ORDER="4212" O_E="0.0" SE="0.8762088423908257" STUDY_ID="STD-Chiang-2005" TOTAL_1="30" TOTAL_2="31" VAR="0.7677419354838709" WEIGHT="24.455160182342027"/>
<DICH_DATA CI_END="3.1808562605954176" CI_START="0.4506575194344198" EFFECT_SIZE="1.1972789115646258" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5025440442596159" LOG_CI_START="-0.3461533781276684" LOG_EFFECT_SIZE="0.07819533306597372" ORDER="4213" O_E="0.0" SE="0.4985290670302864" STUDY_ID="STD-Joy-2003" TOTAL_1="49" TOTAL_2="44" VAR="0.24853123067408775" WEIGHT="75.54483981765797"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.13253229277026674" CI_END="-1.4988135541252594" CI_START="-2.5205015034392177" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0096575287822387" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2010-12-08 12:02:50 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.7158208751319783" P_Q="1.0" P_Z="1.2533746047820058E-14" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="75" UNITS="mg/dL" WEIGHT="99.99999999999999" Z="7.710488080666533">
<NAME>Serum phosphorus</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.3946413137324205" CI_START="-2.8053586862675806" EFFECT_SIZE="-2.1000000000000005" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="7.2" ORDER="4215" SD_1="1.5" SD_2="1.3" SE="0.3598834936924144" STUDY_ID="STD-Chiang-2005" TOTAL_1="30" TOTAL_2="31" WEIGHT="52.451330938020384"/>
<CONT_DATA CI_END="-1.1691690926369185" CI_START="-2.65083090736308" EFFECT_SIZE="-1.9099999999999993" ESTIMABLE="YES" MEAN_1="5.94" MEAN_2="7.85" ORDER="4216" SD_1="1.65" SD_2="1.96" SE="0.37798189824234546" STUDY_ID="STD-Joy-2003" TOTAL_1="49" TOTAL_2="44" WEIGHT="47.5486690619796"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.04" MODIFIED="2010-12-08 12:02:50 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="49" TOTAL_2="44" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Total calcium</NAME>
<CONT_DATA CI_END="0.6558303730793146" CI_START="0.04416962692068471" EFFECT_SIZE="0.34999999999999964" ESTIMABLE="YES" MEAN_1="8.83" MEAN_2="8.48" ORDER="4214" SD_1="0.68" SD_2="0.81" SE="0.15603877188135387" STUDY_ID="STD-Joy-2003" TOTAL_1="49" TOTAL_2="44" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Ionised calcium</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.05" MODIFIED="2010-12-08 12:02:53 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="49" TOTAL_2="44" UNITS="mg²/dL²" WEIGHT="0.0" Z="0.0">
<NAME>Serum calcium x phosphorus product</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-7.370445749385047" CI_START="-21.029554250614943" EFFECT_SIZE="-14.199999999999996" ESTIMABLE="YES" MEAN_1="52.4" MEAN_2="66.6" ORDER="4218" SD_1="14.9" SD_2="18.3" SE="3.484530483460717" STUDY_ID="STD-Joy-2003" TOTAL_1="49" TOTAL_2="44" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2010-12-08 12:02:53 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="49" TOTAL_2="44" UNITS="pg/mL" WEIGHT="0.0" Z="0.0">
<NAME>Serum iPTH</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-11.368350524806445" CI_START="-154.63164947519357" EFFECT_SIZE="-83.0" ESTIMABLE="YES" MEAN_1="209.0" MEAN_2="292.0" ORDER="4217" SD_1="152.0" SD_2="195.0" SE="36.547431503953575" STUDY_ID="STD-Joy-2003" TOTAL_1="49" TOTAL_2="44" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-12-22 11:00:10 +1100" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Lanthanum carbonate versus calcium salts</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-07 22:43:34 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="172" TOTAL_2="179" WEIGHT="0.0" Z="0.0">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-07 22:43:05 +1100" MODIFIED_BY="Narelle S Willis" ORDER="177" O_E="0.0" SE="0.0" STUDY_ID="STD-D_x0027_Haese-2003" TOTAL_1="49" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-07 22:43:12 +1100" MODIFIED_BY="Narelle S Willis" ORDER="178" O_E="0.0" SE="0.0" STUDY_ID="STD-Shigematsu-2008" TOTAL_1="123" TOTAL_2="130" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3585546360308809" CI_END="0.3139175640271131" CI_START="0.08824815364836089" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.16644111698490804" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-0.5031843843743286" LOG_CI_START="-1.0542943722712088" LOG_EFFECT_SIZE="-0.7787393783227686" METHOD="MH" MODIFIED="2010-12-07 16:51:57 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.5493102855069437" P_Q="0.0" P_Z="3.041908913831942E-8" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="172" TOTAL_2="179" WEIGHT="100.00000000000001" Z="5.539007342909303">
<NAME>Hypercalcaemia</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.38813060786857084" CI_START="0.04025706729444785" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="24" LOG_CI_END="-0.41102210757105173" LOG_CI_START="-1.3951578664128352" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="4223" O_E="0.0" SE="0.5780862162942373" STUDY_ID="STD-D_x0027_Haese-2003" TOTAL_1="49" TOTAL_2="49" VAR="0.3341836734693877" WEIGHT="31.359312954135998"/>
<DICH_DATA CI_END="0.4080073823687488" CI_START="0.08820136911167906" EFFECT_SIZE="0.1897018970189702" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="39" LOG_CI_END="-0.3893319788390282" LOG_CI_START="-1.0545246734505787" LOG_EFFECT_SIZE="-0.7219283261448035" MODIFIED="2009-04-09 04:59:30 +1000" MODIFIED_BY="[Empty name]" ORDER="1411" O_E="0.0" SE="0.3907374815717681" STUDY_ID="STD-Shigematsu-2008" TOTAL_1="123" TOTAL_2="130" VAR="0.1526757795050478" WEIGHT="68.64068704586401"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-07 22:46:06 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="49" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Adverse gastrointestinal events</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gastritis</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-03 16:49:07 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhoea</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-21 23:29:51 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Constipation</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="24" I2="0.0" ID="CMP-007.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-12-07 22:46:06 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="49" WEIGHT="0.0" Z="0.0">
<NAME>Combined</NAME>
<DICH_DATA CI_END="1.5479933355457096" CI_START="0.7009522712589251" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.18976908661692962" LOG_CI_START="-0.15431155269606642" LOG_EFFECT_SIZE="0.017728766960431616" ORDER="4227" O_E="0.0" SE="0.20211467075908773" STUDY_ID="STD-D_x0027_Haese-2003" TOTAL_1="49" TOTAL_2="49" VAR="0.04085034013605443" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.185250700299916" CI_END="0.7535203400627265" CI_START="-0.3221251748537862" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21569758260447014" ESTIMABLE="YES" I2="15.629663855337956" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2010-12-08 12:02:56 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.2762897016994975" P_Q="1.0" P_Z="0.43183393762553035" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.024507312925169878" TOTALS="YES" TOTAL_1="61" TOTAL_2="61" UNITS="mg/dL" WEIGHT="100.0" Z="0.786057279269979">
<NAME>Serum phosphorus</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0632008716971233" CI_START="-0.1832008716971243" EFFECT_SIZE="0.4399999999999995" ESTIMABLE="YES" MEAN_1="5.59" MEAN_2="5.15" ORDER="4231" SD_1="1.46" SD_2="1.68" SE="0.31796547110704726" STUDY_ID="STD-D_x0027_Haese-2003" TOTAL_1="49" TOTAL_2="49" WEIGHT="59.94599689365544"/>
<CONT_DATA CI_END="0.6724736543695388" CI_START="-0.912473654369539" EFFECT_SIZE="-0.1200000000000001" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.92" ORDER="4233" SD_1="0.77" SD_2="1.17" SE="0.4043307227175958" STUDY_ID="STD-Spasovski-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="40.05400310634457"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9163812675568525" CI_END="-0.027085101550188784" CI_START="-0.5687820628012179" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2979335821757033" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.05" MODIFIED="2010-12-08 12:02:56 +1100" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.33842706725648897" P_Q="1.0" P_Z="0.03108661553033346" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="61" TOTAL_2="61" UNITS="mg/dL" WEIGHT="100.0" Z="2.1559622173282915">
<NAME>Serum calcium</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9163812675568525" CI_END="-0.027085101550188784" CI_START="-0.5687820628012179" DF="1" EFFECT_SIZE="-0.2979335821757033" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" MODIFIED="2009-07-21 23:29:51 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.33842706725648897" P_Z="0.03108661553033346" STUDIES="2" TAU2="0.0" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0" Z="2.1559622173282915">
<NAME>Total calcium</NAME>
<CONT_DATA CI_END="0.05568305138145235" CI_START="-0.5356830513814528" EFFECT_SIZE="-0.2400000000000002" ESTIMABLE="YES" MEAN_1="9.32" MEAN_2="9.56" ORDER="4228" SD_1="0.64" SD_2="0.84" SE="0.15086147179936096" STUDY_ID="STD-D_x0027_Haese-2003" TOTAL_1="49" TOTAL_2="49" WEIGHT="83.90733828452687"/>
<CONT_DATA CI_END="0.07516895173655369" CI_START="-1.275168951736553" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="8.72" MEAN_2="9.32" ORDER="4230" SD_1="0.76" SD_2="0.92" SE="0.3444802848737017" STUDY_ID="STD-Spasovski-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="16.09266171547312"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Ionised calcium</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.06" MODIFIED="2010-12-08 12:02:59 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="49" TOTAL_2="49" UNITS="mg²/dL²" WEIGHT="0.0" Z="0.0">
<NAME>Serum calcium x phosphorus product</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.3593137365359724" CI_START="-9.660686263464024" EFFECT_SIZE="-6.009999999999998" ESTIMABLE="YES" MEAN_1="52.09" MEAN_2="58.1" ORDER="4236" SD_1="9.8" SD_2="8.6" SE="1.8626292586293283" STUDY_ID="STD-D_x0027_Haese-2003" TOTAL_1="49" TOTAL_2="49" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.5269479225041174" CI_END="277.1239686739166" CI_START="-75.30384415433375" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="100.91006225979143" ESTIMABLE="YES" I2="71.6468736717268" I2_Q="0.0" ID="CMP-007.07" MODIFIED="2010-12-22 11:00:10 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.06037897524177327" P_Q="1.0" P_Z="0.2616982131986416" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="12230.104462925023" TOTALS="YES" TOTAL_1="238" TOTAL_2="126" UNITS="pg/mL" WEIGHT="100.0" Z="1.1223863753526768">
<NAME>Serum iPTH</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_DATA CI_END="88.9889886447179" CI_START="-29.428988644717904" EFFECT_SIZE="29.78" ESTIMABLE="YES" MEAN_1="251.3" MEAN_2="221.52" MODIFIED="2010-12-22 05:01:11 +1100" MODIFIED_BY="[Empty name]" ORDER="179" SD_1="239.88" SD_2="273.88" SE="30.2092227774341" STUDY_ID="STD-Hutchison-2005" TOTAL_1="226" TOTAL_2="114" WEIGHT="61.50345713059945"/>
<CONT_DATA CI_END="398.06739300466563" CI_START="31.032606995334362" EFFECT_SIZE="214.55" ESTIMABLE="YES" MEAN_1="374.55" MEAN_2="160.0" MODIFIED="2010-12-08 15:30:25 +1100" MODIFIED_BY="Narelle S Willis" ORDER="179" SD_1="296.36" SD_2="131.82" SE="93.63304349071076" STUDY_ID="STD-Spasovski-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="38.49654286940056"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.040498237676797" CI_END="55.74146170449068" CI_START="2.283751185079929" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="29.012606444785305" ESTIMABLE="YES" I2="50.992361496055636" I2_Q="0.0" ID="CMP-007.08" MODIFIED="2010-12-08 12:03:04 +1100" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.15315989900950844" P_Q="1.0" P_Z="0.03338469724759871" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="229.1597745479974" TOTALS="YES" TOTAL_1="545" TOTAL_2="279" UNITS="IU/L" WEIGHT="100.0" Z="2.1274260785548007">
<NAME>Serum alkaline phosphatase</NAME>
<GROUP_LABEL_1>Lanthanum carbonate</GROUP_LABEL_1>
<GROUP_LABEL_2>Calcium salts</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lanthanum carbonate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours calcium salts</GRAPH_LABEL_2>
<CONT_DATA CI_END="49.15567625697325" CI_START="26.404323743026747" EFFECT_SIZE="37.78" ESTIMABLE="YES" MEAN_1="230.75" MEAN_2="192.97" ORDER="4239" SD_1="34.24" SD_2="91.69" SE="5.804023107926032" STUDY_ID="STD-D_x0027_Haese-2003" TOTAL_1="533" TOTAL_2="267" WEIGHT="70.75585872176553"/>
<CONT_DATA CI_END="47.330785974333764" CI_START="-31.73078597433377" EFFECT_SIZE="7.799999999999997" ESTIMABLE="YES" MEAN_1="100.6" MEAN_2="92.8" ORDER="4240" SD_1="20.8" SD_2="66.7" SE="20.169138966913454" STUDY_ID="STD-Spasovski-2006" TOTAL_1="12" TOTAL_2="12" WEIGHT="29.24414127823447"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-12-22 08:30:31 +1100" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="119 flow chartb.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-12-22 08:30:31 +1100" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart showing study selection procedure</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-12-16 14:47:00 +1100" MODIFIED_BY="Narelle S Willis">
<APPENDIX ID="APP-01" MODIFIED="2010-12-08 17:05:37 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2010-03-10 12:18:31 +1100" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-08 17:05:37 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>KIDNEY DISEASES</LI>
<LI>KIDNEY FAILURE CHRONIC</LI>
<LI>KIDNEY FAILURE</LI>
<LI>RENAL REPLACEMENT THERAPY</LI>
<LI>RENAL DIALYSIS</LI>
<LI>HEMOFILTRATION</LI>
<LI>((chronic next kidney) or (chronic next renal))</LI>
<LI>(ckd or ckf or crd or crf or eskd or esrd or eskf or esrf)</LI>
<LI>(predialysis or dialysis)</LI>
<LI>(haemodialysis or haemodialysis)</LI>
<LI>(capd or ccpd or apd)</LI>
<LI>(#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11)</LI>
<LI>BONE DISEASES</LI>
<LI>RENAL OSTEODYSTROPHY</LI>
<LI>(bone next disease*)</LI>
<LI>(bone* and (atroph* or formation or deform* or destruct* or necrosis or resorption or metabol* or turnover or demineral* or decalcif* or density))</LI>
<LI>(#13 or #14 or #15 or #16)</LI>
<LI>(#12 and #17)</LI>
<LI>aluminium HYDROXIDE</LI>
<LI>CALCIUM CARBONATE</LI>
<LI>CALCIUM GLUCONATE</LI>
<LI>POLYAMINES</LI>
<LI>ANION EXCHANGE RESINS</LI>
<LI>((phosphate next buffer*) or (phosphate next binder*))</LI>
<LI>((aluminium next carbonate*) or (aluminium next carbonate*))</LI>
<LI>(calcium next acetate*)</LI>
<LI>(calcium next ketoglutarate*)</LI>
<LI>sevelamer</LI>
<LI>(lanthanum next carbonate*)</LI>
<LI>(magnesium next carbonate*)</LI>
<LI>((aluminium next hydroxide*) or (aluminium next hydroxide*))</LI>
<LI>colestimide</LI>
<LI>phoslo</LI>
<LI>renagel</LI>
<LI>fosrenol</LI>
<LI>(#19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35)</LI>
<LI>(#18 and #36)</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>Kidney Diseases/</LI>
<LI>Kidney Failure, Chronic/</LI>
<LI>Kidney Failure/</LI>
<LI>renal replacement therapy/ or exp renal dialysis/ or exp hemofiltration/</LI>
<LI>(chronic kidney or chronic renal).tw.</LI>
<LI>(CKD or CKF or CRD or CRF or ESKD or ESRD or ESKF or ESRF).tw.</LI>
<LI>(predialysis or dialysis).tw.</LI>
<LI>(haemodialysis or haemodialysis).tw.</LI>
<LI>(CAPD or CCPD or APD).tw.</LI>
<LI>or/1-9</LI>
<LI>exp Bone Diseases/</LI>
<LI>Renal Osteodystrophy/</LI>
<LI>bone disease$.tw.</LI>
<LI>(bone$ and (atroph$ or formation or deform$ or destruct$ or necrosis or resorption or metabol$ or turnover or demineral$ or decalcif$ or density)).tw.</LI>
<LI>(osteo$ or hyperparathyroid$ or hyperphosphat$).tw.</LI>
<LI>or/11-15</LI>
<LI>and/10,16</LI>
<LI>aluminium Hydroxide/</LI>
<LI>Calcium Carbonate/</LI>
<LI>Calcium Gluconate/</LI>
<LI>Polyamines/</LI>
<LI>Anion Exchange Resins/</LI>
<LI>(phosphate buffer$ or phosphate bind$).tw.</LI>
<LI>alumin?um carbonate$.tw.</LI>
<LI>calcium acetate$.tw.</LI>
<LI>calcium ketoglutarate$.tw.</LI>
<LI>sevelamer.tw.</LI>
<LI>lanthanum carbonate$.tw.</LI>
<LI>magnesium carbonate$.tw.</LI>
<LI>alumin?um hydroxide$.tw.</LI>
<LI>colestimide.tw.</LI>
<LI>phoslo.tw.</LI>
<LI>renagel.tw.</LI>
<LI>fosrenol.tw.</LI>
<LI>or/18-34</LI>
<LI>and/17,35</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>Kidney Disease/</LI>
<LI>Kidney Failure/</LI>
<LI>Chronic Kidney Failure/</LI>
<LI>exp haemodialysis/</LI>
<LI>(haemodialysis or haemodialysis).tw.</LI>
<LI>dialysis.tw.</LI>
<LI>(CAPD or CCPD or APD).tw.</LI>
<LI>predialysis.tw.</LI>
<LI>(chronic renal or chronic kidney).tw.</LI>
<LI>(CKD or CKF or CRD or CRF or ESKD or ESRD or ESKF or ESRF).tw.</LI>
<LI>or/1-10</LI>
<LI>exp Bone Disease/</LI>
<LI>bone disease$.tw.</LI>
<LI>(bone$ and (atroph$ or formation or deform$ or destruct$ or necrosis or resorption or metabol$ or turnover or demineral$ or decalcif$ or density)).tw.</LI>
<LI>(osteo$ or hyperparathyroid$ or hyperphosphat$).tw.</LI>
<LI>or/12-15</LI>
<LI>aluminium Hydroxide/</LI>
<LI>Calcium Carbonate/</LI>
<LI>Gluconate Calcium/</LI>
<LI>Polyamine/</LI>
<LI>Anion Exchange Resin/</LI>
<LI>Sevelamer/</LI>
<LI>Lanthanum Carbonate/</LI>
<LI>Magnesium Carbonate/</LI>
<LI>aluminium Carbonate/</LI>
<LI>Calcium Acetate/</LI>
<LI>Phosphate Binding Agent/</LI>
<LI>aluminium Hydroxide/</LI>
<LI>Colestilan/</LI>
<LI>(phosphate buffer$ or phosphate bind$).tw.</LI>
<LI>alumin?um carbonate$.tw.</LI>
<LI>calcium acetate$.tw.</LI>
<LI>calcium ketoglutarate$.tw.</LI>
<LI>sevelamer.tw.</LI>
<LI>colestimide.tw.</LI>
<LI>phoslo.tw.</LI>
<LI>renagel.tw.</LI>
<LI>fosrenol.tw.</LI>
<LI>lanthanum carbonate$.tw.</LI>
<LI>magnesium carbonate$.tw.</LI>
<LI>alumin?um hydroxide$.tw.</LI>
<LI>or/17-41</LI>
<LI>and/11,16,42</LI>
</OL>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-12-16 14:47:00 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2010-10-03 17:16:49 +1100" MODIFIED_BY="Narelle S Willis">Quality checklist</TITLE>
<APPENDIX_BODY MODIFIED="2010-10-04 17:28:40 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f3&quot;&gt;&lt;span coll_flag=&quot;f3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Title&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s0&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Review information&lt;/h1&gt;&lt;p&gt;Replaced trials with studies; renal with kidney (where appropriate)&lt;/p&gt;&lt;p&gt;When to use person/people vs patient/patients vs participant/participants - you participate or are a participant in a study; people have the condition; you are usually a patient while in hospital or being treat by a medical practitioner. We have used participant or person instead of patient, unless it changed the meaning of the text&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s51&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Navaneethan, Sankar&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s53&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Palmer, Suetonia&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s55&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vecchio, Mariacristina&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s57&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Craig, Jonathan&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s59&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Elder, Grahame&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s61&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Strippoli, Giovanni&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contact person&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s6&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dates&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s10&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;What's new&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s11&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;History&lt;/h2&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s49&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abstract&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f210&quot;&gt;&lt;span coll_flag=&quot;f210&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f212&quot;&gt;&lt;span coll_flag=&quot;f212&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f214&quot;&gt;&lt;span coll_flag=&quot;f214&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f216&quot;&gt;&lt;span coll_flag=&quot;f216&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection criteria&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f218&quot;&gt;&lt;span coll_flag=&quot;f218&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f220&quot;&gt;&lt;span coll_flag=&quot;f220&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f222&quot;&gt;&lt;span coll_flag=&quot;f222&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s48&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language summary&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f205&quot;&gt;&lt;span coll_flag=&quot;f205&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language title&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f207&quot;&gt;&lt;span coll_flag=&quot;f207&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary text&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f235&quot;&gt;&lt;span coll_flag=&quot;f235&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f245&quot;&gt;&lt;span coll_flag=&quot;f245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f247&quot;&gt;&lt;span coll_flag=&quot;f247&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Methods&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f249&quot;&gt;&lt;span coll_flag=&quot;f249&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Criteria for considering studies for this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f251&quot;&gt;&lt;span coll_flag=&quot;f251&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f253&quot;&gt;&lt;span coll_flag=&quot;f253&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of participants&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f255&quot;&gt;&lt;span coll_flag=&quot;f255&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of interventions&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f257&quot;&gt;&lt;span coll_flag=&quot;f257&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of outcome measures&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f263&quot;&gt;&lt;span coll_flag=&quot;f263&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods for identification of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f265&quot;&gt;&lt;span coll_flag=&quot;f265&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Electronic searches&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f267&quot;&gt;&lt;span coll_flag=&quot;f267&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Searching other resources&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f269&quot;&gt;&lt;span coll_flag=&quot;f269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;RevMan headings have been activated and text moved&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f271&quot;&gt;&lt;span coll_flag=&quot;f271&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f273&quot;&gt;&lt;span coll_flag=&quot;f273&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data extraction and management&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f275&quot;&gt;&lt;span coll_flag=&quot;f275&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Assessment of risk of bias in included studies&lt;/h3&gt;&lt;p&gt;Quality checklist has been moved to appendix 2&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f277&quot;&gt;&lt;span coll_flag=&quot;f277&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Measures of treatment effect&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f281&quot;&gt;&lt;span coll_flag=&quot;f281&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dealing with missing data&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f283&quot;&gt;&lt;span coll_flag=&quot;f283&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Assessment of heterogeneity&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f285&quot;&gt;&lt;span coll_flag=&quot;f285&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Assessment of reporting biases&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f287&quot;&gt;&lt;span coll_flag=&quot;f287&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data synthesis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f289&quot;&gt;&lt;span coll_flag=&quot;f289&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Subgroup analysis and investigation of heterogeneity&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f293&quot;&gt;&lt;span coll_flag=&quot;f293&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f295&quot;&gt;&lt;span coll_flag=&quot;f295&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f297&quot;&gt;&lt;span coll_flag=&quot;f297&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results of the search&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f299&quot;&gt;&lt;span coll_flag=&quot;f299&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h3&gt;&lt;p&gt;The number of participants ranged from 10 to 2100 with 27/40 (67%) of studies enrolling fewer that 100 participants &lt;span class=&quot;marker&quot;&gt;- this was changed to 27/60 (45%)&lt;/span&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f303&quot;&gt;&lt;span coll_flag=&quot;f303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias in included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f315&quot;&gt;&lt;span coll_flag=&quot;f315&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Effects of interventions&lt;/h2&gt;&lt;p&gt;Added links to forest plots, and reordered some to match the order in the text&lt;/p&gt;&lt;p&gt;Added hypercalcaemia and hospitalisation as a heading - if there were no data this has been stated&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f317&quot;&gt;&lt;span coll_flag=&quot;f317&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Discussion&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f319&quot;&gt;&lt;span coll_flag=&quot;f319&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of main results&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f327&quot;&gt;&lt;span coll_flag=&quot;f327&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Agreements and disagreements with other studies or reviews&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f329&quot;&gt;&lt;span coll_flag=&quot;f329&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f331&quot;&gt;&lt;span coll_flag=&quot;f331&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for practice&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f333&quot;&gt;&lt;span coll_flag=&quot;f333&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for research&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f224&quot;&gt;&lt;span coll_flag=&quot;f224&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Acknowledgements&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f228&quot;&gt;&lt;span coll_flag=&quot;f228&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contributions of authors&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f226&quot;&gt;&lt;span coll_flag=&quot;f226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Declarations of interest&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f230&quot;&gt;&lt;span coll_flag=&quot;f230&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Differences between protocol and review&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f232&quot;&gt;&lt;span coll_flag=&quot;f232&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Published notes&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s19&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s20&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of included studies&lt;/h2&gt;&lt;p&gt;Tables have been reformatted and missing data added&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s632&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Al-Baaj 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4500&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4500&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4502&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4502&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4504&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4504&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4506&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4506&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4508&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4508&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s70&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1021&quot; id=&quot;s1021&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6574&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6574&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1081&quot; id=&quot;s1081&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6754&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6754&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1143&quot; id=&quot;s1143&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6942&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6942&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1204&quot; id=&quot;s1204&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7127&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7127&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1265&quot; id=&quot;s1265&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7312&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7312&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1326&quot; id=&quot;s1326&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7497&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7497&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1387&quot; id=&quot;s1387&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7682&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7682&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s633&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Almirall 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4511&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4511&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4513&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4513&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4515&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4515&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4517&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4517&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4519&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4519&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s77&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1022&quot; id=&quot;s1022&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6577&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6577&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1082&quot; id=&quot;s1082&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6757&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6757&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1144&quot; id=&quot;s1144&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6945&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6945&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1205&quot; id=&quot;s1205&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7130&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7130&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1266&quot; id=&quot;s1266&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7315&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7315&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1327&quot; id=&quot;s1327&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7500&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7500&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1388&quot; id=&quot;s1388&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7685&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7685&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s634&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barreto 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4522&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4522&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4524&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4524&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4526&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4526&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4528&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4528&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4530&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4530&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s87&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1023&quot; id=&quot;s1023&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6580&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6580&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1083&quot; id=&quot;s1083&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6760&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6760&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1145&quot; id=&quot;s1145&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6948&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6948&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1206&quot; id=&quot;s1206&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7133&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7133&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1267&quot; id=&quot;s1267&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7318&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7318&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1328&quot; id=&quot;s1328&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7503&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7503&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1389&quot; id=&quot;s1389&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7688&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7688&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s635&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Birck 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4533&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4533&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4535&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4535&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4537&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4537&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4539&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4539&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4541&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4541&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s94&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1024&quot; id=&quot;s1024&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6583&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6583&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1084&quot; id=&quot;s1084&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6763&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6763&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1146&quot; id=&quot;s1146&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6951&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6951&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1207&quot; id=&quot;s1207&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7136&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7136&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1268&quot; id=&quot;s1268&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7321&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7321&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1329&quot; id=&quot;s1329&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7506&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7506&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1390&quot; id=&quot;s1390&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7691&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7691&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s636&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bleyer 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4544&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4544&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4546&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4546&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4548&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4548&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4550&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4550&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4552&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4552&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s101&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1025&quot; id=&quot;s1025&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6586&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6586&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1085&quot; id=&quot;s1085&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6766&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6766&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1147&quot; id=&quot;s1147&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6954&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6954&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1208&quot; id=&quot;s1208&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7139&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7139&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1269&quot; id=&quot;s1269&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7324&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7324&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1330&quot; id=&quot;s1330&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7509&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7509&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1391&quot; id=&quot;s1391&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7694&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7694&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s637&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Block 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4555&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4555&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4557&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4557&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4559&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4559&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4561&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4561&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4563&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4563&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s111&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1026&quot; id=&quot;s1026&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6589&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6589&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1086&quot; id=&quot;s1086&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6769&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6769&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1148&quot; id=&quot;s1148&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6957&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6957&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1209&quot; id=&quot;s1209&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7142&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7142&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1270&quot; id=&quot;s1270&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7327&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7327&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1331&quot; id=&quot;s1331&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7512&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7512&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1392&quot; id=&quot;s1392&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7697&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7697&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s638&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Borrego 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4566&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4566&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4568&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4568&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4570&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4570&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4572&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4572&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4574&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4574&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s118&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1027&quot; id=&quot;s1027&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6592&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6592&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1087&quot; id=&quot;s1087&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6772&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6772&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1149&quot; id=&quot;s1149&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6960&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6960&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1210&quot; id=&quot;s1210&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7145&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7145&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1271&quot; id=&quot;s1271&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7330&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7330&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1332&quot; id=&quot;s1332&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7515&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7515&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1393&quot; id=&quot;s1393&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7700&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7700&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s639&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bro 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4577&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4577&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4579&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4579&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4581&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4581&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4583&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4583&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4585&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4585&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s125&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1028&quot; id=&quot;s1028&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6595&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6595&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1088&quot; id=&quot;s1088&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6775&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6775&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1150&quot; id=&quot;s1150&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6963&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6963&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1211&quot; id=&quot;s1211&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7148&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7148&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1272&quot; id=&quot;s1272&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7333&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7333&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1333&quot; id=&quot;s1333&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7518&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7518&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1394&quot; id=&quot;s1394&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7703&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7703&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s640&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Caravaca 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4588&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4588&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4590&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4590&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4592&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4592&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4594&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4594&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4596&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4596&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s132&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1031&quot; id=&quot;s1031&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6604&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6604&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1091&quot; id=&quot;s1091&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6784&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6784&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1153&quot; id=&quot;s1153&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6972&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6972&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1214&quot; id=&quot;s1214&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7157&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7157&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1275&quot; id=&quot;s1275&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7342&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7342&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1336&quot; id=&quot;s1336&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7527&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7527&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1397&quot; id=&quot;s1397&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7712&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7712&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s641&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CARE Study 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4599&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4599&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4601&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4601&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4603&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4603&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4605&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4605&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4607&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4607&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s139&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1029&quot; id=&quot;s1029&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6598&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6598&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1089&quot; id=&quot;s1089&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6778&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6778&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1151&quot; id=&quot;s1151&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6966&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6966&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1212&quot; id=&quot;s1212&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7151&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7151&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1273&quot; id=&quot;s1273&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7336&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7336&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1334&quot; id=&quot;s1334&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7521&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7521&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1395&quot; id=&quot;s1395&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7706&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7706&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s642&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CARE-2 Study 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4610&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4610&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4612&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4612&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4614&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4614&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4616&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4616&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4618&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4618&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s147&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1030&quot; id=&quot;s1030&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6601&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6601&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1090&quot; id=&quot;s1090&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6781&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6781&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1152&quot; id=&quot;s1152&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6969&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6969&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1213&quot; id=&quot;s1213&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7154&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7154&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1274&quot; id=&quot;s1274&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7339&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7339&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1335&quot; id=&quot;s1335&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7524&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7524&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1396&quot; id=&quot;s1396&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7709&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7709&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s643&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4621&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4621&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4623&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4623&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4625&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4625&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4627&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4627&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4629&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4629&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s154&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1032&quot; id=&quot;s1032&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6607&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6607&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1092&quot; id=&quot;s1092&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6787&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6787&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1154&quot; id=&quot;s1154&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6975&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6975&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1215&quot; id=&quot;s1215&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7160&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7160&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1276&quot; id=&quot;s1276&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7345&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7345&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1337&quot; id=&quot;s1337&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7530&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7530&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1398&quot; id=&quot;s1398&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7715&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7715&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s644&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4632&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4632&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4634&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4634&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4636&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4636&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4638&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4638&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4640&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4640&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s161&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1033&quot; id=&quot;s1033&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6610&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6610&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1093&quot; id=&quot;s1093&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6790&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6790&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1155&quot; id=&quot;s1155&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6978&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6978&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1216&quot; id=&quot;s1216&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7163&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7163&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1277&quot; id=&quot;s1277&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7348&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7348&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1338&quot; id=&quot;s1338&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7533&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7533&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1399&quot; id=&quot;s1399&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7718&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7718&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s645&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4643&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4643&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4645&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4645&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4647&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4647&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4649&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4649&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4651&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4651&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s168&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1034&quot; id=&quot;s1034&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6613&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6613&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1094&quot; id=&quot;s1094&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6793&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6793&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1156&quot; id=&quot;s1156&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6981&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6981&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1217&quot; id=&quot;s1217&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7166&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7166&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1278&quot; id=&quot;s1278&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7351&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7351&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1339&quot; id=&quot;s1339&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7536&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7536&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1400&quot; id=&quot;s1400&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7721&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7721&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s646&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4654&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4654&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4656&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4656&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4658&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4658&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4660&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4660&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4662&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4662&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s184&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1035&quot; id=&quot;s1035&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6616&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6616&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1095&quot; id=&quot;s1095&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6796&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6796&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1157&quot; id=&quot;s1157&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6984&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6984&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1218&quot; id=&quot;s1218&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7169&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7169&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1279&quot; id=&quot;s1279&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7354&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7354&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1340&quot; id=&quot;s1340&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7539&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7539&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1401&quot; id=&quot;s1401&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7724&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7724&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s647&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chiang 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4665&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4665&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4667&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4667&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4669&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4669&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4671&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4671&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4673&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4673&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s191&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1036&quot; id=&quot;s1036&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6619&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6619&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1096&quot; id=&quot;s1096&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6799&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6799&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1158&quot; id=&quot;s1158&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6987&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6987&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1219&quot; id=&quot;s1219&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7172&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7172&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1280&quot; id=&quot;s1280&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7357&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7357&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1341&quot; id=&quot;s1341&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7542&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7542&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1402&quot; id=&quot;s1402&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7727&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7727&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s648&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Haese 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4676&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4676&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4678&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4678&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4680&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4680&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4682&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4682&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4684&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4684&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s198&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1037&quot; id=&quot;s1037&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6622&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6622&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1097&quot; id=&quot;s1097&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6802&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6802&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1159&quot; id=&quot;s1159&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6990&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6990&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1220&quot; id=&quot;s1220&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7175&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7175&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1281&quot; id=&quot;s1281&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7360&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7360&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1342&quot; id=&quot;s1342&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7545&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7545&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1403&quot; id=&quot;s1403&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7730&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7730&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s649&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;DCOR Study 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4687&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4687&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4689&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4689&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4691&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4691&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4693&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4693&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4695&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4695&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s206&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1038&quot; id=&quot;s1038&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6625&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6625&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1098&quot; id=&quot;s1098&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6805&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6805&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1160&quot; id=&quot;s1160&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6993&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6993&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1221&quot; id=&quot;s1221&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7178&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7178&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1282&quot; id=&quot;s1282&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7363&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7363&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1343&quot; id=&quot;s1343&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7548&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7548&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1404&quot; id=&quot;s1404&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7733&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7733&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s650&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Santo 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4698&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4698&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4700&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4700&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4702&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4702&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4704&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4704&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4706&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4706&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s213&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1039&quot; id=&quot;s1039&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6628&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6628&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1099&quot; id=&quot;s1099&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6808&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6808&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1161&quot; id=&quot;s1161&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6996&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6996&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1222&quot; id=&quot;s1222&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7181&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7181&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1283&quot; id=&quot;s1283&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7366&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7366&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1344&quot; id=&quot;s1344&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7551&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7551&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1405&quot; id=&quot;s1405&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7736&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7736&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s651&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Deuber 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4709&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4709&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4711&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4711&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4713&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4713&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4715&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4715&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4717&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4717&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s220&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1040&quot; id=&quot;s1040&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6631&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6631&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1100&quot; id=&quot;s1100&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6811&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6811&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1162&quot; id=&quot;s1162&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6999&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6999&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1223&quot; id=&quot;s1223&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7184&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7184&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1284&quot; id=&quot;s1284&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7369&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7369&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1345&quot; id=&quot;s1345&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7554&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7554&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1406&quot; id=&quot;s1406&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7739&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7739&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s652&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Emmett 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4720&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4720&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4722&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4722&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4724&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4724&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4726&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4726&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4728&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4728&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s227&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1041&quot; id=&quot;s1041&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6634&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6634&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1101&quot; id=&quot;s1101&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6814&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6814&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1163&quot; id=&quot;s1163&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7002&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7002&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1224&quot; id=&quot;s1224&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7187&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7187&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1285&quot; id=&quot;s1285&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7372&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7372&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1346&quot; id=&quot;s1346&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7557&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7557&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1407&quot; id=&quot;s1407&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7742&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7742&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s653&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evenepoel 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4731&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4731&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4733&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4733&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4735&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4735&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4737&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4737&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4739&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4739&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s234&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1042&quot; id=&quot;s1042&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6637&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6637&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1102&quot; id=&quot;s1102&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6817&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6817&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1164&quot; id=&quot;s1164&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7005&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7005&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1225&quot; id=&quot;s1225&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7190&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7190&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1286&quot; id=&quot;s1286&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7375&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7375&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1347&quot; id=&quot;s1347&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7560&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7560&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1408&quot; id=&quot;s1408&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7745&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7745&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s654&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fan 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4742&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4742&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4744&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4744&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4746&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4746&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4748&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4748&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4750&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4750&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s241&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1043&quot; id=&quot;s1043&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6640&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6640&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1103&quot; id=&quot;s1103&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6820&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6820&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1165&quot; id=&quot;s1165&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7008&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7008&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1226&quot; id=&quot;s1226&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7193&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7193&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1287&quot; id=&quot;s1287&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7378&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7378&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1348&quot; id=&quot;s1348&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7563&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7563&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1409&quot; id=&quot;s1409&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7748&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7748&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s655&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4753&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4753&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4755&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4755&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4757&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4757&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4759&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4759&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4761&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4761&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s248&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1044&quot; id=&quot;s1044&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6643&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6643&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1104&quot; id=&quot;s1104&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6823&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6823&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1166&quot; id=&quot;s1166&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7011&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7011&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1227&quot; id=&quot;s1227&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7196&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7196&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1288&quot; id=&quot;s1288&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7381&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7381&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1349&quot; id=&quot;s1349&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7566&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7566&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1410&quot; id=&quot;s1410&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7751&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7751&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s656&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Filho 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4764&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4764&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4766&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4766&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4768&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4768&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4770&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4770&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4772&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4772&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s255&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1045&quot; id=&quot;s1045&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6646&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6646&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1105&quot; id=&quot;s1105&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6826&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6826&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1167&quot; id=&quot;s1167&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7014&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7014&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1228&quot; id=&quot;s1228&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7199&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7199&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1289&quot; id=&quot;s1289&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7384&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7384&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1350&quot; id=&quot;s1350&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7569&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7569&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1411&quot; id=&quot;s1411&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7754&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7754&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s657&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Finn 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4775&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4775&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4777&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4777&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4779&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4779&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4781&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4781&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4783&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4783&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s265&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1046&quot; id=&quot;s1046&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6649&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6649&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1106&quot; id=&quot;s1106&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6829&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6829&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1168&quot; id=&quot;s1168&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7017&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7017&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1229&quot; id=&quot;s1229&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7202&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7202&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1290&quot; id=&quot;s1290&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7387&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7387&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1351&quot; id=&quot;s1351&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7572&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7572&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1412&quot; id=&quot;s1412&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7757&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7757&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s658&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fischer 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4786&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4786&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4788&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4788&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4790&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4790&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4792&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4792&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4794&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4794&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s272&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1047&quot; id=&quot;s1047&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6652&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6652&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1107&quot; id=&quot;s1107&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6832&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6832&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1169&quot; id=&quot;s1169&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7020&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7020&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1230&quot; id=&quot;s1230&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7205&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7205&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1291&quot; id=&quot;s1291&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7390&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7390&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1352&quot; id=&quot;s1352&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7575&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7575&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1413&quot; id=&quot;s1413&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7760&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7760&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s659&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gallieni 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4797&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4797&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4799&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4799&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4801&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4801&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4803&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4803&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4805&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4805&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s279&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1048&quot; id=&quot;s1048&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6655&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6655&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1108&quot; id=&quot;s1108&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6835&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6835&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1170&quot; id=&quot;s1170&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7023&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7023&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1231&quot; id=&quot;s1231&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7208&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7208&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1292&quot; id=&quot;s1292&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7393&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7393&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1353&quot; id=&quot;s1353&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7578&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7578&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1414&quot; id=&quot;s1414&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7763&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7763&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s660&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hervas 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4808&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4808&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4810&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4810&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4812&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4812&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4814&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4814&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4816&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4816&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s286&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1049&quot; id=&quot;s1049&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6658&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6658&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1109&quot; id=&quot;s1109&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6838&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6838&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1171&quot; id=&quot;s1171&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7026&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7026&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1232&quot; id=&quot;s1232&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7211&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7211&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1293&quot; id=&quot;s1293&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7396&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7396&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1354&quot; id=&quot;s1354&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7581&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7581&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1415&quot; id=&quot;s1415&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7766&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7766&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s661&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hutchison 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4819&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4819&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4821&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4821&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4823&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4823&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4825&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4825&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4827&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4827&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s296&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1050&quot; id=&quot;s1050&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6661&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6661&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1110&quot; id=&quot;s1110&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6841&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6841&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1172&quot; id=&quot;s1172&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7029&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7029&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1233&quot; id=&quot;s1233&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7214&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7214&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1294&quot; id=&quot;s1294&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7399&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7399&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1355&quot; id=&quot;s1355&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7584&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7584&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1416&quot; id=&quot;s1416&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7769&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7769&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s662&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Itoh 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4830&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4830&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4832&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4832&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4834&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4834&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4836&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4836&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4838&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4838&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1051&quot; id=&quot;s1051&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6664&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6664&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1111&quot; id=&quot;s1111&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6844&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6844&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1173&quot; id=&quot;s1173&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7032&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7032&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1234&quot; id=&quot;s1234&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7217&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7217&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1295&quot; id=&quot;s1295&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7402&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7402&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1356&quot; id=&quot;s1356&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7587&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7587&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1417&quot; id=&quot;s1417&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7772&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7772&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s663&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ittel 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4841&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4841&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4843&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4843&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4845&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4845&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4847&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4847&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4849&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4849&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s310&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1052&quot; id=&quot;s1052&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6667&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6667&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1112&quot; id=&quot;s1112&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6847&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6847&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1174&quot; id=&quot;s1174&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7035&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7035&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1235&quot; id=&quot;s1235&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7220&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7220&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1296&quot; id=&quot;s1296&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7405&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7405&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1357&quot; id=&quot;s1357&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7590&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7590&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1418&quot; id=&quot;s1418&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7775&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7775&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s664&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Janssen 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4852&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4852&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4854&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4854&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4856&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4856&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4858&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4858&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4860&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4860&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s317&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1053&quot; id=&quot;s1053&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6670&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6670&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1113&quot; id=&quot;s1113&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6850&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6850&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1175&quot; id=&quot;s1175&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7038&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7038&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1236&quot; id=&quot;s1236&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7223&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7223&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1297&quot; id=&quot;s1297&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7408&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7408&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1358&quot; id=&quot;s1358&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7593&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7593&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1419&quot; id=&quot;s1419&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7778&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7778&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s665&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jespersen 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4863&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4863&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4865&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4865&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4867&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4867&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4869&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4869&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4871&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4871&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s324&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1054&quot; id=&quot;s1054&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6673&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6673&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1114&quot; id=&quot;s1114&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6853&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6853&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1176&quot; id=&quot;s1176&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7041&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7041&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1237&quot; id=&quot;s1237&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7226&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7226&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1298&quot; id=&quot;s1298&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7411&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7411&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1359&quot; id=&quot;s1359&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7596&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7596&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1420&quot; id=&quot;s1420&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7781&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7781&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s666&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Joy 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4874&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4874&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4876&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4876&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4878&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4878&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4880&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4880&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4882&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4882&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s331&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1055&quot; id=&quot;s1055&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6676&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6676&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1115&quot; id=&quot;s1115&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6856&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6856&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1177&quot; id=&quot;s1177&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7044&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7044&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1238&quot; id=&quot;s1238&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7229&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7229&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1299&quot; id=&quot;s1299&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7414&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7414&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1360&quot; id=&quot;s1360&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7599&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7599&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1421&quot; id=&quot;s1421&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7784&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7784&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s667&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kinugusa 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4885&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4885&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4887&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4887&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4889&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4889&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4891&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4891&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4893&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4893&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s338&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1056&quot; id=&quot;s1056&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6679&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6679&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1116&quot; id=&quot;s1116&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6859&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6859&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1178&quot; id=&quot;s1178&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7047&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7047&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1239&quot; id=&quot;s1239&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7232&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7232&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1300&quot; id=&quot;s1300&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7417&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7417&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1361&quot; id=&quot;s1361&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7602&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7602&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1422&quot; id=&quot;s1422&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7787&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7787&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s668&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Koiwa 2005a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4896&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4896&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4898&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4898&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4900&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4900&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4902&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4902&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4904&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4904&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s345&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1057&quot; id=&quot;s1057&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6682&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6682&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1117&quot; id=&quot;s1117&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6862&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6862&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1179&quot; id=&quot;s1179&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7050&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7050&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1240&quot; id=&quot;s1240&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7235&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7235&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1301&quot; id=&quot;s1301&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7420&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7420&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1362&quot; id=&quot;s1362&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7605&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7605&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1423&quot; id=&quot;s1423&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7790&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7790&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s669&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kurihara 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4907&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4907&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4909&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4909&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4911&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4911&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4913&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4913&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4915&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4915&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s352&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1058&quot; id=&quot;s1058&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6685&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6685&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1118&quot; id=&quot;s1118&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6865&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6865&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1180&quot; id=&quot;s1180&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7053&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7053&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1241&quot; id=&quot;s1241&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7238&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7238&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1302&quot; id=&quot;s1302&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7423&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7423&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1363&quot; id=&quot;s1363&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7608&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7608&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1424&quot; id=&quot;s1424&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7793&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7793&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s670&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Liu 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4918&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4918&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4920&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4920&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4922&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4922&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4924&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4924&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4926&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4926&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s359&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1059&quot; id=&quot;s1059&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6688&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6688&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1119&quot; id=&quot;s1119&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6868&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6868&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1181&quot; id=&quot;s1181&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7056&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7056&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1242&quot; id=&quot;s1242&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7241&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7241&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1303&quot; id=&quot;s1303&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7426&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7426&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1364&quot; id=&quot;s1364&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7611&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7611&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1425&quot; id=&quot;s1425&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7796&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7796&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s671&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Malluche 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4929&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4929&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4931&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4931&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4933&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4933&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4935&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4935&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4937&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4937&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s366&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1060&quot; id=&quot;s1060&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6691&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6691&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1120&quot; id=&quot;s1120&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6871&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6871&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1182&quot; id=&quot;s1182&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7059&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7059&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1243&quot; id=&quot;s1243&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7244&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7244&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1304&quot; id=&quot;s1304&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7429&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7429&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1365&quot; id=&quot;s1365&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7614&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7614&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1426&quot; id=&quot;s1426&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7799&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7799&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s672&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McIntyre 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4940&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4940&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4942&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4942&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4944&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4944&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4946&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4946&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4948&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4948&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s373&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1061&quot; id=&quot;s1061&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6694&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6694&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1121&quot; id=&quot;s1121&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6874&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6874&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1183&quot; id=&quot;s1183&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7062&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7062&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1244&quot; id=&quot;s1244&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7247&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7247&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1305&quot; id=&quot;s1305&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7432&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7432&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1366&quot; id=&quot;s1366&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7617&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7617&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1427&quot; id=&quot;s1427&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7802&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7802&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s673&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mehrotra 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4951&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4951&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4953&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4953&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4955&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4955&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4957&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4957&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4959&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4959&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s380&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1062&quot; id=&quot;s1062&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6697&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6697&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1122&quot; id=&quot;s1122&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6877&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6877&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1184&quot; id=&quot;s1184&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7065&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7065&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1245&quot; id=&quot;s1245&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7250&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7250&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1306&quot; id=&quot;s1306&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7435&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7435&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1367&quot; id=&quot;s1367&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7620&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7620&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1428&quot; id=&quot;s1428&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7805&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7805&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s674&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pflanz 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4962&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4962&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4964&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4964&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4966&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4966&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4968&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4968&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4970&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4970&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s387&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1063&quot; id=&quot;s1063&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6700&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6700&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1123&quot; id=&quot;s1123&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6880&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6880&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1185&quot; id=&quot;s1185&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7068&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7068&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1246&quot; id=&quot;s1246&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7253&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7253&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1307&quot; id=&quot;s1307&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7438&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7438&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1368&quot; id=&quot;s1368&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7623&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7623&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1429&quot; id=&quot;s1429&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7808&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7808&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s675&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Phelps 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4973&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4973&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4975&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4975&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4977&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4977&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4979&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4979&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4981&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4981&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s394&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1064&quot; id=&quot;s1064&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6703&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6703&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1124&quot; id=&quot;s1124&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6883&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6883&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1186&quot; id=&quot;s1186&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7071&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7071&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1247&quot; id=&quot;s1247&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7256&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7256&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1308&quot; id=&quot;s1308&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7441&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7441&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1369&quot; id=&quot;s1369&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7626&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7626&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1430&quot; id=&quot;s1430&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7811&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7811&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s676&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ring 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4984&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4984&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4986&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4986&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4988&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4988&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4990&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4990&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4992&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4992&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s401&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1065&quot; id=&quot;s1065&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6706&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6706&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1125&quot; id=&quot;s1125&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6886&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6886&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1187&quot; id=&quot;s1187&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7074&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7074&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1248&quot; id=&quot;s1248&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7259&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7259&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1309&quot; id=&quot;s1309&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7444&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7444&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1370&quot; id=&quot;s1370&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7629&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7629&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1431&quot; id=&quot;s1431&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7814&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7814&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s677&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roxe 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4995&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4995&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4997&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4997&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4999&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4999&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5001&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5001&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5003&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5003&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s408&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1066&quot; id=&quot;s1066&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6709&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6709&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1126&quot; id=&quot;s1126&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6889&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6889&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1188&quot; id=&quot;s1188&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7077&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7077&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1249&quot; id=&quot;s1249&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7262&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7262&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1310&quot; id=&quot;s1310&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7447&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7447&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1371&quot; id=&quot;s1371&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7632&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7632&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1432&quot; id=&quot;s1432&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7817&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7817&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s678&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rudnicki 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5006&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5006&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5008&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5008&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5010&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5010&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5012&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5012&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5014&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5014&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s415&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1067&quot; id=&quot;s1067&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6712&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6712&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1127&quot; id=&quot;s1127&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6892&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6892&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1189&quot; id=&quot;s1189&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7080&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7080&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1250&quot; id=&quot;s1250&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7265&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7265&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1311&quot; id=&quot;s1311&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7450&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7450&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1372&quot; id=&quot;s1372&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7635&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7635&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1433&quot; id=&quot;s1433&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7820&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7820&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s679&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Russo 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5017&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5017&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5019&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5019&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5021&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5021&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5023&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5023&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5025&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5025&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s422&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1068&quot; id=&quot;s1068&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6715&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6715&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1128&quot; id=&quot;s1128&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6895&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6895&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1190&quot; id=&quot;s1190&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7083&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7083&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1251&quot; id=&quot;s1251&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7268&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7268&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1312&quot; id=&quot;s1312&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7453&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7453&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1373&quot; id=&quot;s1373&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7638&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7638&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1434&quot; id=&quot;s1434&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7823&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7823&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s680&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sadek 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5028&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5028&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5030&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5030&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5032&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5032&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5034&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5034&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5036&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5036&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s429&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1069&quot; id=&quot;s1069&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6718&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6718&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1129&quot; id=&quot;s1129&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6898&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6898&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1191&quot; id=&quot;s1191&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7086&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7086&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1252&quot; id=&quot;s1252&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7271&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7271&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1313&quot; id=&quot;s1313&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7456&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7456&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1374&quot; id=&quot;s1374&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7641&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7641&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1435&quot; id=&quot;s1435&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7826&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7826&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s681&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Saif 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5039&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5039&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5041&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5041&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5043&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5043&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5045&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5045&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5047&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5047&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s436&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1070&quot; id=&quot;s1070&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6721&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6721&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1130&quot; id=&quot;s1130&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6901&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6901&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1192&quot; id=&quot;s1192&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7089&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7089&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1253&quot; id=&quot;s1253&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7274&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7274&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1314&quot; id=&quot;s1314&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7459&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7459&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1375&quot; id=&quot;s1375&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7644&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7644&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1436&quot; id=&quot;s1436&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7829&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7829&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s682&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Salusky 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5050&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5050&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5052&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5052&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5054&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5054&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5056&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5056&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5058&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5058&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s443&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1071&quot; id=&quot;s1071&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6724&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6724&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1131&quot; id=&quot;s1131&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6904&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6904&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1193&quot; id=&quot;s1193&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7092&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7092&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1254&quot; id=&quot;s1254&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7277&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7277&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1315&quot; id=&quot;s1315&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7462&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7462&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1376&quot; id=&quot;s1376&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7647&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7647&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1437&quot; id=&quot;s1437&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7832&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7832&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s683&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schaefer 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5061&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5061&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5063&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5063&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5065&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5065&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5067&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5067&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5069&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5069&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s450&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1072&quot; id=&quot;s1072&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6727&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6727&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1132&quot; id=&quot;s1132&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6907&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6907&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1194&quot; id=&quot;s1194&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7095&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7095&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1255&quot; id=&quot;s1255&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7280&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7280&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1316&quot; id=&quot;s1316&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7465&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7465&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1377&quot; id=&quot;s1377&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7650&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7650&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1438&quot; id=&quot;s1438&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7835&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7835&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s684&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shaheen 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5072&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5072&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5074&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5074&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5076&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5076&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5078&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5078&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5080&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5080&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s457&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1073&quot; id=&quot;s1073&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6730&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6730&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1133&quot; id=&quot;s1133&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6910&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6910&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1195&quot; id=&quot;s1195&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7098&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7098&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1256&quot; id=&quot;s1256&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7283&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7283&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1317&quot; id=&quot;s1317&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7468&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7468&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1378&quot; id=&quot;s1378&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7653&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7653&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1439&quot; id=&quot;s1439&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7838&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7838&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s685&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shigmetsu 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5083&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5083&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5085&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5085&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5087&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5087&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5089&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5089&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5091&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5091&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s464&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1074&quot; id=&quot;s1074&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6733&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6733&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1134&quot; id=&quot;s1134&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6913&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6913&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1196&quot; id=&quot;s1196&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7101&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7101&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1257&quot; id=&quot;s1257&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7286&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7286&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1318&quot; id=&quot;s1318&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7471&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7471&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1379&quot; id=&quot;s1379&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7656&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7656&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1440&quot; id=&quot;s1440&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7841&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7841&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s686&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spasovski 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5094&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5094&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5096&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5096&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5098&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5098&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5100&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5100&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5102&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5102&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s471&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1075&quot; id=&quot;s1075&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6736&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6736&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1135&quot; id=&quot;s1135&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6916&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6916&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1197&quot; id=&quot;s1197&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7104&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7104&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1258&quot; id=&quot;s1258&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7289&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7289&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1319&quot; id=&quot;s1319&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7474&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7474&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1380&quot; id=&quot;s1380&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7659&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7659&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1441&quot; id=&quot;s1441&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7844&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7844&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s687&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spiegel 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5105&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5105&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5107&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5107&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5109&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5109&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5111&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5111&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5113&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5113&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s478&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1076&quot; id=&quot;s1076&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6739&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6739&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1136&quot; id=&quot;s1136&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6919&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6919&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1198&quot; id=&quot;s1198&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7107&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7107&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1259&quot; id=&quot;s1259&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7292&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7292&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1320&quot; id=&quot;s1320&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7477&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7477&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1381&quot; id=&quot;s1381&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7662&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7662&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1442&quot; id=&quot;s1442&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7847&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7847&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s688&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sprague 2009a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5116&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5116&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5118&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5118&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5120&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5120&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5122&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5122&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5124&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5124&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s485&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1077&quot; id=&quot;s1077&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6742&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6742&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1137&quot; id=&quot;s1137&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6922&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6922&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1199&quot; id=&quot;s1199&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7110&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7110&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1260&quot; id=&quot;s1260&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7295&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7295&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1321&quot; id=&quot;s1321&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7480&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7480&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1382&quot; id=&quot;s1382&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7665&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7665&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1443&quot; id=&quot;s1443&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7850&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7850&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s689&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sprague 2009b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5127&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5127&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5129&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5129&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5131&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5131&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5133&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5133&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5135&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5135&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s492&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1078&quot; id=&quot;s1078&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6745&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6745&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1138&quot; id=&quot;s1138&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6925&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6925&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1200&quot; id=&quot;s1200&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7113&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7113&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1261&quot; id=&quot;s1261&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7298&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7298&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1322&quot; id=&quot;s1322&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7483&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7483&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1383&quot; id=&quot;s1383&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7668&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7668&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1444&quot; id=&quot;s1444&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7853&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7853&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s690&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tzanakis 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5138&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5138&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5140&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5140&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5142&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5142&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5144&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5144&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5146&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5146&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s499&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1079&quot; id=&quot;s1079&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6748&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6748&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1139&quot; id=&quot;s1139&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6928&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6928&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1201&quot; id=&quot;s1201&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7116&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7116&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1262&quot; id=&quot;s1262&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7301&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7301&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1323&quot; id=&quot;s1323&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7486&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7486&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1384&quot; id=&quot;s1384&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7671&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7671&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1445&quot; id=&quot;s1445&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7856&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7856&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s691&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wu-Chang 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f5149&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5149&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f5151&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5151&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f5153&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5153&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5155&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5155&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f5157&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5157&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s506&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;8&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1080&quot; id=&quot;s1080&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f160&quot; class=&quot;fixedcell&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6751&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6751&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1140&quot; id=&quot;s1140&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6931&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6931&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1202&quot; id=&quot;s1202&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f6941&quot; class=&quot;fixedcell&quot;&gt;Blinding of participants?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7119&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7119&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1263&quot; id=&quot;s1263&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7126&quot; class=&quot;fixedcell&quot;&gt;Blinding of investigators?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7304&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7304&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1324&quot; id=&quot;s1324&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7311&quot; class=&quot;fixedcell&quot;&gt;Blinding of outcome assessors?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7489&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7489&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1385&quot; id=&quot;s1385&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7496&quot; class=&quot;fixedcell&quot;&gt;Blinding of data analysers?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7674&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7674&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s1446&quot; id=&quot;s1446&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f7681&quot; class=&quot;fixedcell&quot;&gt;Intention to treat?&lt;/td&gt;&lt;td doc_fld_id=&quot;f7859&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f7859&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s21&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s22&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s23&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s31&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of findings tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s32&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional tables&lt;/h1&gt;&lt;p&gt;Tables have been formatted and standardised&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s692&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Characteristics and key results of studies analyzing the effects of various phosphate binders on bone densitometry, bone histomorphometry and vascular calcification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s693&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Serum phosphorus data from miscellaneous studies those were not included in the meta-analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s694&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3 Serum calcium data from miscellaneous studies that were not included in the meta-analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s695&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4 . Serum parathyroid hormone (PTH) data from miscellaneous studies that were not included in the meta-analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s696&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5 Subgroup analyses to explore the reasons for heterogeneity in trials that compared newer agents with older phosphate binding agents&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s34&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;References to studies&lt;/h1&gt;&lt;p&gt;Referenes have been formatted&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s35&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s64&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Al-Baaj 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s67&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Al-Baaj F, Speake M, Hutchinson J. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuos ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrology Dialysis Transplantation 2005;20(4):775-85.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s71&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Almirall 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s74&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Almirall J, Veciana L, Llibre J. Calcium acetate versus calcium carbonate for the control of serum phosphorus in haemodialysis patients. American Journal of Nephrology 1994;14(3):192-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s78&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barreto 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s81&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barreto DV, Barreto FC, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study. Nephron 2008;110(4):c273-83.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s84&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peres AT, Dalboni MA, Canziani ME, Manfredi SR, Carvalho JT, Batista MC, et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International 2009;13(3):271-7.&lt;/h4&gt;journal article. research support, non-u.s. gov't&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s88&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Birck 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s91&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study. Nephrology Dialysis Transplantation 1999;14(6):1475-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s95&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bleyer 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s98&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in haemodialysis patients. American Journal of Kidney Diseases 1999;33(4):694-701.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s102&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Block 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s105&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of cornoary calcification and phosphate binder choice in incident haemodialysis patients. Kidney International 2007;71(5):438-41.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s108&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to haemodialysis. Kidney International 2005;68(4):1815-24.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s112&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Borrego 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s115&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Borrego J, Perez del Barrio P, Serrano P, Garcia Cortes MJ, Sanchez Perales MC, Borrego FJ, et al. A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis. Nefrologia 2000;20(4):348-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s119&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bro 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s122&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bro S, Rasmussen RA, Handberg J, Olgaard K, Feld-Rasmussen B. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic haemodialysis. American Journal of Kidney Diseases 1998;31(2):257-62.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s126&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Caravaca 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s129&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Caravaca F, Santos I, Cubero JJ, Esparrago JF, Arrobas M, Pizarro JL, et al. Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients. Nephron 1992;60(4):423-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s133&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CARE Study 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s136&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney International 2004;65(5):1914-26.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s140&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;CARE-2 Study 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s143&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. American Journal of Kidney Diseases 2008;51(6):952-65.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s148&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s151&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in haemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(4):1131-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s155&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s158&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow GM, Burke SK, Lazarus MJ, Stenzel KH, Wombolt D, Goldberg D, et al. Poly(allylamine hydrochloride) (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. American Journal of Kidney Diseases 1997;29(1):66-71.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s162&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s165&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in haemodialysis patients. Clinical Nephrology 1999;51(1):18-26.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s169&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s172&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrology Dialysis Transplantation 2005;20(8):1653-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s175&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients. Kidney International 2002;62(1):245-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s178&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal 2005;149(5):820-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s181&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raggi P, James G, Burke SK, Bommer S, Chasan-Taber S, Holzer H, et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. Journal of Bone &amp;amp; Mineral Research 2005;20(5):764-72.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s185&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chiang 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s188&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clinical Nephrology 2005;63(6):461-70.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s192&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Haese 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s195&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;D'Haese PC, Spasovski GB, Sikole A, Hutchinson A, Freemont TJ, Sulkova S, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International - Supplement 2003;(85):73-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s199&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;DCOR Study 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s202&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney International 2007;72(9):1130-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s207&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Santo 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s210&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. Journal of Nephrology 2006;19 Suppl 9:S108-14.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s214&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Deuber 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s217&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Deuber HJ. Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract]. Nephrology Dialysis Transplantation 2003;18 Suppl 4:680-1.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s221&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Emmett 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s224&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Emmett M, Sirmon MD, Kirkpatrick GW, Nolan C, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. American Journal of Kidney Diseases 1991;17(5):544-50.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s228&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evenepoel 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s231&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation 2009;24(1):278-85.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s235&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fan 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s238&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fan S, Ross C, Mitra S, Kalra P, Heaton J, Hunter J, et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrology Dialysis Transplantation 2009;24(12):3794-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s242&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira A, Fraz&amp;#227;o JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in haemodialysis patients. Journal of the American Society of Nephrology 2008;19(2):405-12.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s249&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Filho 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s252&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;d'Almeida Filho EJ, da Cruz EA, Hoette M, Ruzany F, Keen LN, Lugon JR. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients. Revista Paulista de Medicina [Sao Paulo Medical Journa] 2000;118(6):179-84.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s256&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Finn 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s259&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Altmann P, Barnett ME, Finn WF; SPD405-307 Lanthanum Carbonate Study Group. Cognitive function in Stage 5 chronic kidney disease patients on haemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney International. 2007;71(3):252-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s262&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Finn WF, Joy MS, Hladik G, Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clinical Nephrology 2004;62(3):193-201.&lt;/h4&gt;&lt;p&gt;Less than 6 weeks - ? should this be Finn 2006 Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clinical Nephrology 65(3):191-202&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s266&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fischer 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT. Results of a randomized crossover study comparing once daily and thrice-daily sevelamer dosing. American Journal of Kidney Diseases 2006;48(3):437-44.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s273&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gallieni 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s276&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gallieni M, Cicchetti T, Salvadori M, Sorba G, Stalteri A, Tarchini R, et al. Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial - Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract]. Journal of the American Society of Nephrology 2005;16:746A.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s280&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hervas 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s283&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hervas JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney International - Supplement 2003;(85):69-72.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s287&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hutchison 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s290&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus Calcium carbonate. Nephron 2005;100(1):c8-19.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s293&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron 2006;102(2):c61-71.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s297&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Itoh 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s300&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, et al. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Therapeutic Apheresis &amp;amp; Dialysis 2008;12(2):126-32.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s304&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ittel 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s307&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ittel TH, Schfer C, Schmitt H, Gladziwa U, Sieberth HG. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional Aluminium hydroxide on hyperaluminaemia. Klinische Wochenschrift 1991;69(2):59-67.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s311&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Janssen 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s314&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology 1996;45(2):111-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s318&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jespersen 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s321&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jespersen B, Jensen JD, Nielsen HK, Lauridsen IN, Andersen MJ, Poulsen JH, et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients. Nephology Dialysis Transplantation 1991;6(2):98-104.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s325&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Joy 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s328&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Joy MS, Finn WF, LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. American Journal of Kdney Diseases 2003;42(1):96-107.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s332&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kinugusa 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s335&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kinugasa E, Koshikawa S, PB-94 Study Group. Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients - a randomized, open label, dose titration study of PB-94 versus caltan&amp;#174; tablet 500 (calcium carbonate) [abstract]. Journal of the American Society of Nephrology 2001;12(Program &amp;amp; Abstracts):755A.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s339&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Koiwa 2005a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s342&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Therapeutic Apheresis &amp;amp; Dialysis 2005;9(4):340-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s346&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kurihara 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s349&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kurihara S, Tsuruta Y, Akizawa T. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrology Dialysis Transplantation 2005;20(2):424-30.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s353&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Liu 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s356&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Renal Failure 2006;28(8):701-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s360&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Malluche 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s363&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clinical Nephrology 2008;70(4):284-95.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s367&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McIntyre 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s370&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McIntyre CW, Pai P, WarwickG, Wilkie M, Toft AJ, Hutchison AJ. Iron-magnesium hydroxycarbonate (Fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(2):401-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s374&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mehrotra 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s377&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, Fosrenol Overview Research Evaluation Study for Early Experience Study Group. Higher strength lanthanum carbonate provides serum phosphorus control with a low&amp;#160; tablet burden and is preferred by patients and physicians: a multicenter study. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(5):1437-45.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s381&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pflanz 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s384&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pflanz S, Henderson IS, McElduff N, Jones MC. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrology Dialysis Transplantation 1994;9(8):1121-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s388&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Phelps 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s391&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Phelps KR, Stern M, Slingerland A, Heravi M, Strogatz DS, Haqqie SS. Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure. American Journal of Nephrology 2002;22(5-6):445-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s395&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ring 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s398&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study. Nephrology Dialysis Transplantation 1993;8(4):341-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s402&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roxe 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s405&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. American Journal of Kidney Diseases 1989;13(3):194-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s409&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rudnicki 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s412&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rudnicki M, Hyldstrup L, Petersen LJ, Hojsted J, Tranbol I. Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double-blind placebo-controlled study. Mineral &amp;amp; Electrolyte Metabolism 1994;20(3):130-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s416&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Russo 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s419&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International 2007;72(10):1255-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s423&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sadek 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s426&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sadek T, Mazouz H, Bahlou H, Oprisiu R, El Esper N, El Esper I, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients An open-label, randomized study. Nephrology Dialysis Transplantation 2003;18(3):582-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s430&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Saif 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s433&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Saif I, Halim A, Altaf A, Saif M, Khalid M, Ahmad D, et al. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis. Journal of Ayub Medical College, Abbottabad: JAMC 2007;19(4):26-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s437&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Salusky 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s440&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. New England Journal of Medicine 1991;324(8):527-31.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s444&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schaefer 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s447&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrology Dialysis Transplantation 1991;6(3):170-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s451&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shaheen 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s454&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shaheen A, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Medical Journal 2004;25(6):785-91.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s458&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shigmetsu 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s461&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shigematsu T, Lanthanum Carbonate Group. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology 2008;70(5):404-10.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s465&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spasovski 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s468&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrology Dialysis Transplantation 2006;21(8):2217-24.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s472&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spiegel 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s475&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. Journal of Renal Nutrition 2007;17(6):416-22.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s479&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sprague 2009a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s482&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sprague SM, Abboud H, Qui P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(1):178-85.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s486&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sprague 2009b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s489&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clinical Nephrology 2009;72(4):252-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s493&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tzanakis 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s496&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. International Urology &amp;amp; Nephrology 2008;40(1):193-201.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s500&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wu-Chang 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s503&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrology Dialysis Transplantation 2002;17(2):265-70.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s36&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s37&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s38&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s39&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other references&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s40&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional references&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s507&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Block 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s510&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Block 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s513&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Burke 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s516&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bushinsky 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s519&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cozzolino 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s522&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dersimonian 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s525&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Elder 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s528&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fellstrom 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s531&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Friedman 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s534&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Guerin 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s537&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gutierrez 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s540&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Higgins 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s543&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hurska 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s546&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hutchinson 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s549&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jamal 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s552&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;K/DOQI 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s555&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;KDIGO 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s558&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Koiwa 2005b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s561&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Manns 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s564&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Manns 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s567&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McCullough 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s570&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Moe 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s573&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nagano 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s576&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Palmer 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s579&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Qunibi 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s582&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Salusky 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s585&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schulz 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s588&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Silver 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s591&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Silver 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s594&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;St Peter 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s597&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;St Peter 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s600&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stevens 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s603&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Strippoli 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s606&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Strippoli 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s609&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Strippoli 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s612&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Taylor 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s615&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tentori 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s618&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tonelli 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s621&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;USRDS 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s41&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other published versions of this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s623&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Navaneethan 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s42&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Classification pending references&lt;/h2&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s46&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data and analyses&lt;/h1&gt;&lt;p&gt;Changed Hypercalcaemic events to hypercalcaemia (to match wording in text)&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s697&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Calcium salts versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s698&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1 All-cause mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s701&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.2 Hypercalcaemia&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s704&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.3 Serum phosphorus [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1455&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.4 Serum calcium [mg/dL]&lt;/h3&gt;&lt;p&gt;Added serum calcium to forest plots&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s707&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Calcium acetate versus calcium carbonate&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s708&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.1 All-cause mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s712&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.2 Hypercalcaemia&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s716&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.3 Adverse gastrointestinal events&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s717&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.3.1 Gastritis&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s719&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.3.2 Diarrhoea&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s722&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.3.3 Constipation&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s725&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.3.4 Abdominal bloating&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s726&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.3.5 Combined&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s727&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.4 Serum calcium [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s734&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.5 Serum phosphorus [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s741&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.6 Serum iPTH [pg/mL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s744&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.7 Serum calcium x phosphorus product [mg&amp;#178;/mg&amp;#178;]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s748&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.8 Serum alkaline phosphatase [IU/L]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s754&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.9 Serum bicarbonate [mEq/L]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s758&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3 Calcium ketoglutarate versus other calcium salts&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s759&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.1 All-cause mortality&lt;/h3&gt;&lt;p&gt;Added Birck 1999 to plot (even though zero events) to keep in context with other comparisons&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s762&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.2 Adverse gastrointestinal events&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s763&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.2.1 Gastritis&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s764&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.2.2 Diarrhoea&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s765&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.2.3 Gastroparesis&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s766&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.2.4 Combined&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s768&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.3 Serum calcium [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s769&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.3.1 Total calcium&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s770&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.3.2 Ionised calcium&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s772&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.4 Serum phosphorus [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s776&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.5 Serum iPTH [pg/mL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s779&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.6 Serum calcium x phosphorus product [mg&amp;#178;/mg&amp;#178;]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s782&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.7 Serum bicarbonate [mEq/L]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s786&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4 Sevelamer versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s787&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.1 All-cause mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s790&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.2 Adverse gastrointestinal events&lt;/h3&gt;&lt;p&gt;Turned off the totals and left subtotals only as it gave the impression that there were 72 patients when there are only 36&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s791&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.2.1 Gastritis&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s793&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.2.2 Diarrhoea&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s795&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.2.3 Gastroparesis&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s796&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.3 Serum calcium [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s797&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.3.1 Total calcium&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s799&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.3.2 Ionised calcium&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s800&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.4 Serum phosphorus [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s803&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.5 Serum bicarbonate [mEq/L]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s806&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.6 Serum total cholesterol [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s809&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5 Sevelamer versus calcium salts&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s810&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.1 All-cause mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s811&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.1.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s818&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.1.2 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s820&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.1.3 Sevelamer versus calcium salts (calcium acetate and calcium carbonate)&lt;/h4&gt;&lt;p&gt;Replaced Block 2007 with Block 2005&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s824&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.2 Hypercalcaemia&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s825&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.2.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s832&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.2.2 Sevelamer versus calcium salts (calcium acetate and calcium carbonate)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s835&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.2.3 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s840&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.3 Gatrointestinal adverse events&lt;/h3&gt;&lt;p&gt;Turned off totals and left as subtotals only&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s841&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.3.1 Nausea/vomiting&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s843&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.3.2 Diarrhoea&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s845&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.3.3 Abdominal bloating&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s847&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.3.4 Constipation&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s850&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.3.5 Combined&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s856&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.4 Serum calcium [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s857&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.4.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s864&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.4.2 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s871&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.4.3 Sevelamer versus calcium salts (calcium acetate and calcium carbonate)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s875&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.5 Serum phosphorus [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s876&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.5.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s884&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.5.2 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s891&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.5.3 Sevelamer versus calcium salts (calcium acetate and calcium carbonate)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s895&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.6 Serum iPTH [pg/mL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s896&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.6.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s902&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.6.2 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s908&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.6.3 Sevelamer versus calcium salts (calcium acetate and calcium carbonate)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s911&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.7 Serum calcium x phosphorus product [mg&amp;#178;/mg&amp;#178;]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s912&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.7.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s918&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.7.2 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s922&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.7.3 Sevelamer versus calcium salts (calcium acetate and calcium carbonate)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s926&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.8 Serum 1, 25 dihydroxyvitamin D&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s927&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.8.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s929&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.9 Serum alkaline phosphatase [IU/L]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s930&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.9.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;Replaced Peres 2009 with Barret 2008&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s934&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.9.2 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s936&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.10 Serum bicarbonate [mEq/L]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s937&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.10.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s940&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.10.2 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s944&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.11 Serum total cholesterol [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s945&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.11.1 Sevelamer versus calcium acetate&lt;/h4&gt;&lt;p&gt;Replaced Peres 2009 with Barreto 2008&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s949&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.11.2 Sevelamer versus calcium carbonate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s954&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.11.3 Sevelamer versus calcium salts (calcium acetate and calcium carbonate)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s958&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6 Lanthanum carbonate versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s959&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.1 All-cause mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s963&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.2 Adverse gastrointestinal events&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s964&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.2.1 Gastritis&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s965&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.2.2 Diarrhoea&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s966&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.2.3 Gastroparesis&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s967&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.2.4 Combined&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s970&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.3 Serum calcium [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s971&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.3.1 Total calcium&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s973&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.3.2 Ionised calcium&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s974&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.4 Serum phosphorus [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s978&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.5 Serum iPTH [pg/mL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s981&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.6 Serum calcium x phosphorus product [mg&amp;#178;/mg&amp;#178;]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s984&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7 Lanthanum carbonate versus calcium salts&lt;/h2&gt;&lt;p&gt;added all-cause mortality to forest plots - to be consistent with text&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s985&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.1 All-cause mortality&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s989&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.2 Hypercalcaemia&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s993&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.3 Adverse gastrointestinal events&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s994&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.3.1 Gastritis&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s995&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.3.2 Diarrhoea&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s996&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.3.3 Constipation&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s997&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.3.4 Combined&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s999&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.4 Serum calcium [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1000&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.4.1 Total calcium&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1003&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.4.2 Ionised calcium&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1004&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.5 Serum phosphorus [mg/dL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1008&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.6 Serum iPTH [pg/mL]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1011&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.7 Serum calcium x phosphorus product [mg&amp;#178;/mg&amp;#178;]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1014&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.8 Serum 1, 25 dihydroxyvitamin D&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1017&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.9 Serum alkaline phosphatase [IU/L]&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s43&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figures&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1447&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 1&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s12&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sources of support&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s13&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Internal sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s14&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;External sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s63&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;SDN is supported by Multidisciplinary Clinical Research Career Development Program CTSA KL2 Grant #:&amp;#160; RR024990, USA&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s44&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feedback&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s17&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendices&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1448&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Electronic search strategies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f7867&quot;&gt;&lt;span coll_flag=&quot;f7867&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f7869&quot;&gt;&lt;span coll_flag=&quot;f7869&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1449&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Quality checklist&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f7872&quot;&gt;&lt;span coll_flag=&quot;f7872&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f7874&quot;&gt;&lt;span coll_flag=&quot;f7874&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-04 17:28:40 +1100" NOTES_MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<UL>
<LI>Adequate (A): randomisation method described that would not allow investigator or participant to know or influence intervention group before eligible participant entered the study</LI>
<LI>Unclear (B): randomisation stated but no information on method used was available</LI>
<LI>Inadequate (C): the method of randomisation used such as alternate medical record numbers or unsealed envelopes; information in the study that indicated that investigators or participants could influence intervention group</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<UL>
<LI>Blinding of investigators: Yes, No, not stated</LI>
<LI>Blinding of participants: Yes, No, not stated</LI>
<LI>Blinding of outcome assessor: Yes, No, not stated</LI>
<LI>Blinding of data analysis: Yes, No, not stated</LI>
</UL>
<P>The above are considered not blinded if the treatment group can be identified in &gt; 20% of participants because of the side effects of treatment</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention-to-treat analysis</HEADING>
<UL>
<LI>Yes: specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.</LI>
<LI>Yes: not stated but confirmed on study assessment</LI>
<LI>No: not reported and lack of intention-to-treat analysis confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study, or were not included because of protocol violation)</LI>
<LI>No: stated but not confirmed upon study assessment</LI>
<LI>Not stated</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness of follow-up</HEADING>
<P>Percentage of participants excluded or lost to follow-up</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>